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Q U I L L  O N  S C A L P E L  This section
provides a medium through which Canadian 
surgeons can declare themselves, briefly and in­
formally, on the day-to-day affairs of surgery.
LUNG CANCER
The problem that lung cancer now poses 
can be viewed in much the same light as that 
of tuberculosis 50 years ago, the difference 
being that even in those days, before the in­
troduction of antibiotics, the results of treat­
ment were better for tuberculosis than the 
results of all our treatments for lung cancer 
today. The incidence of lung cancer is in­
creasing, both in men and women; it is now 
the most common cause of death from cancer 
in men and about the fourth most common 
in women. Two of the most disturbing fea­
tures are the rapid increase in the incidence 
in women and the comparatively small effect 
on the incidence of the disease that the wide­
spread publicity given to the dangers of ciga­
rette smoking has had. It is estimated that in 
Canada, in 1973, 34 170 potential years of 
life were lost by men as a result of lung 
cancer, and 8840 years by women. In the 
United States, it is estimated that there were 
93 000 new cases of lung cancer in 1976 
and 83 000 deaths as a result of it. The 
curves of increased incidence of the disease 
are now parallel for the two sexes.
The results of surgery vary and though 
surgeons now operate on cases that formerly 
would have been considered inoperable, in 
order to reduce the volume of disease, and 
though methods of detection have been re­
fined, the 5-year survival of operable lung 
cancer remains at 40 to 60%. Unquestion­
ably radiotherapy has a place in the manage­
ment of lung cancer,1 both as adjuvant treat­
ment when there is minimal residual disease 
in the hilar or mediastinal lymph nodes after 
resection and in the palliation of symptoms 
in the late stages of the disease. Chemo­
therapy generally has been unsuccessful, 
particularly when single agents have been 
used; however, a new era is dawning in the
understanding of how drugs may best be 
used in the treatment of this and other 
malignant diseases.
Spectacular successes have been reported 
for combinations of drugs and the combin­
ation of drugs and irradiation, not only in 
the treatment of oat cell cancer of lung,2 
but also in non-oat-cell disease.3'5 From the 
chemotherapist’s viewpoint, a number of 
considerations are of paramount importance: 
first, the drugs should be used in logical com­
binations; second, the earlier in the disease 
treatment is started the better is the result; 
and third, the fitter the patient is at the start 
of treatment the better is the result.6 Drugs 
have to be chosen so that they meet the re­
quirements not only of the histologic type of 
the disease but also of acceptable toxicity 
for the patient. When considering the latter 
it must be remembered that a certain degree 
of toxicity is probably necessary to achieve 
any result at all and that, unfortunately, 
“pour faire une omelette il faut casser des 
oeufs”. It is the constant cry of the conser­
vatives, whose view it is, in general, that lung 
cancer ought not to be treated until it causes 
the patients severe or life-threatening symp­
toms, that chemotherapy is worse than the 
disease itself — if this is so then the fault 
lies with the chemotherapist because this 
need no longer be true if sufficient care is 
taken.
The place of immunotherapy in the treat­
ment of lung cancer, indeed in any form of 
cancer, is still under investigation. Immuno­
therapy has been practised for the last 80 
years in various forms in the hope that it 
would provide the oncologist’s silver bullet 
but the results have been disappointing in 
terms of clinical criteria.7 Many attempts 
have been made to measure the immune re-
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sponses of patients with cancer, but the 
significance of a diminished response to a 
common skin test recall antigen such as puri­
fied protein derivative (PPD) is not entirely 
understood. For example an individual who 
has never been exposed to tuberculosis will 
have a negative result; a person may become 
temporarily unresponsive as a result of many 
factors such as recent operation or inter­
current infection; or a patient may be truly 
anergic as a result of being the host to a tu­
mour. It is obvious that the further advanced 
the tumour is the greater is the chance of 
a patient being anergic; however, use of 
this kind of test to determine the amount of 
tumour present has been generally unsuc­
cessful. The prognostic value of such tests, 
with the possible exception of the dinitro- 
chlorobenzene (DNCB) test, is still unproven 
though different investigators claim prognos­
tic value for various common antigens. The 
only true test of immunologic reactivity to 
a tumour is the host’s specific reaction to 
the autologous tumour antigen. And herein 
lies the greatest difficulty of all —  tumour 
antigens are not only difficult to isolate in 
their pure form but the amount of antigen 
that can be prepared from any one tumour 
is so small that investigators have to use al­
most all their material to prove that it exists 
without being able to put it to therapeutic 
use. The use of allogeneic tumour antigen 
enables the investigator to obtain more ma­
terial for use, but raises the vexing question 
of specificity. Is the patient into whom the 
antigen is injected reacting to the tumour 
antigen alone or to any of a number of other 
antigens that must be present in such prepa­
rations however carefully they have been 
prepared?
The phenomenon of “immunologic re­
bound” has been described in animal and 
human systems, usually after the use of cy­
clophosphamide. What is doubtful, how­
ever, is whether any clinical use can be made 
of such a phenomenon. It is hard to see how 
such rebound can take place if the immune 
system has never been depressed. This is 
one of the reasons for folinic acid rescue fol­
lowing methotrexate administration. The 
use of the powerful Freund’s complete ad­
juvant, which consists of dead Mycobacte­
rium tuberculosis mixed in oil, would also
complicate any study in which immunologic 
parameters are to be measured, quite apart 
from the fact that the use of this material 
produces severe indolent ulceration at the 
site of injection.
One of the factors that has made it so 
difficult to evaluate most so-called immuno­
therapy trials is that they have been con­
ducted on small numbers of patients without 
the use of proper controls. Such studies have 
to be rigorously controlled and statistically 
evaluated, and any investigators who ignore 
randomization procedures will have diffi­
culty convincing others of the validity of 
their studies. In this respect multicentre, co­
operative trials are probably indicated.
The results of a study of immunotherapy 
in lung cancer reported by Stewart and col­
leagues in this issue of the Journal (page 
370) are striking, and other workers 
are beginning to report equally impressive 
trials,8 10 but these results must be con­
firmed under much more rigorously con­
trolled conditions. This could be done with­
in a single institution, provided enough pa­
tients were available; by the cooperation of 
a small number of centres within which treat­
ment and control criteria can be closely su­
pervised; or by a multicentre trial. Of the 
three alternatives the first is obviously the 
best, but few single institutions have enough 
patients of any except very common diseases 
to make such a trial realistic in terms of the 
time needed for completion. Also, it lends 
veracity to any study to have it confirmed 
in more than one centre at a time. The sec­
ond alternative is less easy than the first, 
but, with a complicated study, is far superior 
to the first alternative, which often leads 
to the oversimplification of a trial and to a 
diffusion of results that make analysis dif­
ficult; its only real advantage seems to be 
the rate at which patients can be entered 
into the study.
It is to be hoped that these results can, 
indeed, be confirmed in some way, but in 
spite of these encouraging preliminary re­
sults immunotherapy should not be regarded 
as a panacea. The future seems to lie in well- 
designed multimodality treatment combining 
surgery, irradiation, chemotherapy and im­
munotherapy in logical combinations given 
early, rather than late, in the disease. Lung
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cancer is now a major threat and in the fu­
ture much of the work of oncologists will 
need to be directed against it.
P. W. A. Mansell, md, frcs
Chief, education and training,
Comprehensive Cancer Center for 
the State of Florida,
University of Miami School of medicine,
Jackson Memorial Medical Center,
Miami, FL 33152.
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TREATMENT OF CANCER OF THE RECTUM
The treatment of cancer of the rectum by 
abdominoperineal resection has never given 
satisfaction to surgeons or to patients 
because the mutilation produced is often 
not matched by the expected results. More­
over, survival for cancer of the rectum has 
improved little and what improvement there 
has been can be attributed to better anes­
thesia and supportive care.
There is little chance of metastatic spread 
in tumours that are small, low, well diffe­
rentiated and minimally invasive. These tu­
mours have been successfully treated by 
either local resection or low-voltage irradia­
tion with preservation of rectal continuity 
and anal function; the results have been 
comparable to those of radical resection, thus 
refuting the old surgical dictum, “small tu­
mour — large operation”. However, these 
treatment methods have not been associated 
with a decrease in mortality.
This leads to the much larger question of 
how to treat the more aggressive rectal car­
cinomas — those that kill. How do we im­
prove on the results of surgery alone? Ad­
juvant chemotherapy has been and is being 
tried, but the prospects are not encouraging.
Recently the results of an increasing num­
ber of trials using pre- or postoperative irra­
diation have been reported, and have en­
couraged the implementation of further 
trials that have not yet been completed. Most 
therapeutic radiologists would prefer to 
irradiate before operation when the tumour 
bed has not been disturbed, when the inter­
val between irradiation and operation can 
be planned, and when there is unlikely to be 
a delay in either form of therapy. Moreover 
with modern radiotherapy the complication 
rate from surgery is not increased.
An example of the results obtained with 
preoperative irradiation is that of the Vet­
erans’ Administration trial1 in which 700 
patients were entered. The patients were 
randomized into those receiving no preoper­
ative radiotherapy and those in whom 2000 
rads were given in 2 weeks with operation 
following soon afterwards. The 5-year sur­
vival rate in patients who had an abdomino­
perineal resection was 41 % in the treated 
group and 28% in the untreated group. Ad­
ditional interesting observations were that 
the improvement in results was most appa­
rent after a 3-year follow-up, and also that
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the proportion of patients with Dukes’ stage 
C lesions (with positive lymph nodes) de­
creased from 40 to 21% .  Other observers 
have reported a similar decrease in the pro­
portion of patients with involved lymph 
nodes.
The results of Rider and associates in this 
issue of the Journal (page 335) are interest­
ing. They purport to show a statistical dif­
ference in survival in two groups of patients 
with Dukes’ stage C lesions, randomized 
between sham irradiation and a single treat­
ment of 500 rads given a few hours before 
surgery. The results appear to be based 
mainly on the information given in one of 
the illustrations (Fig. 2), in which a P value 
of 0.014 is calculated on the difference in 
survival between the two groups. [See Corre­
spondence section page 385.] I am un­
able to see any statistical difference between 
the survival of these two groups of patients; 
a correct P value is 0.24 (Dunnett CW: 
Personal communication, 1977).
Preoperative radiotherapy for cancer of 
the rectum appears promising and certainly 
should be considered before radical surgery, 
possibly at a higher dosage than that recom­
mended by Rider and associates. We await 
the results of further trials with interest.
R. G. C. M acLaren , m b , frcs, f r c p [c]
Acting director,
The Ontario Cancer Foundation,
Hamilton clinic,
Hamilton, Ont.
R eference
1. Rosw it B, H iggins GA, K eehn RJ: Preoper­
ative irradiation for carcinoma of rectum: 
report of National Veterans Administration 
randomized study. Cancer 35: 1591, 1975
Notice
Reprints for the article “Complete Tran­
section of the Body of the Stomach Re­
sulting from Blunt Trauma” (Can 1 
Surg 20: 264, May 1977) may also be 
obtained from Dr. E. M. S. Frew, De­
partment of surgery, Lethbridge Muni­
cipal Hospital, Lethbridge, Alta. T1J 
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BENEFITS OF VASOPRESSIN IN GASTROINTESTINAL HEMORRHAGE —
FACT, FICTION, OR FANCY?
The role of vasopressin (Pitressin, Parke 
Davis) in the management of gastrointes­
tinal hemorrhage in cirrhotic patients is 
controversial. Mackenzie and his colleagues, 
in this issue of the Journal (page 356), 
report their experience with its use in 24 cir­
rhotic patients bleeding from varices or gas­
tric erosions. Their report is timely, be­
cause current methods of animal slaughter 
have led to severe shortage of vasopressin. 
(Synthetic vasopressin is available, but has 
not yet been approved for clinical use in 
Canada or the United States.)
Because of the disappointing experience 
of Mackenzie and associates a careful reap­
praisal of the effects, advantages and dis­
advantages of vasopressin therapy in the 
management of bleeding in cirrhotic and 
noncirrhotic patients is of value.
Unfortunately the study of Mackenzie 
and colleagues was uncontrolled, nonran- 
domized and retrospective. Also, of the 24 
patients reported only 8 were bleeding from 
esophageal varices; 15 were clearly differen­
tiated as bleeding only from gastric ero­
sions. This unusually high percentage of 
gastric bleeding suggests that some unstated 
preselection process led to the choice of 
this form of therapy. Nevertheless in all 
these patients vasopressin was infused into 
the superior mesenteric artery (SMA). Quite 
clearly this route of administration is not 
the preferred one for patients bleeding from 
gastric erosions. Athanasoulis and as­
sociates1 emphasized that a high rate of 
hemorrhagic control in nonvariceal upper 
gastrointestinal bleeding can be achieved 
only when the vasoconstrictive agent is se­
lectively infused into the bleeding artery 
or the vessel more directly feeding the area 
of bleeding; in the majority of patients the 
ideal vessel is the left gastric artery. With 
such selective catheterization and infusion, 
these authors achieved control of bleeding 
in 31 of 37 patients with acute gastric mu­
cosal hemorrhage. Whether the cirrhotic 
patients fared less well is not reported.
A third criticism centres around the 
dosage and technique used for control and 
eventual cessation of therapy. Mackenzie 
and colleagues used a dosage of 0.2 pressor
units per minute (U/min), monitored only 
by clinical arrest of bleeding; 24 hours later 
the infusion was discontinued and the ca­
theter withdrawn. Not all patients respond 
in the same way to vasopressin, particularly 
cirrhotic patients.2 As stressed repeatedly 
in the initial reports of Nusbaum,3- 4 the 
effectiveness of the administered dose (as 
well as the efficacy of catheter placement) 
during infusion must be carefully and re­
peatedly monitored by angiography. Rates 
up to 0.4 U/min may be required to achieve 
satisfactory and safe vasoconstriction. The 
criteria for this are constriction of peri­
pheral vessels, evidence of increased peri­
pheral resistance causing aortic reflux and 
arrest of contrast extravasation. In addition 
good forward flow into the capillary and 
venous phases must also be achieved with­
out notable constriction of the proximal 
vessels. Once satisfactory cessation of he­
morrhage occurs, a careful program of 
weaning from the vasopressin should be fol­
lowed over several days to minimize re­
bleeding. If rebleeding occurs, the full in­
fusion should be restarted and the weaning 
process repeated. Using this technique only 
2 of 37 patients with upper gastrointestinal 
bleeding1 and 4 of 15 patients with massive 
colonic (diverticular) hemorrhage3 suffered 
episodes of rebleeding in the Massachusetts 
General Hospital series.
Most of the patients described by Mac­
kenzie and associates suffered from cirrhosis 
secondary to long-standing alcoholism. All 
had severe hepatocellular failure such that 
primary surgical treatment was precluded; 
indeed, of the five patients in whom bleed­
ing was completely controlled three died of 
liver failure shortly after treatment. It is re­
markable that even with the criticism noted 
above, initial success was achieved in 70%. 
However, the ultimate failure merits a close 
examination of the physiologic and pharma­
cologic effects of the infusion.
Systemic intravenous administration of 
vasopressin for the control of portal hyper­
tension has been used for many years. In­
itially success in controlling hemorrhage 
from esophageal varices was reported.6'8 
Large doses of 40 to 80 U over 1 to 2
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hours or bolus injections every 4 hours were 
used. Initial cessation of hemorrhage re­
sulted, but in most cases bleeding recurred 
within hours of cessation of treatment. In­
creasing dosages of vasopressin caused 
coronary vasoconstriction, decreased cardiac 
output and in some instances peripheral 
vascular collapse. In addition, repeated 
dosages cause a tachyphylactic reaction with 
diminished vascular response.
In 1967 Nusbaum and colleagues9 de­
scribed a technique in dogs for control of 
induced portal hypertension by the selective 
infusion of vasopressin into the SMA. They 
demonstrated that the continuous infusion 
of fractional doses of vasopressin resulted 
in a decrease in portal pressure and 
SMA flow without systemic side effects. 
This technique was later applied to patients 
with bleeding esophageal varices, and its 
effectiveness in decreasing portal pressure 
and arresting the hemorrhage was demon­
strated.3’ 4 With dosages in the vicinity of 
0.2 U/min, reductions of 51% in portal 
pressure and 60% in SMA flow were re­
ported without systemic effects. Its use was 
further extended to intraoperative selective 
infusion as an adjunct during portosystemic 
shunt surgery.10 A decrease in operative 
blood loss from collaterals resulted, again 
without appreciable coronary or hyperten­
sive effects. Subsequent reports have ex­
tended its use to bleeding from causes other 
than portal hypertension and varices. Safety 
and effectiveness have been demonstrated 
in acute gastric mucosal hemorrhage,1 
colonic diverticular bleeding5, 11 and other 
causes of hemorrhage.12'14
In 1975, Conn and colleagues14 reported 
the first prospective randomized controlled 
trial of vasopressin in upper gastrointestinal 
hemorrhage. Vasopressin was significantly 
more effective in controlling hemorrhage 
(70 to 75% initial control) than conven­
tional therapy (25 to 30% initial control). 
It is noteworthy that 34 of the 53 patients 
studied had cirrhosis. The results were 
similar for both cirrhotic and noncirrhotic 
patients and both variceal and nonvariceal 
hemorrhage. Recurrence of bleeding within 
5 days of initial control occurred in 33 to 
45% of patients. This must be considered 
a disappointingly high percentage, but sig­
nificantly less than the 70% reported in the
study by Mackenzie and colleagues. Perhaps 
these differences may be related to the de­
tails of dosage and technique that we have 
already discussed. The frequency of recur­
rence was similar for variceal and nonvar­
iceal bleeding sites. As mentioned by Mac­
kenzie, Conn and associates14 failed to de­
monstrate an improved survival in the vaso­
pressin treated group. However, Conn did 
point out that vasopressin may have con­
tributed to a relatively low mortality in the 
conventionally treated group, since 20 pa­
tients whose bleeding was not controlled by 
standard therapy were given vasopressin; 10 
responded and 7 ultimately survived. It is 
interesting that survival was similar in both 
cirrhotic and noncirrhotic patients.
The possible deleterious effects of pa­
renteral vasopressin upon hepatic blood 
flow and, in particular, hepatic arterial flow 
have been of great concern. With selective 
infusion of vasopressin into visceral ar­
teries, it is possible that if the hepatic ar­
tery was directly exposed to vasopressin 
during celiac axis or selective SMA infu­
sions, hepatic ischemia secondary to 
decreased hepatic artery blood flow might re­
sult. Drapanas and colleagues,15 using high- 
dose intravenous bolus injections, showed 
that, while hepatic blood flow decreased, the 
greatest decrease was in portal venous flow; 
hepatic arterial flow was essentially un­
changed. Heimberger, Teramoto and Schu­
macher,10 using direct cannulation, con­
cluded that because the decrease in total 
hepatic circulation was less pronounced and 
less well maintained than that of portal 
blood flow, increasing flow into the liver 
from the hepatic artery during systemic 
vasopressin infusion must occur. Fingeroth 
and associates,17 using noncannulating elec­
tromagnetic flow probes in dogs, and Conn, 
Ramsby and Storer,18 using angiographic 
techniques in man, have shown that, with 
direct intraceliac infusion of vasopressin, 
the hepatic circulation is characterized by 
a sustained autoregulatory escape. A com­
pensatory increment in hepatic arterial 
blood flow after transient vasopressin-in­
duced vasoconstriction protects against he­
patic ischemia. This has been confirmed also 
with direct hepatic artery infusions.19
Although selective intra-arterial infusion 
of vasopressin is effective, injection into a
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peripheral vein remains the most rapid and 
practical route of administration, because 
the problems associated with the former 
method — the need for a skilled angio- 
grapher and special equipment, complica­
tions of clotting, bleeding and embolism 
from the catheter, technical difficulties en­
countered in obese or arteriosclerotic pa­
tients — are avoided. Recently a study 
in normal dogs and cirrhotic patients with 
continuous low-dose intravenous infusion 
of vasopressin has demonstrated notable 
sustained reductions in portal venous pres­
sure.20 These experiments were associated 
with a greater initial reduction of portal 
venous pressure and less adverse systemic 
hemodynamic effects than those encoun­
tered by earlier investigators using intra­
venous high-dose bolus injections. Further 
studies have shown that isoproterenol off­
sets these adverse systemic effects while per­
mitting a mean reduction of 30% in the 
portal pressure of cirrhotic patients.21 In­
terest therefore has once again been re­
vived in the intravenous administration of 
vasopressin for control of variceal bleeding. 
Barr, Lakin and Rosch22 have shown that 
minimal differences exist between SMA and 
intravenous infusions of vasopressin on both 
splanchnic and systemic hemodynamics in 
normal dogs and dogs with acute portal hy­
pertension. There was no statistically sig­
nificant difference between the degree of 
changes in portal flow, portal and systemic 
blood pressure and cardiac output among 
those treated with selective arterial and 
intravenous infusions. However, SMA flow 
did show a greater decrease with selective 
arterial injection. Further, when a low-dose 
infusion, comparable to that used intra­
arterially, was used and when it was com­
pared with the high doses previously used 
clinically, a 40% lesser systemic effect was 
achieved with maintenance of 80 to 85% 
of the desired splanchnic effect on the portal 
flow and pressure.
Since vasopressin has a biologic half- 
life in man ranging from 20 to 25 min­
utes,23 the difference between the effects 
of intra-arterial v. intravenous continuous 
infusion of a similar dosage upon central 
hemodynamic events should be small. This 
is particularly so in cirrhotic patients who 
have extensive spontaneous portosystemic
shunts, for these shunts allow drugs in the 
SMA to bypass the liver and return to the 
systemic circulation. Millette and asso­
ciates24 selectively infused vasopressin in­
tra-arterially in cirrhotic patients; contrary 
to the results of earlier reports3’ 4- 9 they 
were able to demonstrate significant sys­
temic effects of increased arterial pressure 
and decreased arterial oxygen pressure and, 
in three of eight patients, a marked de­
crease in cardiac output. An interesting 
negative correlation was found between the 
changes in the systemic effects as evaluated 
by cardiac output, and in the mesenteri- 
coportal effects reflected in portal pressure. 
This relationship was not seen by Thomford 
and Sirinek.20 However, since systemic peri­
pheral vasopressin effectively reduces portal 
pressure, it is unlikely that the explanation 
lies in the existence of portosystemic shunts 
as suggested by Millette and colleagues. 
Portal venous pressure was not lowered in 
all patients and therefore they concluded 
that the efficacious effect of vasopressin in 
controlling variceal bleeding may not be 
explained totally by this mechanism. They 
suggested that other factors such as local 
constrictive effects on the smooth muscle 
of the lower esophagus may be responsible. 
There is no experimental evidence to sup­
port this hypothesis and since their patients 
were not bleeding at the time, one cannot 
state how those without portal pressure 
reductions would have responded. Com­
bining data of several investigators, Nus- 
baum and Conn2 showed that whereas 83% 
of nonbleeding patients had a decrease in 
portal pressure, only 43% had a similar 
decrease during variceal bleeding. Clearly, 
multiple hemodynamic, neural and hor­
monal phenomena are in effect. A more 
plausible explanation for the lack of uni­
form response is the variable ability of the 
hepatic artery to increase its flow rate in 
attempting to compensate for the fall in 
portal flow induced by vasopressin. Kessler, 
Tice and Zimmon23 have suggested that the 
response of portal pressure to vasopressin 
in cirrhotic patients can identify a specific 
group of patients whose hepatic vasculature 
can compensate for a reduced mesenteric 
blood flow by increasing hepatic arterial 
flow and therefore, by inference, can toler­
ate portocaval shunt. Conversely, cirrhotic
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patients who are unable to compensate for 
mesenteric vasoconstriction would not toler­
ate shunting and have a poor prognosis.
The therapeutic value of vasopressin is 
uncertain in cirrhotic patients. Clearly, it is 
most valuable for the initial arrest of hemor­
rhage, but rebleeding is frequent; since it 
may not improve ultimate survival from the 
bleeding episode, its role may be limited. 
An easily applied intravenous infusion could 
again become the primary method for vaso­
constrictive therapy of massive variceal 
bleeding. This, however, does not apply to 
bleeding from other sites where selective in­
fusion into the artery more directly feeding 
the area of bleeding is necessary. A con­
trolled clinical trial to confirm in man the 
benefits of low-dose systemic infusions al­
ready achieved in the canine model by Barr, 
Lakin and Rosch22 is clearly necessary. Fur­
ther studies to correlate the response to 
vasopressin in stable and bleeding cirrhotic 
patients with decreases in portal pressure, 
cardiac output and ultimate survival after 
shunting are also needed.
Marvin J. Wexler, m sc, md, frcs[c]
Assistant professor,
Department of surgery,
Royal Victoria Hospital,
Montreal, PQ.
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REVIEW ARTICLE
NORMAL PROCESSES AND RESTRAINTS IN WOUND HEALING*
N. H. CARPENTER, BSc, MD,t D. J. GATES, MSct and 
H. T. G. WILLIAMS, MB, ChB, FRCS, FACS, FRCS[C]§
Wound healing normally follows an uninterrupted 
course but, for the purposes of description, it 
can be considered in four phases —  hemostasis, 
acute inflammation, repair and consolidation. 
Arrest of healing may occur at any phase and 
lead to a number of clinical problems. Repair 
cannot begin until the phase of acute inflamma­
tion has begun to subside; this fact is of special 
importance in clinical surgery. Wound healing in 
gastrointestinal tract and abdominal incisions is 
emphasized because healing problems are com­
mon in these areas and failure to heal results 
in morbidity and a regrettable mortality.
La guerison d'une blessure suit normalement un 
deroulement ininterrompu mais, pour fin de des­
cription. on peut considerer qu'elle comporte 
quatre phases: I'hemostase, I'inflammation
aigiie, la cicatrisation et la consolidation. La 
guerison peut s’arreter a I'une ou I’autre de ces 
phases, entrainant plusieurs problemes cliniques. 
La cicatrisation ne peut commencer aussi long- 
temps que la phase d'inflammation aigiie n'est 
pas disparue. Ce fait est de premiere importance 
en chirurgie. On en souligne I'interet en ce qui 
a trait a la guerison des incisions de I’appareil 
gastro-intestinal et de I'abdomen, car les pro­
blemes de guerison y sont frequents et I'echec 
de guerison entraine une morbidity et une re­
grettable mortality.
W ound healing is normally a continuous and 
uninterrupted process beginning at the time 
of injury and lasting for about 2 years. For 
descriptive purposes we consider the process 
in four phases —  hemostasis, acute inflam­
mation, repair, and consolidation and re­
construction —  realizing that these divisions 
are somewhat artificial and overlap.
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H emostasis
Hemostasis is essential not only to avoid 
serious or fatal blood loss but also to prevent 
an accumulation of blood within the wound 
and separation of the wound surfaces. Na­
tural hemostasis is achieved by constriction 
and retraction of the blood vessels and by 
plugging of these vessels with platelet aggre­
gates. It is a remarkably efficient process 
and, in its absence, any measures to control 
bleeding at operation are of little value.
Vasoconstriction and Retraction
The reason for the immediate vasocon­
striction of the divided vessels is unknown, 
but the retraction is due to shortening of the 
divided vessels and is a common observation 
at operation. Hemostasis from a lateral in­
jury to a blood vessel is not as good because 
constriction and retraction cannot take place 
as readily. Blood that escapes into the in­
terstitial spaces increases tissue turgor and 
compresses the vessels; this helps to reduce 
blood loss.
Platelet Aggregates
The occlusion of the blood-vessel lumen 
depends on the properties of the blood plate­
lets. Within seconds of the injury the plate­
lets stick to the exposed subendothelial colla­
gen. It is possible that the process is initiated 
by the formation of trace amounts of throm­
bin on the platelets. Probably as a result of 
interaction with adenosine diphosphate 
(ADP), the platelets change from smooth 
discs to very sticky spheres covered with 
small spines, so that further aggregation oc­
curs. This is accompanied initially by a 
central concentration of the granules in the 
platelets and later by loss of these granules 
with a release of ADP, serotonin and epine­
phrine.1- 2 Fibrin strands then appear and 
these hold the platelet mass together and 
help to anchor it to the surrounding collagen. 
Thus the platelet mass becomes a compact, 
attached, fused and amorphous structure, the
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so-called platelet plug, and the process is 
called viscous metamorphosis.3 Of the pro­
tein in platelets, 15% is in the form of 
thrombasthenin, which can contract.4 Its 
function is not fully understood but it may 
play a role in platelet compaction.
Ligature Control
The control of bleeding from a wound 
can be difficult when natural hemostasis is 
deficient. Surgical hemostasis at operation 
by ligature or cautery controls bleeding from 
only the larger vessels. Every effort should 
be made to control blood loss from these 
vessels without producing excessive necrosis. 
Ties should be accurate and delicate and 
cautery used with discretion.
Pressure Control
The arrest of bleeding from the smaller 
blood vessels depends on the body’s power 
of 'hemostasis and this can be aided by gen­
tle pressure with sponges. It is of interest 
that in attempting to control oozing from a 
wound surface, gentle pressure with absor­
bent material is more effective than firm 
pressure. The former removes blood that has 
leaked from the vessels but encourages plate­
let plugs to form, while the latter empties 
the vessels, and bleeding recurs once the 
pressure is removed and the small vessels 
refill.
Uncontrolled oozing from injured tissue 
separates the wound surfaces and seriously 
delays healing. Furthermore, the blood in 
the wound is an excellent culture medium 
for bacteria that may have been implanted.
A cute Inflammation
Acute inflammation begins as soon as 
tissue is damaged and is a process whereby 
cells and exudate accumulate in irritated 
tissue; it protects that tissue from further 
injury5 and helps to remove dead tissue and 
debris. In any wound there is some destruc­
tion of tissue, and if the entodermal or ecto­
dermal epithelial barriers are breeched, bac­
teria can also enter the wound. Acute in­
flammation is therefore essential to clear ne­
crotic debris and clot from the wound; in 
addition, acute inflammation helps to over­
come bacterial contamination. An important 
fundamental point in wound healing is that 
the phases of acute inflammation and repair
are mutually exclusive and that acute inflam­
mation must begin to subside before repair 
begins.
Vasoactive Substances 
An injury to the body releases vasoactive 
substances. These include amines (histamine 
and serotonin) and polypeptides (bradyki- 
nin) from the plasma, and acidic lipids (pros­
taglandins) from the tissues, which initiate 
the inflammatory reaction.0 The vasodilata­
tion in the capillaries, venules and arterioles, 
and the increased permeability of the capil­
laries and venules allow plasma and leuko­
cytes to escape into the tissues. The cells 
and the fluid exudate work together to over­
come bacterial invasion by diluting, neutral­
izing and precipitating toxins, forming a 
fibrin network in the interstitial spaces, and 
clumping, ingesting and killing bacteria. 
Dead tissue and clots are removed by phago­
cytosis and enzymatic digestion by the leuko­
cytes, especially the macrophages.7
Ischemia
Acute inflammation is associated with at 
least a 10-fold increase of blood flow through 
the tissues. Ischemia or anergy,8 especially 
in the presence of heavy bacterial conta­
mination, may interfere with the body’s abi­
lity to mount an effective inflammatory re­
sponse; necrosis, spreading infection and 
septicemia result.
Many of the problems of wound healing 
after surgery can be attributed to lack of 
attention to the fact that tissue repair cannot 
take place until the stage of acute inflamma­
tion has started to subside. Every effort 
should be made, therefore, to keep the phase 
of acute inflammation to the minimum re­
quired for removing tissue damaged in the 
incision, small amounts of clot and any bac­
teria implanted in the wound.
Necrosis and Bacterial
Contamination in the Wound
Necrosis in the wound can be increased by 
rough retraction, prolonged retraction with 
self-retaining instruments, the use of gross 
ligatures in attempting to achieve hemosta­
sis and in the overenthusiastic application of 
electrocautery. Blood clot in the wound 
should be regarded as necrotic tissue. Even
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in clean operations some bacteria inevitably 
enter the wound from the surrounding en­
vironment, especially in long, difficult proce­
dures.9 Under the usual modern hospital 
conditions it is as unrealistic to have a germ- 
free wound as it is a dust-free home. Usually 
the few bacteria introduced during the course 
of surgery into a clean wound do not pre­
sent problems unless they are highly patho­
genic or are encouraged to grow by the 
presence of large amounts of necrotic tissue 
and blood clot within the wound. The use 
of various prostheses within the tissues, es­
pecially in cardiovascular and orthopedic 
operations, increases the chance of serious 
infection arising from a small inoculum of 
bacteria. It is likely that the surface of the 
prosthetic material provides a protected ni­
dus for bacteria to multiply. If any of the 
bacteria-containing cavities of the body are 
entered at the time of operation, far more 
bacteria will contaminate the wound, and the 
chances of wound infection and delayed 
healing are greatly increased.
Suture Materials
The choice of suture materials is impor­
tant in reducing the phase of acute inflam­
mation. Wounds heal in spite of sutures, al­
though there is no alternative to their use 
in many areas to keep wound edges in appo­
sition. Catgut, especially plain catgut, ex­
cites an acute inflammatory reaction and 
so delays healing in the vicinity of the stitch. 
The ideal suture is one that elicits the least 
inflammatory reaction. In this respect mono­
filaments of stainless steel or polypropylene 
are the most satisfactory. But, handling 
characteristics, strength' and absorbability 
must be considered as well. At present, poly- 
glycolic acid sutures seem to be the best 
compromise. Where wound surfaces can be 
kept apposed by the use of skin tapes in­
stead of sutures, healing is very satisfactory.
R epair
During the phase of acute inflammation 
the wound is held together by a small quan­
tity of fibrin, aided by tapes or sutures. As 
the acute inflammation subsides the capillary 
loops on either side of the wound sprout 
endothelial buds that canalize and join to 
form new loops; eventually these join up
with new capillaries growing from the other 
side of the wound. These new capillaries 
produce a plasminogen activator that brings 
about local fibrinolysis and facilitates their 
penetration into the fibrin network.10 At 
first the new capillaries are supported by 
the fibrin, but soon this is replaced by a 
collagen framework.
Fibroblasts and Collagen
New capillaries are accompanied by fibro­
blasts that are active in the synthesis of 
collagen, a fibrous protein. The origin of 
fibroblasts remains a mystery. They may be 
derived from primitive circulating cells, from 
inactive precursors of fibrocytes in the 
tissues and there is some evidence that they 
are simply modified macrophages.11 Re­
traction of the small amount of clot in the 
wound results in a centripetal orientation 
of the fibrin strands. The fibroblasts arrange 
themselves along the fibrin and are con­
ducted towards the centre of the wound. 
Contact inhibition between fibroblasts en­
sures that they move in the required direc­
tion to fill the wound.
Tropocollagen.— The basic monomer of 
collagen, tropocollagen, is 3000 A long and 
12.5 A in diameter,12 and is precipitated 
in the intercellular space. The collagen fibres 
seen on histologic preparation consist of nu­
merous tropocollagen molecules arranged in 
a repeating order to form a fibre. Each mole­
cule consists of three polypeptide chains, 
termed a-chains, each of which contains 
about 1000 amino-acid residues arranged in 
a left-handed helical conformation. Short 
extensions of both the amino- and carboxy- 
terminal regions do not possess this helical 
structure.13 The tropocollagen molecule, 
consisting of three entwined a-chains, is 
formed into a superhelix that is largely re­
sponsible for the molecule’s rigidity. This 
arrangement resembles a piece of three- 
stranded rope with frayed ends. The portion 
of the a-chain that forms a minor helix has 
a characteristic amino-acid sequence. The 
repeat distance in the minor helix is 9 A, 
which is the distance occupied by three 
amino-acid residues. Glycine at every 
third position permits the tight helical struc­
ture to exist by allowing residues to come 
into close contact after each turn.
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Registration peptides and procollagen.— 
The a-chains are 30% longer when they are 
assembled within the fibroblasts, than with 
the extracellular collagen molecule.11 The 
increased length is in the nonhelical amino- 
and carboxy-terminal portions and these 
parts of the chains do not have the charac­
teristic amino-acid sequence of the minor 
helix. With a few exceptions, glycine does 
not occur at every third position. Cysteine is 
found in both extensions and allows the 
pro-a-chains to be held together by inter­
chain disulfide bonds in the carboxy-ter- 
minus.11 These nonhelical “registration 
peptides” facilitate the alignment and sta­
bilization of the polypeptide chains so that 
helix formation can take place intracellular- 
ly.1 - This longer molecule is called procol­
lagen and is readily soluble under physio­
logic conditions. Cleavage of the registration 
peptides by procollagen peptidase produces 
the ultimate monomeric collagen molecule 
that is precipitated extracellularly.
Proline and hydroxy proline.— Three other 
features of intracellular collagen are im­
portant. As the polypeptide chains are 
synthesized, proline residues occupying the 
third position of a triplet are oxidized to 
hydroxyproline by the enzyme prolyl hy­
droxylase.13 These two amino acids, pro­
line and hydroxyproline, stabilize both the 
minor- and superhelices by restricting free­
dom of rotation along the a-chains and are 
essential for the formation of stable collagen 
molecules.13' 14 Prolyl hydroxylase requires 
four cofactors: divalent iron, molecular oxy­
gen, a-ketoglutarate and ascorbic acid. At 
the same stage, a variable number of lysine 
residues are also hydroxylated, and the ap­
propriate enzyme (lysyl hydroxylase) re­
quires the same cofactors.13 Galactosyl or 
glucosyl-galactosyl residues are attached to 
some of the hydroxylysines, with manganese 
being one of the cofactors necessary in this 
process of glycosylation.13 Adequate hy- 
droxylation and glucosylation must take 
place before collagen can be secreted from 
the cell.12
Lysine residues.— Certain lysine and hy- 
droxylysine residues are modified extracel­
lularly by lysyl oxidase, an enzyme that re­
quires divalent copper ions and molecular 
oxygen as cofactors. Aldehyde intermediates, 
which participate in cross-linking tropocol-
lagen molecules after initial fibre formation, 
are produced by this oxidative deamination. 
Although fibre formation seems to be an in­
herent property of the collagen molecule, 
cross-links between the molecules greatly 
increase the strength of the fibres. Cross­
links increase with age and make collagen 
fibrils more resistant to thermal denaturation 
and collagen breakdown.
Banding of collagen.— Several models 
have been proposed to explain the character­
istic banding pattern of fibrils observed in 
electron microscopy. One highly favoured 
model suggests that tropocollagen molecules 
aggregate in a repeating, quarter-staggered 
array into cylindrical “protofibrils”, five 
molecules in circumference.15 It is this 
staggered arrangement and the distinctive 
charged regions along each tropocollagen 
molecule that impart to the fibrils the char­
acteristic banding pattern with a repeating 
interunit distance of 680 A.
Lathyrism and weak collagen.— Lathyr- 
ism is a condition characterized by weakness 
of fibrous tissue in various parts of the body 
and is due to the ingestion of lathrogens such 
as /J-amino-propionitrile, which is found in 
the sweet pea Lathyrus odoratus. The com­
pound prevents the formation of aldehyde 
intermediates in the cross-linking process, 
thereby reducing the strength of the collagen 
bundles.
Ground substance.—Fibroblasts also pro­
duce ground substance, the amorphous 
material that lies within and around the 
collagen fibres. In the ground substance, 
carbohydrates and proteins are built up into 
large molecules that are associated with wa­
ter and electrolytes. The molecules of glyco- 
saminoglycans are attached to a protein core 
to form a proteoglycan subunit. Several sub­
units, in turn, interact with a long molecule 
of hyaluronate to form proteoglycan aggre­
gate.13 The ground substance helps to ce­
ment the collagen fibres together and also 
confers elasticity and resiliency on the struc­
ture as a whole.
Nutrition and Anemia
Active synthesis of collagen and ground 
substance characterizes the phase of repair. 
The rate-limiting step in wound collagen 
synthesis, under conditions of reasonable nu-
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trition, is the hydroxylation of proline. In 
patients on a normal diet with an adequate 
intake of vitamin C, the rate-limiting co­
factor is the availability of oxygen to the fi­
broblast. A good blood supply is necessary 
to deliver oxygen and molecular building 
blocks to the tissues. Ischemia of the wound 
may be due to arterial disease, hypovolemia, 
hypotension or occasionally direct pressure.
Mild anemia has little effect on collagen 
synthesis, because the normal physiologic 
adjustments, such as an increased blood cir­
culation rate, are able to compensate.11- 17 
Only when the hematocrit is 20% or less 
will anemia seriously affect oxygen delivery 
to the tissues.
Tight Sutures
Tight sutures always cut through tissue. 
Tension in the suture produces ischemia and 
necrosis within the stitch followed by an 
acute inflammatory reaction. Lysozymes 
liberated from the leukocytes can act syner- 
gistically with collagenase to disrupt colla­
gen.18 In some areas this cutting through of 
sutures is inconvenient, but in the gastroin­
testinal tract and cardiovascular system it 
may be disastrous.
Edema
Healing is poor in edematous regions. The 
expansion of tissue fluid increases the dis­
tance between the capillaries and the syn­
thesizing fibroblasts, reducing the oxygen 
tension around the fibroblast. Frequently the 
edema may be the result of increased venous 
pressure, and the reduced flow of blood 
through the capillaries would render such a 
wound hypoxic. Plastic surgeons have long 
appreciated the great importance of a free 
venous return in ensuring good tissue oxy­
genation.
Drugs
Patients on long-term cortisone therapy 
heal poorly. There is experimental evidence 
to suggest that cortisone reduces the secre­
tion of collagen by fibroblasts18 and that 
this effect can be counteracted by the ad­
ministration of vitamin A .111 Nevertheless, 
clinical experience with vitamin A has not 
been impressive. The fact that there is a 
considerable individual variation in the
effect of long-term steroid therapy on wound 
healing makes the clinical assessment of the 
value of vitamin A therapy difficult.
Wound Contraction
All wounds show some degree of contrac­
tion; this is most evident in the healing of an 
open wound. The degree to which an open 
wound will contract depends on the loose­
ness of the skin and can be estimated at the 
time of operation by attempting to bring the 
skin edges together. Wound contraction can 
be readily appreciated in the healing of a 
large venous ulcer but is also responsible 
for closing off drainage tracts once tubes 
are removed. The great difficulty experi­
enced in reinserting a gastrostomy or cystos- 
tomy tube as little as 12 hours after removal 
clearly illustrates this power of contraction. 
Contraction also accounts for much of the 
rapid decrease in size of abscess cavities once 
they have been drained; this applies to 
any surgically created cavity in the body 
that is adequately drained.
The power of a wound to contract rests in 
the granulation tissue, but the mechanism is 
not understood. Collagen is apparently not 
capable of contraction at any stage, but 
poisoning the cells in granulation tissue will 
arrest contraction. Therefore, it is believed 
that in some way these cells are responsible 
for the contraction phenomenon. Specialized 
cells with contractile powers, called myofi­
broblasts, have been described in granulation 
tissue.20
In some parts of the body contraction as­
sociated with healing may result in limita­
tion of movement in related areas particular­
ly the front of the neck, the axillas and the 
groin. Contraction is the active process of 
reduction in wound size, while a contracture 
is a deformity produced by scar tissue caus­
ing limitation of movement in a part of the 
body. The presence of subcutaneous fat 
makes it easier for contraction to close the 
wound without interfering with movement 
in the nearby joints, and this may be the 
most important reason why some parts of 
the body such as the abdominal wall, con­
sistently exhibit beneficial contraction while 
in others disabling contractures are common.
The wound is not closed until it is covered 
with epithelium and is best demonstrated by 
the closure of a surface ulcer. Associated
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with contraction of the wound as a whole, 
the epithelium grows over the exposed granu­
lation tissue. Healthy granulation tissue has 
a fine granular appearance and the level re­
mains below that of the surrounding epithe­
lium. There is increased mitotic activity be­
hind the advancing edge of epithelium and 
the new cells appear to roll over the granu­
lation tissue. They eventually acquire basal 
or prickle cell characteristics according to 
their final position.21
Epithelialization
When a granulating wound is exposed to 
the air and allowed to dry it will form a scab 
consisting of dehydrated necrotic cells, dried 
serum and fibrin. The scab is firmly attached 
to the underlying granulation tissue through 
fibrin strands. The advancing edge of epi­
thelium possesses intense collagenase activity 
and cuts its way through the collagen under 
the scab.22 When the wound is completely 
epithelialized, the scab falls off.
Epithelialization in a sutured wound is 
essentially the same process. A sutured 
wound forms a narrow scab and the new 
epithelial cells push down to the level of the 
dermis before passing under the scab to join 
with cells from the opposite side. Presum­
ably they extend downwards until they be­
come supported by the small amount of 
granulation tissue that is formed deep to the 
scab.23 There is, therefore, no fundamental 
difference in healing between an open wound 
and a sutured wound.
A skin suture causes a type of tubular 
injury around the suture material. This will 
elicit acute inflammation to be followed 
later by repair. If the suture is left in place 
for over a week, epithelium will grow down 
into the suture tracts around the suture ma­
terial. When the suture is removed, the 
buried epithelium will continue to act as an 
irritant and will maintain an inflammatory 
reaction until it is absorbed.21 These tracts 
may also conduct infection from the surface 
into deeper layers of the wound.24
Consolidation and R econstruction
Collagen synthesis can be detected in a 
wound around the 3rd day. However, the 
strength of the wound does not begin to in­
crease until the 5th or 6th days. This in­
crease is rapid for the first 2 to 3 weeks and
then slows down over the next 2 months. 
There follows a very gradual increase in 
strength for about 2 years.25 During the 
whole of this period there is a constant turn­
over of collagen, with new fibres being laid 
down and old fibres being removed by the 
collagenase activity of the fibroblasts. But 
the scar never attains the tensile strength of 
uninjured tissue.
Collagen fibres are laid down in a seem­
ingly random manner during the phase of 
repair when the wound strength is rapidly 
increasing. At this time the wound relies 
more on quantity of collagen rather than on 
quality for its strength. The total amount of 
collagen is reduced during the long period 
of consolidation, but it comes to be laid 
down in a more efficient pattern so that the 
overall strength remains about the same or 
is slightly increased.26 Collagenase activity 
within a scar can be demonstrated after 2 
weeks of healing and a high degree of ac­
tivity is known to persist for several years. 
Presumably the high degree of collagenolysis 
is associated with a similar degree of colla­
gen production.
The decreasing activity within a scar over 
the 2 years after injury is matched by its de­
creasing vascularity and the disappearance 
of any hypertrophy along the line of the scar. 
However, little is known about the changes 
that take place.
Keloid Formation
Clinically the most troublesome complica­
tions are hypertrophic scars and keloids. 
These conditions are believed to be due to 
an imbalance between collagen production 
and collagen lysis.27 While most hypertro­
phic scars will eventually settle down, many 
keloids give rise to so much discomfort and 
inconvenience that they are managed by 
excision, followed by local irradiation or 
local cortisone injections to reduce collagen 
production.
Sp e c if ic  H ealing  P r o b lem s
Healing of Bowel Anastomoses
There must be a great deal of bacterial 
contamination in bowel anastomoses no mat­
ter how careful the surgeon is. It is therefore 
surprising how well these anastomoses heal. 
This is probably attributable to the excellent 
blood supply of the gastrointestinal tract and
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Drainage of peritoneal abscess occurring 
as a complication of abdominal stab wound 
prior to initiation of antibiotic therapy.
<
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an emerging 
problem...
bacteroides
infection
"Bacteroides species are often overlooked as a 
cause of serious infection both by clinicians 
and microbiologists. They are most commonly 
associated with intra-abdominal and pelvic 
sepsis following gastrointestinal surgery."
Tracy, O., et al. (29 Jan. '72). Brit. m e d . p .  280.
"Our experience with this series of seriously 
ill patients provides clinical confirmation to 
complement recent in vitro evidence that clin­
damycin is the antibiotic of choice for use in 
bacteroides infections. Not only was the 
response in 1 7 of the 1 8 patients favourable, 
but in several it was dramatic."
Haldane, E.V. and van Rooyen, C. E. (1972). C.M.A.J., p. 11 77.
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in anaerobic infections
INDICATIONS
Dalacin C Phosphate (clindamycin phosphate injection N.F.) Dalacin C  Phosphate Sterile Solution is 
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pain at the injection site, two demonstrated induration at the infection site and two developed sterile 
abscesses.
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Hypertension............................................................................................................................................’ ”  j ‘ |
Shortness of Breath ............................................................................................................................................ 1
Superinfection*.................................................................................................................................................. 4
Cardiac arrest** .............................................................................................................................  1
Bad or bitter taste in mouth ...........................................................................................................................  5
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of clindamycin phosphate 
**Due to underlying myocarditis in this patient
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Symptoms and Treatment of Overdosage: No cases of overdosage have been reported. No specific 
antidote is known. Doses as high as 1 200 mg every six hours (4800 mg/day) by infusion for five days have 
been given without adverse effect.
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the comparative lack of fatty tissue. The 
same principles apply in the healing of 
wounds in the gastrointestinal tract as else­
where in the body.
Hemostasis should be achieved without 
producing ischemia. The major vascular 
plexus in the wall of the gastrointestinal tract 
lies on the outer surface of the submucosa. 
The bowel is divided by cutting through the 
serous and muscle coats down to the vas­
cular plexus; the displayed vessels are then 
accurately secured before the submucosa and 
mucous membrane are divided. In this way 
complete hemostasis from the divided bowel 
is achieved without the use of bowel clamps 
and without clamping and tying portions of 
the bowel wall.28 The organs are anasto­
mosed using a single layer of interrupted su­
tures in order to bring the bowel ends to­
gether without any inversion or eversion. 
The sutures are placed 2 to 3 mm apart and 
simply pick up the seromuscular and sub­
mucosal coats. The submucosa is the only 
layer in the bowel that has much strength. A  
simple experiment will show that the mucous 
membrane will stand a pull of 60 g, the sero­
muscular coat about 90 g, while the submu­
cosa, even though it looks thin and delicate, 
will stand a pull of 500 to 600 g.
The first two sutures are placed on either 
side of the mesentery and the remaining su­
tures are placed anteriorly and posteriorly 
until the anastomosis is completed. Although 
the point of a hemostat can be pushed into 
the lumen between the sutures, fibrin soon 
seals off these spaces. There must be obvi­
ous slack in the bowel on each side of the 
anastomosis.
The anastomosis becomes adherent to, 
and derives some of its blood supply from, 
the surrounding living tissues within the pe­
ritoneal cavity. These adhesions account for 
some 50% of the strength of the anastomo­
sis during the critical first 4 to 5 days.20 
This simple method of anastomosis has 
proved most reliable in practice and the 
abandoning of cumbersome clamps makes 
the method applicable even when exposure 
is difficult.
Healing of Abdominal Incisions
The highest incidence of wound infections 
in a general hospital occurs in abdominal in-
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cisions. Many such wounds are contaminated 
from the gastrointestinal tract and there is 
frequently a thick layer of subcutaneous fat 
that has a poor blood supply. While much 
can be done to reduce the likelihood of in­
fection by preparing the gastrointestinal tract 
before operation and giving antibacterial 
drugs before, during and immediately after 
operation,30- 31 a good deal more can be 
done by applying good surgical principles to 
the management of the abdominal incision 
itself.
The muscle and fascial layers of the abdo­
minal wall must be closed to avoid eviscera­
tion or incisional hernia. These layers have 
comparatively good blood supply, and, ex­
cept when there is gross contamination or an 
underlying active purulent peritonitis, they 
heal without difficulty. Closure of these lay­
ers with a single row of far-and-near sutures, 
taking good bites of tissue on either side of 
the wound, is recommended.32 These stitches 
can all be placed before they are tied and 
they keep the wound together without ex­
cessive tension. This method may not seem 
as anatomically perfect as a layered closure, 
but it does eliminate the collection of blood 
between the various layers, which may act as 
foci for infection. Should further surgery be 
required, the surgeon will find that a year 
or so later, a single-layer closure is indis­
tinguishable from a layered closure.
No attempt should be made to close peri­
toneum in an upper midline incision. This 
does not add to the strength of the wound 
and merely encloses a dead space between 
the linea alba and the peritoneum where 
blood may collect and infection develop.
Most abdominal wound infections arise 
in the subcutaneous fat. Even when the 
muscle layers and the skin and dermis with 
their good blood supplies appear healed, a 
wound abscess may form within the fatty 
layers. Attempts to close the space in such 
a wound are rarely successful and may lead 
to more necrosis of fatty tissue. A simpler 
method is to leave skin and subcutaneous fat 
open to allow any blood and serum to es­
cape.33' 34 The wound is closed secondarily 
in 4 to 5 days with skin tapes.
Delayed closure of an abdominal incision 
in this way is more readily achieved with 
transverse than with vertical incisions be­
cause the skin comes together more readily. 
Care should be taken to avoid any disparity 
between the level of the skin on either side 
of the wound, but if this does occur the 
wound will smooth off within 12 weeks. This 
method is not associated with delay in heal­
ing or an increase in hospital stay, and it 
significantly reduces the infection rate of 
abdominal wounds.35’ 36 If one accepts that 
there is no fundamental difference between 
primary and secondary healing then there 
should be no difficulty in accepting this 
method of wound closure.
In wounds where the risk of contamina­
tion is high, such as after a colon resection, 
the skin should not be taped together until 
the subcutaneous fat has become covered 
with a layer of granulation tissue. Under no 
circumstances should the wound be closed 
if the skin margins show a narrow 1- to 2- 
mm zone of erythema along the skin edge. 
This indicates that the acute inflammation 
is persisting and if such a wound is closed 
an abscess will form within a few days.
In general, defective healing in an ab­
dominal incision occurs because the disrup­
tive forces break down the closure or, more 
commonly, because infection and acute in­
flammation arrest healing. The result is a 
wound disruption in the early postoperative 
period or an incisional hernia some months 
later.
The social and economic importance of 
trouble-free wound healing is evident be­
cause approximately one-half of the major 
complications that follow surgical proce­
dures are wound complications. Many could 
be avoided by conscientously applying sound 
surgical principles.
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SELF-ASSESSMENT
SESAP II QUESTION
253. The most important cellular bulwark against diseases caused by bacteria is the
(A) lymphocyte
(B) wandering macrophage
(C) neutrophil
(D) fixed macrophage
(E) eosinophil
For this incomplete statement select the one completion that is BEST from those noted 
above.
For the critique of Item 253 see page 388 of this issue.
(Reproduced by permission of the American College of Surgeons from SESAP II Syllabus: 
Surgical Education and Self-assessment Program No. 2.)
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GLIMPSES OF SURGICAL HISTORY: 
P FOR PLASTIC SURGERY
D A V ID  A. E. SH E PH A R D
Human folly, weakness and wickedness have 
often acted as stimulants of surgical technique 
—  war is one example of human behaviour 
causing a flurry of surgical activity, and bodily 
disfigurement resulting from revenge or punish­
ment is another. Both these examples illustrate 
how PLASTIC SU RGERY in particular has 
advanced; both, too, remind us how old and 
noble is the art of surgery as a response to 
man’s injury to man.
Although the term “plastic surgery” is little 
over a century old —  it dates from the 1863 
book by Zeis  —  the basic techniques of plastic 
surgery were known to Indian surgeons of the 
great Susruta’s era, in the 6th century BC. 
Mutilation of appendages such as the ear lobes, 
nose and genitals required treatment by these 
surgeons, who became inventive and skilled in 
the need to make man whole. Crude though 
their operative technique was by modern stand­
ards it was in ancient India that the basic con­
cept of all plastic surgery was born —  that of 
the attached flap. Susruta’s description of use 
of a flap incised in the cheek is well worth read­
ing, and his account of rhinoplasty, one of the 
earliest complex operations ever performed, 
remains a fine testament to his surgical under­
standing.
As so often has happened in human history 
early sophisticated advances were not devel­
oped until the renascence of human genius. 
Then in the 15th century the Brancas perfected 
the Italian method of rhinoplasty by which 
cheek scars were avoided, and in the 16th cen­
tury Tagliacozzi continued Italian surgical su­
premacy by putting rhinoplasty on a more 
scientific basis. Tagliacozzi also treated hare­
lip. Yet once again darkness fell'. Tagliacozzi 
was scorned by the church, his surgical skill 
being considered a sacrilegious attempt to im­
prove on God's creation.
The human need for a bodily image whole 
and handsome has long been deeply felt. Men 
and women justifiably hold the surgeon’s skill 
in awe; yet the surgeon must remain ever hum­
ble, knowing as Pare did that surgeons cut and 
close but that another source makes whole.
HOWTO 
PROTECT AND INSPECT 
A DRAINING WOUND 
AND NEVER 
TOUCH WET GAUZE
Finally there’s a better alternative to absorbent 
dressings, one that offers you more convenience 
and the patient greater protection than gauze. It 
brings together a sterile Karaya Blanket that pro­
tects skin from wound drainage...a transparent 
Collector that confines fluid discharge and odor... 
and an Access Cap which can be removed from the 
Collector to advance the drain tube or treat the 
wound. No more need for time-consuming and 
traumatic dressing changes, so post-operative care 
will be simpler and generally less expensive. Sup­
plied sterile for quick application in surgery, 
recovery, ICU, or patient's room. Write for complete 
information.
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LINCOMYCIN-CLINDAMYCIN COLITIS IS NOT AN ENTITY*
GHISLAIN DEVROEDE, MD, FRCS[C], JACQUES POISSON, MD, FRCS[C], 
PROMETEO MADARNAS, MD, FRCP[C], RENE BEAUDRY, MD. FRCP[C], 
HENRY HADDAD, MD, FRCP[C], BERTIL STROM, MD, JEAN LEPINE, MD, 
HENRI NAVERT, MD and BERNARD PEREY, MD, FRCS[C]
Between 1969 and 1975, after the ingestion of 
antibiotics, pseudomembranous colitis developed 
in 10 patients and nonpseudomembranous colitis 
in 13. All recovered. During the same period, an 
erroneous diagnosis of pseudomembranous coli­
tis was made in three patients who had not re­
ceived antibiotics, who had focal accumulation of 
pus on the rectal mucosa, and who became 
chronically ill. In this retrospective series, more 
cases of colitis were associated with the penicil­
lins than with clindamycin or lincomycin. Patients 
with pseudomembranous colitis were more se­
riously ill than those with nonpseudomembran­
ous colitis and their disease lasted longer (31 
v. 15 d, P <  0.01). They had more frequent ab­
dominal distension (P <  0.001), a faster pulse 
rate (P <  0.05) and a higher temperature (P <  
0.001) or one of longer duration (P <  0.001). The 
leukocyte count was higher in patients with 
pseudomembranous colitis (P <  0.005), and va­
lues for serum protein (P <  0.001), hemoglobin 
(P <  0.005), potassium (P <  0.01), sodium (P <  
0.05) and total carbon dioxide (P <  0.025) were 
lower. Seven patients with nonpseudomembran­
ous colitis had "target” lesions in the rectosig­
moid mucosa; at follow-up endoscopy, pseudo­
membranes were not present even if the disease 
had not been of shorter duration (P >  0.05) than 
that of the patients with pseudomembranous 
colitis.
Nonpseudomembranous colitis and pseudo­
membranous colitis although they have different 
clinicopathological manifestations are possibly 
of identical etiology. Use of the term lincomy- 
cin-clindamycin colitis is unjustified.
Entre 1969 et 1975, apres I'absorption d'antibio- 
tiques, une colite pseudo-membraneuse est ap- 
parue chez 10 patients, et une colite non pseudo- 
membraneuse chez 13. Tous s'en ont survecu. 
Pendant la meme periode, un diagnostic erronne 
de colite pseudo-membraneuse a ete pose chez 
trois patients qui n'avaient pas regu d'antibioti- 
que, qui presentaient un foyer purulent sur la 
muqueuse rectale, et qui sont devenus chroni- 
quement malades. Dans cette serie retrospective,
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un nombre plus grand de colites a ete associe 
aux penicillines qu'a la clindamycine ou a la 
lincomycine. Les patients souffrant de colite 
pseudo-membraneuse ont ete plus serieusement 
malades et leur maladie a ete de plus longue 
duree (31 j v. 15 j, P <  0.01) que ceux qui ont eu 
une colite non pseudo-membraneuse. Ils souf- 
fraient plus souvent de distension abdominale 
(P <0.001), avaient un pouls plus rapide (P <  
0.05) et une temperature plus elevee (P <  0.001) 
ou de plus longue duree (P <  0.001). Le de- 
compte leucocytaire etait plus eleve chez les 
patients atteints de colite pseudo-membraneuse 
(P <  0.005), et les proteines seriques (P <  0.001), 
I'hemoglobine (P <  0.005), le potassium (P <  
0.01), le sodium (P <  0.05) et le dioxyde de car- 
bone total (P <  0.025) etaient plus faibles. Sept 
patients atteints de colite non pseudo-membra­
neuse avaient des lesions “ localisees” a la mu­
queuse du rectum et de I’anse sigmoide; a 
I'endoscopie de rappel, les pseudomembranes 
etaient absentes, meme si la maladie n’avait pas 
ete plus courte (P >  0.05) que celle des patients 
ayant une colite pseudo-membraneuse.
La colite non pseudo-membraneuse et la colite 
pseudo-membraneuse sont des entites clinico- 
pathologiques distinctes, meme si elles parta- 
gent possiblement la meme cause. L'appellation 
colite a la lincomycine ou a la clindamycine n'est 
pas justifiee.
“L incom ycin- clindamycin  colitis” has re­
cently been considered as an entity.1 " 
However, pseudomembranous colitis may 
be associated with lincomycin1 7 and clinda­
mycin^ 812 and may also occur in associa­
tion with other antibiotics,4- 13-15 or with 
no antibiotics at all.1618 In addition, the 
term lincomycin-clindamycin colitis implies 
that this colitis is the result of a specific 
pathologic derangement; in fact these coli- 
tides may present with or without pseudo­
membranes.
Our experience shows that there are clin­
ical and laboratory features which differen­
tiate pseudomembranous colitis (PC) and 
nonpseudomembranous colitis (NPC).
M aterials and M ethods
Between Jan. 1, 1969 and Sept. 1, 1975 
a histologic diagnosis of PC was made in 10
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patients (group 1) and of NPC in 13 pa­
tients (group 2) after antibiotics had been 
administered. During the same period, PC 
was diagnosed three times at endoscopy 
but was not confirmed histologically; the pa­
tients had not received antibiotics and their 
disease became chronic (group 3). In these 
three patients, both clinical and computer- 
aided diagnoses19 were Crohn’s disease of 
the colon, although the pathologic diagnosis 
was more in keeping with ulcerative colitis. 
These cases have been included to emphasize 
the ease with which an erroneous diagnosis 
of PC can be made.
Biopsies were obtained from all patients 
by sigmoidoscopy. Biopsies from all but one 
patient were reviewed by two pathologists 
unaware of the histologic diagnosis made 
previously and of the clinical features. In 
the majority, two or more biopsy specimens 
were available. The first corresponded to 
the early stages of the disease; the other 
specimen or specimens were obtained at 
follow-up.
The following histologic features were 
tabulated: true “fibrin” pseudomembranes 
anchored into dilated crypts; “pus” pseudo­
membranes; atypical epithelial changes; mu­
cosal ulceration; necrosis; vascular conges­
tion; edema; neutrophilic, eosinophilic, 
basophilic, lymphocytic or plasmocytic in­
filtration; muciphages in the mucosa; granu­
lomas; crypt abscesses; mucus plugging of 
crypts; submucosal inflammatory infiltra­
tion; and vasculitis. Each of these parameters 
was graded from 1 to 4 according to the de­
gree of severity. A correlation was made 
later with the clinical history of each case. 
There was 100% agreement between ob­
servers on the presence or absence of all 
features and minor disagreement on the 
grading.
Groups 1 and 2 were compared by Stu­
dent’s t-test and, where applicable, the chi- 
square test.
R esu lts
Antecedent Factors
Antibiotics.—The penicillin class of anti­
biotics was responsible for colitis in six 
cases in group 1 and five in group 2 com­
pared with three and five cases, respectively, 
for the lincomycin-clindamycin class (Table
TABLE I.—Antibiotic T reatment P rior to 
Colitis
Antibiotic
N o . o f patients 
Group 1 Group 2
Ampicillin.......................... 4 3
Penicillin............................ 1 1
Amoxicillin......................... 1 —
Cloxacillin.......................... — 1
Clindamycin...................... 3 2
Lincomycin........................ — 3
Methicillin/sulfisoxazole/
chloramphenicol............ 1 —
Cloxacillin/ampicillin. . . . — 1
Erythromycin/ampicillin. 
Sulfadiazine /  sulfathiazole/
1
sulfamerazine................ — 1
Total........................... 10 13
I). The distribution within the two classes 
was similar for groups 1 and 2 despite the 
marked preponderance of the penicillin class 
in group 1 (P >  0.05). Overall, 47% of 
colitides followed the administration of a 
penicillin derivative compared with only 
35% for lincomycin-clindamycin. This pre­
dominance of the penicillin over lincomy­
cin-clindamycin does not take into account 
the fact that several patients received a com­
bination that included an antibiotic of the 
penicillin group and not of clindamycin or 
lincomycin. None of the patients with in­
determinate colitis had received antibiotics.
Surgery.—PC developed in three patients 
and NPC in three after operation. There 
was no apparent relation between the two 
groups with respect to the type or the 
gravity of the procedure.
Pregnancy.— PC developed in three 
women who received antibiotics (clindamy­
cin, one and ampicillin, two) while they were 
pregnant.
Clinical features.—There were more 
women than men, and this sex distribution 
was significantly (P <  0.02) different from 
an equal one (Table II). A spectrum of clin­
ical manifestations was recognized in both 
groups. When first seen, patients were either 
ambulant or very sick; generally, patients in 
group 1 were more sick than those in group 
2. One patient was admitted to the hospital 
for acute abdominal pain of unspecified na­
ture. Diarrhea developed during the first 
night in hospital and pseudomembranes were 
visualized at endoscopy the next morning.
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Fig. la  Fig. lb  Fig. lc
Fig. 1.—Proctoscopic appearance of pseudomembranous colitis (PC), (a) On admission — yellow, dome-shaped, smooth, well-delimited patches are separated by erythematous mucosa without vascular pattern; (b) 1 week after admission — diffusely granular mucosa without vascular pattern. No free bleeding was present but contact bleeding could be elicited; (c) 2 weeks after admission — healed granular aspect of mucosa where vascular pattern begins to show.
Fig. 2a Fig. 2b Fig. 2c
Fig. 2.—When membrane (a) is sucked off, it leaves small bleeding ulcer (b). Membranes can be confluent to the point of covering almost entire mucosa (c).
Fig. 3a Fig. 3b Fig. 3c
Fig. 3.—(a) During recovery phase of PC, mucosal folds often appear strikingly edematous, (b) Focal accumulation of pus in indeterminate colitis may mimic PC. (c) Target image in non- pseudomembranous colitis (NPC).
July 1977 THE CANADIAN JOURNAL OF SURGERY 329
TABLE II.—Clinical Features
Group
Difference 
between a and b 
(P value or N S)Feature
I*
(n = 10)
2b
(n = 13)
3
(n = 3)
Age, yr, range (and mean).......... 19-68 (42) 28-77 (46) 21-36 NS
Sex, women/men........................... 9/1 9/4 3/0 NS
Delay in diagnosis, d, range (and 
mean).......................................... 1-150 (40) 5-240 (44) 15 d-3 yr NS
No. of patients with abdominal 
pain on palpation...................... 5 2 3 NS
No. of patients with abdominal 
distension................................... 8 0 2 <  0.001
No. of patients with rectal 
bleeding...................................... 2 7 3 NS
Pulse on admission, beats/min, 
range (and m ean)..................... 70-144 (102) 70-100 (87) 107 <  0.05
Average blood pressure on ad­
mission, mm Hg, systolic/ 
diastolic....................................... 126/75 136/85 102/60 NS
Temperature range on admission, 
°C, range (and m ean).............. 36-39.4 (37.5) 36-37 (36.8) 37-38 <  0.005
Highest temperature in hospital 
°C, range (and m ean).............. 37-39.8 (38.8) 36.8-37.8 (37) 38.6-40.2 <  0.001
Duration of temperature after 
diagnosis, d ................................ 2-58 0-1 1-7 <  0.001
Group 2 .— Seven patients had “target” 
lesions —  several 2- to 3-mm pale-white 
spots completely surrounded by a 2-mm 
erythematous rim. The image was neither 
elevated nor depressed from the surround­
ing mucosa. These patients had received a 
penicillin (three times), lincomycin (twice), 
clindamycin (once) or a sulfonamide (once) 
combination. One patient with target lesions 
consistently denied having ingested anti­
biotics. After endoscopy, she acknowl­
edged that she had been taking pills for a 
sore throat that later were found to contain 
penicillin. The other six patients had vari­
ous combinations of edema, patchy absence 
of vascular pattern, focal accumulation of 
pus, granularity and erythema of the mucosa 
(Fig. 3).
Group 3 .—The “pseudomembranes” diag­
nosed at endoscopy were only focal ac­
cumulations of pus; they had hazy contours 
and could be aspirated (Fig. 3). In two of 
the three cases there was at least one dis­
crete ulcer in the rectum or sigmoid colon 
and one patient also had an anal ulcer. 
(None of the patients in groups 1 and 2 had 
ulceration.)
Histologic Examination
The previously reported histologic fea­
tures of PC were present in nine of our 
group 1 patients. The dilated crypts ap­
peared plugged with mucus and fibrin and
Bowel sounds were normal, increased or 
decreased in all three groups, with no obvi­
ous pattern. Because of the subjective nature 
of the evaluation of this sign, no statistical 
analysis was performed on the data.
Endoscopic Image
Group 1 .— In all patients the macro­
scopic diagnosis was confirmed by frozen- 
section examination of a biopsy specimen. 
In five patients the membranes were white 
and in three they were yellow. In one pa­
tient the lesions were clearly confluent. The 
membranes were well delimited, firmly 
attached to the underlying mucosa and 
could not be aspirated. They had to be 
avulsed from the mucosa and this left a 
raw bleeding surface. In two patients, there 
were large pseudomembrane-covered pseu­
dopolyps (diameter, 0.5 to 3 cm). Between 
the pseudomembranes, the mucosa was 
fiery red. The membranes were present 
throughout the region examined at endo­
scopy. In the only patient treated by resec­
tion they covered the entire colonic surface 
and ended abruptly at the ileocecal valve. 
During the recovery phase, the mucosa had 
either a healed granular appearance indis­
tinguishable from ulcerative colitis, or ap­
peared edematous, while the membranes dis­
appeared and the vascular pattern became 
apparent. Focal accumulation of pus was 
not evident (Figs. 1 to 3).
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Fig. 4a
Fig. 4b
Fig. 4c
Fig. 4.—(a) Macroscopic and (b, c) microscopic images in PC (hematoxylin and eosin, [b] x 25, [c] x 63).
the mucosal surface had an adherent, well- 
anchored fibrin pseudomembrane, beneath 
which focal superficial ulceration was oc­
casionally present (Fig. 4).
One patient considered to have NPC by 
endoscopic examination had “pus” pseudo­
membranes at the surface made up of poly­
morphonuclear neutrophils, some mucus and 
fibrin and not anchored to the underlying 
mucosa. Dilated crypts were not found. The 
mucosal surface underneath these “pus” 
pseudomembranes had few ulcers (Fig. 5). 
The pus membranes did not stand the trau­
ma of going through the various steps of 
frozen-section evaluation, in contrast to the 
true fibrin pseudomembranes. Crypt abs­
cesses were a constant and prominent fea­
ture in groups 1 and 3; they were seen 
occasionally in group 2.
Vascular congestion of capillaries within 
the lamina propria, and edema of mucosa 
and submucosa were constant features in 
groups 1 and 2.
The type of inflammatory infiltration was 
not a diagnostic feature. There was no vas­
culitis and granulomas were never seen.
Submucosal involvement was not a fea­
ture in either group 1 or group 2. In con­
trast, the submucosa was clearly involved in 
two patients in group 3.
Atypical epithelial proliferation was not 
identified in groups 1 and 2, but was a 
noticeable feature in group 3.
Radiologic Examinations
Abnormal findings on plain radiographs 
of the abdomen were visualized in all but 
one patient and included edema of the 
colonic mucosa, particularly above the recto­
sigmoid junction (four patients), gaseous dis­
tension, sometimes up to 12 cm, of the 
transverse colon (three patients), air-fluid 
levels in the transverse colon (two patients) 
and ascites (two patients) (Fig. 6).
A barium enema was done in three group 
1 patients. There was edema of the bowel 
wall with spicules and pseudopolyps. Ulcers 
in the transverse and descending colon were 
reported in only one patient. Control barium 
enemas done in the recovery phase were 
normal (Fig. 7). Only one of the barium 
enemas done in group 2 patients was abnor­
mal; it showed mild edema of the descending 
colon. All three barium enemas in group 3
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Fig. 5.—“Pus” pseudomembrane in NPC. There is no fixation of membrane to mucosa. It can be 
aspirated easily at endoscopy and is dislodged during manipulations of frozen-section examination. 
Underlying crypts are not dilated and mucosa is focally ulcerated. This type of membrane was 
found only in a few group 2 patients (hematoxylin and eosin, x 200). Insert is enlargement of mucosal 
surface (x 250).
Fig. 6.—Massive dilatation and thumb-printing 
of colon may be seen on plain film of abdomen 
during acute episode. Air-fluid levels may be 
visualized, as in this figure, in the recovery phase.
were abnormal; two disclosed ulcers and 
skip areas, and in one the findings indicated 
a diagnosis of universal ulcerative colitis.
Laboratory Examinations 
The pertinent features of the laboratory 
investigations are shown in Table III. Clos­
tridium cadaveris was cultured from the
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Fig. 7.—Pseudopolyps due to massive edema may be present anywhere in colon and mimic deep 
fissuring.
blood of one patient. This patient also had 
protein-losing enteropathy; of a dose of 
radioactive chromium chloride given intra­
venously, 2.6% was excreted in the feces 
during the next 4 days (normal, < 0.8%).
The development of a normocytic anemia 
was frequent in the course of PC but not of 
NPC.
Treatment
Treatment followed no set protocol. Of 
note is that three patients received clinda­
mycin as part of their therapy. At the time, 
this antibiotic was not recognized as an
underlying cause of PC or NPC. In retro­
spect these patients had all received clinda­
mycin before the onset of diarrhea. Yet they 
all recovered despite the administration of 
clindamycin associated with adrenocortico­
tropic hormone (ACTH) (Table IV).
In addition to steroids and antibiotics, 
supportive and replacement therapy was 
prescribed. One patient with an erroneous 
diagnosis of perforated viscus underwent 
operation; 3000 ml of straw-coloured, sterile 
fluid was present in the abdomen but there 
was no perforation. The bowel was edema­
tous. A right hemicolectomy was performed 
and only then was the diagnosis made.
TABLE III.—Laboratory Features
Feature
Group
! “■ 2b 3
in = 10) (« = 13) in = 3)
Difference 
between a and b 
(P value or NS)
No. of patients with Staphylococ­
cus aureus in stool...................  4
Maximal leukocyte count, X
109/l, range (and mean).........  5.4-33.4 (18.
Lowest protein concentration,
g/dl, range (and mean)...........  4.2-7 (5.5)
Lowest hemoglobin concentra­
tion, g/dl, range (and mean). . 9-13 (11.3)
No. of patients with serum po­
tassium concentration, below
4 m m ol//..................................  6
No. of patients with serum so­
dium concentration below 140
mmol//.....................................  7
Lowest serum chloride concen­
tration, mean mmol//.............  99
No. of patients with carbon 
dioxide content below 24 
mmol//.....................................  6
0 0 < 0.025
2) 4.4-16.6 (7.9) 6.3 - 18.3 < 0.005
5.9-7.9 (7.0) 4-5 < 0.001
11.4-16.6 (13.8) 9-12 (10.9) < 0.005
0 2 < 0.01
3 0 < 0.05
103 95 NS
2 1 < 0.025
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TABLE IV.—T reatment in Groups 1, 2 and 3
Group
1 2 3
T reatment (:n = 10) In = 13) (» =  J)
Steroids:................. 6 l 1
Betamethasone diso-
dium phosphate
1 1enema.....................
Hydrocortisone........ 2
ACTH...................... 2
ACTH/prednisone.. 
Hydrocortisone
1
foam/hydrocortisone/ 
prednisone/ACTH. 1
Antibiotics:.................. 7 1 3
Salicylazosulfa-
pyridine..................
Clindamycin/peni-
2 1 3
cillin/gentamicin .. 
Clindamycin/peni-
2
cillin /gentamicin/ 
salicylazosulfa- 
pyridine.................. 1
Nystatin/salicyla- 
zosulfapyridine. . .. 
Sulfamethoxazole /
1
nystatin .................. 1
Outcome
All patients in groups 1 and 2 remained 
disease-free for at least 1 year. In contrast, 
all patients in group 3 had a chronic course. 
Diarrhea lasted an average of 31 days 
(range, 9 to 60 d) in group 1, but only 15 
days (range, 2 to 74 d) in group 2 (P <  
0.05). The shortest duration of diarrhea after 
diagnosis in group 1 was that of the patient 
who underwent operation. In this group, 
eight patients had diarrhea after diagnosis 
for more than 1 week, seven for 2 and five 
for 3 weeks, while the figures in group 2 
were 6, 3 and 1, respectively (P <  0.01). 
Pseudomembranes did not develop in any 
patient in group 2 during follow-up.
D iscussion
Pseudomembranous colitis and nonpseu- 
domembranous colitis both occur after anti­
biotic therapy but differ in many aspects; 
these differences can be summarized by the 
statement that the former is a much more 
serious disease. One might argue that pa­
tients with PC were simply seen later in the 
course of their disease. However, the aver­
age duration of diarrhea prior to diagnosis 
was longer in patients with NPC. Patients 
seen as early as 1 day (PC) and 5 days 
(NPC) after the onset of symptoms also
differed with respect to all features. Finally, 
in all patients with NPC who had a target 
image at endoscopy, administration of the 
antibiotic was stopped and control examina­
tions were done weekly until recovery was 
complete; no pseudomembrane developed. 
Thus, no link can be made between NPC 
and PC except for a common previous in­
take of antibiotics and a full recovery from 
the disease. Another study20 has shown 
that in clindamycin-associated colitis, 25% 
of patients in whom PC was diagnosed ma- 
croscopically did not have pseudomem­
branes in the biopsy specimen. It is thus 
incorrect to consider PC and NPC as similar 
clinical entities.
Clindamycin and lincomycin have been 
incriminated recently in the production of 
colitis.1' 12 Lincomycin was recognized as 
capable of producing “ulcerative” colitis in 
1963.21 Two papers were published on the 
association in 1970, 6 in 1973, and 40 in 
1974. Yet in this study, more colitides were 
associated with antibiotics of the penicillin 
group. This association22’ 23 has also been 
reported after the administration of tetra­
cycline.14' 24 To attribute the production of 
colitis to one or another antibiotic is mean­
ingless because the harvest of colitides re­
flects the sales of various antibiotics; in this 
regard, this study is also retrospective be­
cause patients entered it after the onset of 
symptoms. .Recently in our experience, coli­
tis secondary to clindamycin has been vir­
tually replaced by colitis secondary to 
amoxicillin and cloxacillin.
This study does not yield much informa­
tion on the pathogenesis of this disease(s). 
More women than men had either PC or 
NPC and more patients with PC had Sta­
phylococcus sp. in their stools. It is notable 
also that three patients received clindamycin 
as part of their therapy for a disease sec­
ondary to its administration. This does not 
mean that we advocate the use of clindamy­
cin or any other antibiotic in the therapy of 
this type of colitis. The point it brings 
forward, however, is that the administration 
of an antibiotic is not the only agent im­
plicated in the production of these diseases. 
It should be noted here that these patients 
received concurrently ACTH, which in 
animals seems to prevent the adverse effects 
of clindamycin on stool consistence (Robert
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A: Personal communication, 1975). In one 
of our patients Cl. cadaveris was cul­
tured from a rectal biopsy and from the 
blood; this may have been a secondary in­
fection but the organism has been implicated 
in necrotizing25'27 and pseudomembranous 
colitis.28'31 Possibly the distended trans­
verse colon in this patient was secondary 
to the elaboration of “toxins” by the patho­
gens.32' 33 Bowel obstruction18’ 34 did not 
precede colitis in this study. Three women 
became symptomatic in the latter stages of 
their pregnancy; three similar cases have 
been reported.3' 13 After childbirth, there 
was a notable increase in the severity of the 
diarrhea, which brought these patients to 
our attention. A flare-up of symptoms in 
the early postpartum period has also been 
recognized in both ulcerative colitis and 
Crohn’s colitis.35’ 36 Of the six patients who 
underwent surgery, only two had an ab­
dominal procedure.
Most patients in whom NPC and PC de­
veloped had received antibiotics for ques­
tionable indications. A review of the 
adverse-reaction files of the company that 
produces clindamycin and lincomycin yielded 
little information of scientific value. A 
correlation between a specific drug and a 
specific disease has no cause-effect implica­
tion, especially if other drugs are given. 
These files also indicated the dangers of 
erroneous diagnosis: some patients with 
pseudomembranous colitis underwent proc­
tocolectomy for “toxic megacolon”. Ap­
parently, this group of diseases is largely 
iatrogenic and this factor is giving unneces­
sary fuel to emotional responses from lay 
people.37
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PREOPERATIVE IRRADIATION IN OPERABLE CANCER OF 
THE RECTUM: REPORT OF THE TORONTO TRIAL*
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L. J. MAHONEY, MD, FRCS[C]§ and C. T. ROBERTSON, MD, FRCS[C]||
The authors have studied the value of preoper­
ative radiotherapy in 125 patients with cancer 
of the rectum. The patients were divided into 
two groups, control (no irradiation) and experi­
mental (irradiation), and according to Dukes' path­
ological stage. The crude survival indicated no 
difference between the two groups, but analysis 
by stage and group demonstrated that for pa­
tients with a Dukes' stage C lesion, 500 rads of 
cobalt-60 gamma irradiation a few hours before 
excision of the lesion approximately doubles the 
probability of survival at 5 years. The prospect 
of surgical cure is three times higher in cancers 
arising above the peritoneal reflection than in 
those arising below it. If the practice of abdo­
minoperineal resection is to continue the auth­
ors recommend that preoperative irradiation be­
come a routine procedure.
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Cancer Treatment and Research Foundation.
♦Director, radiation oncology, The Princess Mar­
garet Hospital, Toronto, Ont.
tSurgeon, Toronto General Hospital.
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Les auteurs ont etudie la valeur de la radiothe- 
rapie preoperatoire chez 125 patients atteints de 
cancer du rectum. Les patients ont ete repartis 
dans deux groupes, un groupe temoin (sans irra­
diation) et un groupe experimental (irradie), se- 
lon la classification par stade pathologique de 
Dukes. La survie brute n'a indique aucune diffe­
rence entre les groupes, mais I'analyse par stade 
et par groupe a demontre que pour les patients 
souffrant d'une lesion au stade C de Dukes, une 
irradiation gamma de 500 rads au cobalt-60 pra­
tique quelques heures avant I'excision de la le­
sion, double approximativement la probability de 
survie a 5 ans. La perspective d'une guerison 
chirurgicale est trois fois meilleure dans les 
cancers survenant au dessus du repli peritoneal 
que dans ceux qui prennent naissance en des- 
sous. Si la resection abdominoperitoneale doit 
demeurer pratique courante, les auteurs preco- 
nisent le recours systematique a I’irradiation 
preoperatoire.
Preoperative irradiation has been advo­
cated for at least 40 years, but no conclusive 
results have been forthcoming until recently. 
In 1964, Powers and Tolmach,1 reporting 
on an animal study, suggested that a single 
preoperative dose of 500 rads enhanced sur­
vival, provided that the surgery was car­
ried out less than 8 hours after the irradia­
tion.
336 THE CANADIAN JOURNAL OF SURGERY Vol. 20
Powers’ hypothesis had many attractive 
features for application to man, not least of 
which was the absence of delay between the 
irradiation and surgery; both could be done 
on the same day.
We have evaluated preoperative radiothe­
rapy by examining its value in cases of can­
cer of the rectum. Our choice of rectal can­
cer for a study of preoperative irradiation 
was determined by a number of factors, one 
of which was the report by Stearns, Berg and 
Deddish2 that preoperative irradiation en­
hanced the 5-year survival in Dukes’ stage 
C cancer of the rectum.3
Three of us (LJM, JAP and WDR) drew 
up a protocol that was sent to all surgeons 
in the Toronto region. Some 30 surgeons en­
tered a total of 125 patients into the study 
over a 6-year period. The slow rate of entry 
and the absence of any trend in survival dur­
ing the early years caused the study to die a 
natural death. However, further analysis of 
the accumulated data in August 1974 and a 
final update in July 1976 demonstrated a 
statistically significant difference in survival. 
This difference affected only stage C disease 
and mirrors the results of Roswit, Higgins 
and Keehn.4
M et h o d s
Protocol
Surgeons were invited to enter their pa­
tients into the study if the following criteria 
were fulfilled:
1. Adenocarcinoma of rectum was con­
firmed by biopsy.
2. The site of origin included any part of 
the rectum below the pelvic brim.
3. The tumour was considered on clinical 
grounds to be operable —  that is, there was 
evidence of fixation and no distant meta- 
stases.
Randomization
Patients were randomly divided into two 
groups, control and experimental, by draw­
ing envelopes out of a pre-prepared box, 
serially. If the card indicated “experimental” 
the patient received gamma irradiation. If 
the card indicated “control” the patient was 
subjected to a “sham irradiation” of similar 
duration to those who received gamma irra­
diation.
Consent
At the time this trial was started consent, 
informed or otherwise, was not in vogue. 
However, patients were informed verbally 
that “this treatment was being given in the 
hope of improving their chances of cure”.
At their request the surgeons were not in­
formed as to whether their patient was in the 
control or experimental group, because they 
felt that this knowledge might influence their 
surgical judgement.
Radiation Procedure
All patients were “marked up” on ad­
mission; the field of irradiation (15x18 cm) 
extended upwards from the level of the anus 
and adequately covered the pelvis to the 
upper border of the sacrum. A special dou­
ble-headed cobalt-60 unit was used for all 
patients, which meant that anteroposterior 
and posteroanterior fields were irradiated 
concurrently. A tumour dose of 500 rads 
was delivered at the mid-plane in a 6- to 8- 
minute session.
Complications
There were none. One patient died post- 
operatively from intractable loss of serum 
from the perineal wound, and this was clas­
sified by his surgeon as a radiation complica­
tion. However, when the randomization code 
was broken it was found that this patient was 
in the control group.
TABLE I.—Site of Tumour by T ype of Operation in 125 Patients with Carcinoma of the Rectum
Operation
Abdominoperineal Abdominal
Site resection resection Laparotomy Total
Above peritoneal reflection..................  29 26 — 55
Below peritoneal reflection................... 65 4 1 70
Total 94 30 1 125
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Follow-up
The original intention was to have the 
follow-up carried out by the surgeon, with 
reports sent to the biostatistical department 
of the Princess Margaret Hospital. In fact 
the biostatistical department had to trace 
many of these patients, but eventually 100% 
follow-up was achieved. Because of the dif­
ficulty in follow-up it was impossible to de­
termine the exact cause of death, such as 
distant metastases, local recurrence and 
other causes.
Staging
Dukes’3 pathological staging was used 
without modification, based on review of all 
operative and pathological reports supplied 
by the cooperating surgeons. These records 
were of high quality and enabled us to split 
the series by type of procedure into cancers 
above and below the peritoneal reflection 
(Table I).
R esults
Table II shows the distribution of patients 
by stage and group. In Fig. 1 the crude sur­
vival of all cases is broken down into radia­
tion category. Clearly there is no difference 
between the two groups. The overall survival 
rate was 35 to 40% at 5 years and ±30%  
at 7 years.
Analysis by stage and group showed no 
differences except in stage C (Fig. 2). The 
probability of survival in the irradiated group 
was approximately twice that of the control 
(P =  0.014).
The only other finding of consequence was 
the difference in survival of patients with 
cancers arising above, and below, the peri-
TABLE II.—D u k e s ’ Staging  in  125 P a tien ts  
w it h  C arcinoma  o f  th e  R ectum
Group
Dukes’ stage Control Experimental Total
A ......................  24 15 39
B ......................  16 13 29
C ......................  16 22 38
D*.................... 9 10 19
Total___  65 60 125
*Patients found to have hepatic metastases at time 
of resection of cancer.
toneal reflection (Fig. 3). The probability of 
survival was three times greater for cancers 
above the peritoneal reflection than below. 
This difference is unexplained at present and 
is not necessarily in accord with current 
teaching, or many other publications.
Years
Fig. 1.—Survival of patients with rectal carcino­
ma in control (---- ) and irradiated (------ ) groups.
Years
Fig. 2.—Survival of patients with Dukes’ stage
C rectal carcinoma in control (---- ) and irradiated
(------ ■) groups.
Yeors
Fig. 3.—Survival of patients with rectal carcino­
ma above and below peritoneal reflection.
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D iscussion
This small study demonstrates that pre­
operative irradiation materially benefits the 
patient suffering from Dukes’ stage C rectal 
cancer. The technique of delivering the ir­
radiation is simple, atraumatic, free of com­
plications and does not delay operation. 
Thus, there can be few arguments against its 
universal use since it upgrades the probabi­
lity of survival by one stage from C to B 
approximately, particularly in cancers aris­
ing below the peritoneal reflection.
The mechanism of action is uncertain. 
Whether this is due to direct radiation cell 
death, or to the initiation of some obscure 
immunologic process is unknown, but is 
worthy of investigation.
Conclusions
Cobalt-60 gamma irradiation (500 rads) 
delivered to the whole pelvis a few hours 
before surgical excision of Dukes’ stage C 
rectal cancer approximately doubles the 
probability of survival at 5 years.
In this series the prospect of surgical cure 
was three times higher in cancers arising 
above the peritoneal reflection than in those 
arising below it.
If the practice of abdominoperineal exci­
sion is to continue,5 it is suggested that this 
form of preoperative irradiation become 
routine.
We thank the cooperating surgeons for their 
help; the biostatistical department of the Princess 
Hospital and the many radiation oncology resi­
dents who carried out the irradiations in the early 
hours of the morning. We also thank Dr. Alex 
Phillips, statistician of the National Cancer Insti­
tute of Canada for setting up and donating the 
randomization procedure.
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ANGIOSARCOMA OF THE BREAST*
SERGE R. MASSE, MD, FRCP[C], C. JACQUES MONGEAU, M D and 
ANDRE RIOUX, MD, FRCS[C]
The authors report a case of angiosarcoma of 
the breast. The patient, a 44-year-old woman, 
remains free of disease 7 years after biopsy 
and 6 years after a simple mastectomy. The 
authors emphasize the benign appearance of 
the tumour and the importance of early detec­
tion and adequate surgical treatment.
Les auteurs presentent un cas d'angiosarcoma 
du sein. La patiente, une femme de 44 ans, 
demeure sans evidence de recidive 7 ans apres 
biopsie et 6 ans apres une mastectomie simple. 
Les auteurs soulignent I'apparence benigne de 
la tumeur, et (’importance d’un diagnostic pre- 
coce et d'un traitement chirurgical adequat.
P r im a r y  angiosarcoma of the breast is a 
rare neoplasm. Under the term “metastasiz­
ing hemangioma”, Borrmann1 reported the 
first well-documented case. Other terms 
used in the literature include angiosarcoma, 
hemangioblastoma, hemangioendothelioma 
and hemangiosarcoma.2 In their excellent 
review of the literature, Gulesserian and 
Lawton2 collected 42 cases including their 
own. Since then, another eight cases have 
been reported3'9 giving a total of 51 docu­
mented cases. Watanabe and Nakano7 
mentioned three cases in the Japanese litera­
ture but failed to provide references. Angio­
sarcoma of the breast possesses distinctive 
clinicopathologic features; thus, misdiagno­
sis is merely a reflection of its rarity and 
often deceptive benign microscopic appear­
ance. The disease generally runs a rapidly 
fatal course with death resulting from blood- 
borne metastases. Only three long-term sur­
vivors (>  5 yr) have been reported.8' 10
The case described below is the second 
report in the Canadian literature.8 It is 
interesting that long-term survival was 
achieved in both cases.
C ase R e p o r t
A 44-year-old Caucasian woman was ad-
*From the departments of pathology and surgery, 
Centre Hospitalier Universitaire, University of 
Sherbrooke, Sherbrooke, PQ.
Reprint requests to: Dr. Serge R. Masse, Depart­
ment of pathology, Centre Hospitalier Universi­
taire, Sherbrooke, PQ J1H 5N4.
mitted to another hospital with a 2-cm mass 
medial and superior to the right nipple. The 
findings from excision biopsy were reported 
as mammary dysplasia. The patient remained 
well for 8 months but then noticed a recur­
rent tender mass that was enlarging slowly. 
Physical examination at the Centre Hospitalier 
Universitaire revealed a tender, mobile 
mass, measuring 4 x 3  cm, in the right sub­
areolar region; further investigations were 
negative. A biopsy was performed and a pre­
liminary diagnosis of angiosarcoma made. 
Several consultants from the Canadian Tu­
mour Reference Centre concurred with the 
diagnosis. Two weeks after the biopsy, the 
mass recurred and slowly enlarged. A right 
simple mastectomy was performed. Dissection 
of the removed breast revealed a tumour that 
measured 2.0 x 2.5 cm and was pink in colour. 
The patient has been followed up at regular 
intervals for 6 years and has remained free 
of local or metastatic disease.
P ath o lo g y
The features in the two biopsy and mas­
tectomy specimens were so similar as to 
allow a common histopathologic descrip­
tion. Tumour architecture varied from one 
area to another but, although transition 
zones were frequent, two patterns of growth 
could be identified. The first was an angio­
matous pattern with the formation of dilated 
vascular channels (Fig. 1). Frequent anas­
tomoses were seen; these resulted in an in­
tricate network of dissecting collagen 
bundles and adipose tissue. The walls of 
the neoplastic vessels were thin and the lin­
ing cells appeared to be in contact with the 
stromal collagen. The endothelial cells were 
spindle shaped. In some areas they ap­
peared normal; however, in most places they 
showed nuclear enlargement and hyper- 
chromasia. At times prominent endothelial 
cells were seen budding into the lumen. 
Most lumina were empty or contained coa­
gulated proteinaceous material. Character­
istically these angiomatous formations ap­
peared to extend beyond the gross bound­
aries of the tumour.
The second pattern was a solid tumour 
of spindle cells arranged in compact bundles;
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Fig. 1.—Angiomatoid appearance of tumour 
with intercommunicating vascular channels lined 
by atypical endothelial cells in contact with strom­
al collagen (hematoxylin and eosin, reduced by 
40% from x 480).
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Fig. 2.—Solid tumour pattern with encroachment 
on lobular breast tissue (hematoxylin and eosin, 
reduced by 40% from x 250).
in these areas vascular channels could not 
be easily recognized. Where present the 
channels often dissected and encroached on 
the ductal and lobular breast tissue (Fig. 2). 
The nuclei were generally larger than in the 
angiomatous areas; they had a plump ap­
pearance and small nucleoli could be seen 
in a few cells. On careful examination, clefts 
and cytoplasmic vacuoles were observed; 
these formed a sponge-like network of abor­
tive vessels. Red blood cells were seen with­
in the lumina and in the stroma; this gave 
the lesion some histologic similarity to 
Kaposi’s sarcoma (Fig. 3). These spindle 
cell areas were not well circumscribed; at 
their periphery neoplastic cells blended with 
the breast stroma (Fig. 4).
D iscussion
Angiosarcoma of the breast is almost al­
ways fatal; the patient usually dies with 
widespread metastases within 2 years.2 The 
short survival time no doubt reflects the 
aggressive and malignant nature of the neo­
plasm. However, this low salvage rate may 
also indicate that both clinicians and pathol­
ogists lack familiarity with this rare tumour; 
misdiagnosis, delay in diagnosis and failure 
to initiate prompt and adequate surgical 
therapy may result.
Because of its deceptive benign appear­
ance, many cases have been mistakenly diag­
nosed as an angioma2' 3 or an organizing 
hematoma.8 Benign vascular tumours, such 
as the perilobular angioma, have been de­
scribed but they never form a palpable 
mass.11 All reported cases of angiosarcoma 
have presented as an undiagnosed mass or 
an enlargement of the affected breast. An­
giosarcomas may arise in pre-existing peri­
lobular angiomas or de novo, but the clin­
ical and histologic features are distinctive 
and a precise diagnosis should be possible 
since reliable diagnostic criteria have been 
well documented.10’ 12
Though the choice of surgical treatment 
appears controversial, it is essential that the 
disease be eradicated locally. Infiltration by 
tumour tends to extend beyond the limits 
defined by gross palpation and may, as in 
our case, account for the high recurrence 
rate after excisional biopsy. Long-term sur­
vival has been achieved with a wide local 
resection,10 a modified radical mastec-
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Fig. 3.—Higher power view of Fig. 2 showing 
pattern reminiscent of Kaposi’s sarcoma (hema­
toxylin and eosin, reduced by 40% from x 480).
Fig. 4.—Margin of tumour with blending of neo­
plastic and normal breast stroma (arrows) (hema­
toxylin and eosin, reduced by 40% from x 250).
tomy,8 a radical mastectomy10 and, as in 
our case, with a total (simple) mastectomy. 
Since no axillary node metastases were 
found in the patients who submitted to 
radical or modified radical mastectomy, 
it seems logical to recommend a total (sim­
ple) mastectomy. Wide local resection should 
be considered with caution because the 
tumour invades microscopically beyond the 
palpable margins of the lesion.2
Our case presented several unusual fea­
tures. The patient received definitive treat­
ment only 14 months after the first biopsy 
and the tumour recurred twice during that 
period. The rapid recurrence noted after 
the second biopsy could not be explained 
by the histologic features, which were not 
highly malignant; however, post-biopsy rep­
arative granulation tissue could account for 
part of the mass present. Finally, the patient 
is alive and free of any disease more than 
7 years after the tumour was first noted and 
6 years after definitive treatment.
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Three versatile Lilly antibiotics
f Keflin I.V. Kefzol I.M.
cephalothin sodium cefazolin sodium
neutral
Keflex Oral
cephalexin
ACTION
In-vitro tests demonstrate the cephalosporins 
are bactericidal by the inhibition of cell wall 
synthesis.
INDICATIONS
Keflin may be indicated for the treatment of 
infections of the respiratory tract, skin and soft 
tissues, bones and joints, genito-urinary tract, 
peritoneum, and in septicemia and endocarditis 
when the infection is caused by susceptible 
organisms.
CONTRAINDICATION
Keflin is contraindicated in persons who have 
shown hypersensitivity to cephalosporin 
antibiotics.
WARNINGS
Before cephalothin therapy is instituted, careful 
inquiry should be made concerning previous 
hypersensitivity reactions to cephalosporins 
and penicillin.
There is some evidence of partial cross-aller­
genicity of the penicillins and cephalosporins. 
Patients have been reported to have had severe 
reactions (including anaphylaxis) to both drugs.
PRECAUTIONS
Prolonged use of Keflin may result in the over­
growth of non-susceptible organisms. To avoid 
unnecessarily high serum concentrations of 
Keflin in patients with impaired renal function, 
the dosage schedule of Keflin should be adjusted. 
Administration of more than 6 g per day of Keflin, 
for more than three days, may be associated with 
thrombophlebitis, and the veins may have to 
be alternated.
A false-positive reaction for glucose in the urine 
may occur with Benedict's or Fehling’s solution 
or with Clinitest tablets, but not with Tes-Tape. 
The safety of this product for use during preg­
nancy has not been established.
ADVERSE REACTIONS
The following adverse reactions have been 
reported:
Hypersensitivity -  Maculopapular rash, urticaria, 
eosinophilia, drug fever, reactions resembling 
serum sickness, and anaphylaxis.
Blood-Neutropenia, thrombocytopenia, haemo­
lytic anemia, and positive direct Coomb's test. 
Hepatic and Renal-Transient rise in SGOT,
BUN, and alkaline phosphatase levels without 
clinical evidence of renal or hepatic impairment. 
Other-Pain, induration, tenderness, and 
elevation of temperature with repeated intra­
muscular injections; thrombophlebitis has 
occurred and is usually associated with intra­
venous daily doses of over 6 g for more than 
three days.
DOSAGE RANGE
In adults, a dosage of 500 mg every six hours is 
adequate in uncomplicated pneumonia, furuncu­
losis with cellulitis, and most urinary tract 
infections.
In severe infections, the dose may be increased 
to 1 g every four hours.
In life-threatening infections, doses of up to 2 g 
every four hours may be required.
DOSAGE FORMS
Keflin is available in dry powder form in individual 
rubber-stoppered vials:
1 g (equivalent to cephalothin) 10 ml size
2 g (equivalent to cephalothin) 100 ml size 
4 g (equivalent to cephalothin) 100 ml size 
Further information is available on request.
INDICATIONS
Kefzol may be indicated in the treatment of 
infections of the respiratory tract, genito-urinary 
tract, skin and soft tissues, bone and joint, and 
in septicemia and endocarditis when the 
infection is caused by susceptible organisms.
PRECAUTIONS
Prolonged use of Kefzol may result in the over­
growth of non-susceptible organisms.
To avoid unnecessarily high serum concentra­
tions of Kefzol in patients with impaired renal 
function, the dosage schedule of Kefzol should 
be adjusted.
Safety of this product for use in premature infants, 
in infants under one month of age, or during 
pregnancy has not been established.
A false-positive reaction for glucose in the urine 
may occur with Benedict’s or Fehling's solutions 
or with Clinitest tablets, but not with Tes-Tape.
WARNINGS
Before cefazolin therapy is instituted, careful 
inquiry should be made concerning previous 
hypersensitivity reactions to cephalosporins and 
penicillin.
There is some clinical and laboratory evidence of 
partial cross-allergenicity of the penicillins and 
the cephalosporins. Patients have been reported 
to have had severe reactions (including anaphyl­
axis) to both drugs.
ADVERSE REACTIONS
The following reactions have been reported: 
Hypersensitivity-Drug fever, skin rash, vulvar 
pruritus and eosinophilia.
Blood-Neutropenia, leukopenia, thrombocyto­
penia, and positive direct and indirect Coombs' 
tests.
Hepatic and Renal-Transient rise in SGOT,
SGPT, BUN, and alkaline phosphatase levels 
without clinical evidence of renal or hepatic 
impairment.
Gastrointestinal -  Nausea, anorexia, vomiting, 
diarrhea, oral candidiasis (oral thrush), and 
cheilitis.
Other-Pain and phlebitis at the site of injection. 
Genital and anal pruritus, genital moniliasis, 
and vaginitis.
CONTRAINDICATION
Kefzol is contraindicated in persons who have 
shown hypersensitivity to cephalosporin 
antibiotics.
DOSAGE RANGE
Adults-From 250 mg to 1 g every 6 to 8 hours. 
Children -  From 25 to 100 mg per kg, divided into 
two to four equal doses.
In patients with renal impairment, see package 
insert for detailed directions.
HOW SUPPLIED
Kefzol is available in lyophilized form in individual 
rubber-stoppered vials:
500 mg (equivalent to cefazolin), 5 ml size 
1 g (equivalent to cefazolin), 10 ml size 
Further information is available on request.
INDICATIONS
Keflex may be indicated in the treatment of 
bacterial infections of the respiratory tract, 
genito-urinary tract, skin and soft tissues when the 
infection is caused by susceptible organisms.
PRECAUTIONS
Antibiotics, including Keflex, should be admin­
istered cautiously to any patient who has demon­
strated some form of allergy, particularly to drugs. 
In penicillin-allergic patients, cephalosporin 
antibiotics should be used with caution. If severe 
reaction, individual idiosyncrasy, or allergy 
should occur, the drug should be discontinued 
and appropriate treatment initiated. Keflex 
should be administered with caution in the 
presence of markedly impaired renal function.
In long-term therapy, periodic monitoring of 
hematology, renal and hepatic functions should 
be done.
Safety of this product for use during pregnancy 
has not been established.
Positive direct Coombs' tests can occur.
In patients being treated with Keflex, a false­
positive reaction for glucose in the urine may 
occur with Benedict's or Fehling’s solutions or 
with Clinitest tablets, but not with Tes-Tape.
ADVERSE REACTIONS
Diarrhea has been reported; it was very rarely 
severe enough to warrant cessation of therapy. 
Nausea, vomiting, dyspepsia and abdominal pain 
have also occurred.
Allergies (in the form of rash, urticaria, and angio- 
edema) have been observed. These reactions 
usually subsided upon discontinuation of the 
drug.
Other reactions have included genital and anal 
pruritus, genital moniliasis, vaginitis and vaginal 
discharge, dizziness, fatigue and headache. 
Esinophilia, leucopenia due to neutropenia, and 
slight elevation in SGOT and SGPT have been 
reported.
CONTRAINDICATIONS
Keflex is contraindicated in patients with known 
allergy to the cephalosporin group of antibiotics.
DOSAGE RANGE
Adults-From 1 to 4 g daily in divided doses. 
Children — From 25 to 50 mg per kg, divided into 
four doses.
HOW SUPPLIED
Keflex is available in pulvules equivalent to 
250 mg cephalexin; in tablets equivalent to 500 
mg cephalexin; for oral suspension equivalent to 
125 mg and 250 mg cephalexin.
Further information is available on request.
ELI LILLY AND COMPANY (CANADA) LIMITED. TORONTO, ONTARIO ( 
Product information available upon request
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CANINE PANCREATIC EXOCRINE SECRETORY RESPONSE 
TO LOW- AND HIGH-FAT ELEMENTAL DIETS*
JEFFREY W. LEWIS, MD and JOEL B. FREEM AN, MD, FRCS[C]
Elemental or chemically defined diets are used 
in a variety of gastrointestinal disorders to sus­
tain enteral nutrition, avoid the potential danger 
of central venous hyperalimentation and reduce 
intestinal and pancreatic secretions. The two 
diets available commercially are used inter­
changeably despite important differences in 
composition. The present study compared pan­
creatic exocrine secretory responses to these 
two diets in dogs. Infusion of high- and low-fat 
elemental diets resulted in less enzymatic out­
put than a standard blenderized diet. Pancreatic 
volume and bicarbonate content were similar 
with the low-fat elemental diet and the blender­
ized diet, but volume was increased by 30% 
and bicarbonate increased nearly twofold during 
infusion of the high-fat elemental diet. The re­
sults support the hypothesis that a low-fat ele­
mental diet is preferable for intragastric feeding 
when the therapeutic goal is to minimize pan­
creatic secretion.
Les regimes alimentaires a elements et compo­
sition chimique definis sont utilises dans un 
eventail d'affections gastro-intestinales comme 
traitement d’appoint a I’alimentation enterale, 
pour eviter les dangers de I'hyperalimentation 
veineuse et pour diminuer les secretions intes- 
tinales et pancreatiques. Les deux regimes 
alimentaires presentement disponibles dans le 
commerce, sont substitues I'un a I'autre en de­
pit d'importantes differences dans leur compo­
sition. Cette etude a compare les reactions
*From the department of surgery, University of 
Iowa Hospitals and Clinics, Iowa City, IA, USA.
Presented at the annual meeting of the Royal 
College of Physicians and Surgeons of Canada, 
Toronto, Ont., Jan. 27, 1977.
Reprint requests to: Dr. J. B. Freeman, Depart­
ment of surgery, University of Iowa Hospitals, 
Iowa City, IA 52242.
secretaires exocrines du pancreas a ces deux 
regimes, chez le chien. L'infusion de regimes 
a forte ou a faible teneur lipidique a cause une 
moins forte secretion enzymatique qu'un regime 
semi-liquide normal. Le volume de secretion 
pancreatique et le contenu en bicarbonate ont 
ete semblable avec le regime a faible teneur 
lipidique et avec le regime semi-liquide, mais le 
volume secretaire a augmente de 30%  et la 
concentration en bicarbonate a augmente de 
pres du double pendant l'infusion d’un regime 
a forte teneur lipidique. Ces resultats vont a 
I’appui de I'hypothese voulant qu'un regime a 
faible teneur lipidique soit preferable dans I'ali- 
mentation par sonde gastrique lorsque Ton vise 
a diminuer la secretion pancreatique.
Chemically defined or elemental diets are 
frequently used to provide nutrition for pa­
tients with acute pancreatitis, exacerbations 
of chronic pancreatitis, pancreatic fistulas 
and other upper gastrointestinal problems. 
Considerable evidence indicates that these 
diets reduce pancreatic exocrine secretion 
while preserving nutritional status;1’ 2 the 
potential dangers of central venous hyper­
alimentation are therefore avoided. Contro­
versy exists on the effects of these diets on 
pancreatic secretion, and recent evidence3’ 4 
has shown that the diets may not be as ef­
fective as was originally believed. One pos­
sible explanation for these conflicting data 
is that the formulas of the two elemental 
diets currently available commercially (Flex- 
ical and Vivonex) differ in composition; 
30% of the caloric value of Flexical is 
present as fat, whereas Vivonex is essential­
ly fat free (Table I). The study reported 
herein was undertaken to quantitate and 
compare pancreatic exocrine secretory re­
sponse to each of these diets.
TABLE I —Nutritional Composition by Weight of the Low-Fat ( Vivonex) and H igh-Fat (Flexical)
E lemental D iets
Component Vivonex, % Flexical, % Complete-B,* %
1 16 22
5673
(dextrose)
8.5
(sucrose)
11 22
(amino acid) (hydrolysate)
'Values on dry-weight basis.
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M aterial and M ethods
Pancreatic pouches were constructed in 
each of four female mongrel dogs (weight, 
16 to 18 kg), permitting collection of all 
pancreatic output during a given study pe­
riod.u The accessory pancreatic duct was 
ligated to assure complete collection of all 
pancreatic fluids. A minimum of 1 month 
was allowed before the experiments com­
menced, thus assuring a stable condition. 
All dogs attained at least 90% of their pre­
operative weights during this time. Before 
beginning the f studies, and also between 
studies, the pancreatic juice drained into 
the duodenum allowing the animal to main­
tain normal pancreatic function. Also, the 
collection cannulas were infused with 
methylene blue to verify that no fistula had 
developed between the pouch and the intact bowel.
The dogs were fasted overnight before 
each study. They were then placed in Pav­
lov stands, bite blocks were positioned and 
a nasogastric tube was passed into the stom­
ach. Three diets were studied: unflavoured 
Vivonex (low fat) and Flexical (high fat) 
were the two elemental diets while Com- 
plete-B, a standard tube feeding formula, 
served as the control (Table I). The pow­
dered diets were mixed to standard dilutions 
with water to provide 1 kCal/ml (4190 
kJ/m l) and nearly identical osmolarities.
Each of the three diets was infused for a 
2-hour study period on 3 different days in 
each dog. Prior to each study the pancreatic 
secretions were allowed to stabilize at a 
constant output of 1.5 to 3.0 m l/15 min. 
Then the diet was infused at 2 ml/min and 
eight, 15-minute samples were collected 
over the 2-hour study period. The total vol­
ume of each of these 15-minute collections 
was measured and aliquots of each collec­
tion were analyzed for total protein and 
bicarbonate content.
Protein content, which closely parallels 
enzymatic output,6 was measured by light 
absorption on a spectrophotometer at 280 
mp, with a known concentration of human 
albumin as the reference. Bicarbonate con­
centration was determined by acidification 
of the pancreatic fluid and back titration to 
neutral pH with hydrochloric acid.5 Only 
one diet was studied on each day in each
animal. All diets were studied in various 
crossover patterns to verify that the results 
were not influenced by the order of admin­
istration. Nine studies, three for each diet, 
were performed on every dog. The mean 
values of all of the 15-minute collections 
were compared statistically using three-fac­
tor analysis of variance followed by a 
Scheffe-type procedure to test for individual 
comparisons among the mean values.7 Re­
sults are expressed as mean ±  standard 
error of the mean.
R esults
Volume
The mean 15-minute volume of pancreatic 
juice in response to the infusion of the low- 
fat elemental diet (Vivonex) was 4.3 ±  0.3 
ml and for the blenderized diet (Complete- 
B) was 4.4 ±  0.4 ml (P >  0.05). The mean 
15-minute volume for the high-fat elemental 
diet (Flexical) was 5.8 ±  0.4 ml, signifi­
cantly greater than volumes measured for 
either Vivonex or Complete-B (Fig. 1).
Protein
The mean 15-minute total protein in re­
sponse to the Vivonex infusion was 171 ±  
10 mg compared with 174 ±  9 mg for 
Flexical (P >  0.05). The protein response 
to infusion of Complete-B was significantly 
greater (217 ±  10 mg) than either of the 
two elemental diets (P <  0.01) (Fig. 2).
Bicarbonate
The mean 15-minute bicarbonate output 
during infusion of Vivonex was 0.06 ±  
0.01 mmol, which was identical to that 
measured during infusion of Complete-B. 
Bicarbonate output with Flexical was sig­
nificantly greater than both Vivonex 
and Complete-B at 0.11 ±  0.01 mmol 
(P >  0.01) (Fig. 3).
The volume, bicarbonate and protein re­
sponses to each of the three diets tested are 
summarized in Table II.
D iscussion
Infusions of a high-fat elemental diet pro­
duced significantly greater volume and bicar­
bonate output than did similar infusion of a 
low-fat elemental diet. Pancreatic protein 
secretion, a reflection of enzymatic output, 
was significantly reduced during infusions
July 1977 THE CANADIAN
diet.
of both the low- and high-fat elemental diets 
compared with isovolumetric infusions of a 
blenderized diet. In addition, both the vol­
ume and bicarbonate output responses to 
the infusion of the low-fat elemental diet 
were not significantly different from those 
measured during infusion of the blenderized 
diet. In all three diets pancreatic exocrine 
secretory response was significantly greater 
than basal, nonfeeding secretory rates. 
Hence, chemically defined diets reduce, but 
do not completely prevent, pancreatic secre­
tory function. Previous studies have shown 
that maximal gastrointestinal rest is achieved 
when enteral feeding is completely eliminated 
and all calories are given intravenously, 
whereas the effects of chemically defined 
diets are between those of total parenteral 
feeding and regular tube feedings.8
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was noted between low- and high-fat EDs.
Fig. 3.—Infusion of high-fat ED produced signi­
ficantly greater increments in pancreatic bicarbo­
nate secretion than did either low-fat ED or blen­
derized diet.
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TABLE II.—Average 15-Minute Pancreatic 
E xocrine Secretory Activity with Three D iets
Secretory factor Vivonex Flexical Complete-B
Volume, ml. . 
Bicarbonate,
4.4 4.3 5.8
mmol........... 0.06 0.06 0.11
Protein, m g........ 217 171 174
To date the various elemental diets have 
been used interchangeably with regard to 
nomenclature and clinical application and 
in investigative studies. Most reports on the 
effects of these diets in relation to pancreatic 
function have failed to consider their dif­
ferences in composition and this may explain 
some of the conflicting data in the literature. 
Vivonex, a low-fat elemental diet, is com­
posed of crystalline amino acids and glu­
cose with about 1% fat (Table I). Flexical 
is composed of protein hydrolysates and the 
disaccharide sucrose, and contains 30% of 
its calories as fat. Twenty percent of this 
fat is in the form of medium-chain trigly­
cerides, which can be absorbed without bile 
salts or pancreatic enzymes. Protein hydro­
lysates contain peptides as well as individual 
essential and nonessential amino acids. This 
may be advantageous in certain clinical situ­
ations since each of these two protein prod­
ucts has a separate absorptive mechanism in 
the intestinal mucosa.9
In addition to fat, both amino acids and 
peptides are known stimulants of pancreatic 
secretion10 whereas glucose and sucrose 
have little effect in this regard. We believe 
that the essential difference between these 
two elemental diets with respect to their 
effects on pancreatic secretion is their fat 
content. There are certain advantages to 
having fat in an elemental diet. The addition 
of substantial amounts of fat reduces the 
high carbohydrate load, distributes non­
protein calories more physiologically be­
tween fat and carbohydrate, and prevents 
essential fatty acid deficiency. On the other 
hand, fat delays gastric emptying. This 
raises gastrin levels and stimulates pancreatic 
secretion both directly and through the re­
lease of other hormones. The current results 
suggest that secretin is the hormone most 
likely involved since primarily volume and 
bicarbonate secretion were affected by the 
high-fat elemental diet. However, because of 
the possible effects of the amino acids or
the low pH of the diets infused, as well as 
the design of the study, inferences as to 
specific hormonal involvement are purely 
speculative. The results clearly substantiate 
the original hypothesis, however, in that 
pancreatic responses to the high-fat ele­
mental diet were significantly greater than 
the response to the low-fat preparation. 
These differences may not appear large 
since they are expressed as mean 15-minute 
values, but during days or weeks of infusion 
they would become substantial (Figs. 1 to 3).
Ragins and associates3 showed stimula­
tion of both volume and protein secretion 
and, to a lesser extent, bicarbonate secre­
tion with intragastric Vivonex infusions. 
Cassim and Allardyce4 infused a high-fat 
elemental diet into the jejunum of dogs and 
found an increase in volume and bicarbonate 
secretion but a decrease in protein output 
compared with a blenderized diet. Wolfe, 
Keltner and Kaminski11 infused Vivonex 
into the duodenum of dogs and found an 
increase in pancreatic volume and protein. 
These studies are not directly comparable 
because of differences in methodology and 
experimental design, but all of them, includ­
ing our own, show that elemental diet infu­
sions raise pancreatic secretions to levels 
higher than those recorded during basal or 
unstimulated control periods hence support­
ing the contention that elemental diets do 
not rest the pancreas completely. There is 
significantly less volume and bicarbonate 
output with the low-fat than with the high- 
fat preparation, and both elemental diets 
are superior to blenderized tube feedings 
in reducing enzymatic production by the 
pancreas. Extrapolating these laboratory 
findings to the clinical situation, we suggest 
that low-fat elemental diets are preferable 
for enteral nutrition in patients with pan­
creatitis, pancreatic fistulas and other upper 
gastrointestinal disorders where limitation 
of secretions is a primary objective.
References
1. Blackburn GL, Williams LF, Bistrian BR,
et al: New approaches to management of 
severe acute pancreatitis. Am J Sure 131: 
114, 1976
2. Voitk A, Brown RA, Echave V, et al: Use
of elemental diet in treatment of com­
plicated pancreatitis. Am J Sure 125: 223, 
1973
3. Ragins H, Levenson SM, Signer R, et al:
1977 THE CANADIAN JOURNAL OF SURGERY 349
is about to use one of 
the worlds finest 
surgical blades....
... .this happens 
thousands of times 
everyday!
It happens because the blades are by Swann-Morton,
the people who meet the highest requirements in surgical knives.
We need say very little about our superiority.
The world's surgeons have proved it for us!
SWANN-MORTON LIMITED 
PENN WORKS, OWLERTON GREEN, 
SHEFFIELD S6 2BJ. ENGLAND.
350 THE CANADIAN JOURNAL OF SURGERY Vol. 20
Intrajejunal administration of elemental 
diet at neutral pH avoids pancreatic stimu­
lation. Studies in dog and man. Am J Surg 
126: 606, 1973
4. Cassim MM, Allardyce DB: Pancreatic
secretion in response to jejunal feeding of 
elemental diet. Ann Surg 180: 228, 1974
5. Preshaw RM, Grossman Ml: Stimulation of
pancreatic secretion by extracts of pyloric 
gland area of stomach. Gastroenterology 
48: 36, 1965
6. Guth PH, Komarov SA, Shay H, et al: Rela­
tionship between protein nitrogen, proteo­
lytic, amylolytic and lipolytic enzymes in 
canine pancreatic juice obtained under va­
rious conditions of stimulation. Am J 
Physiol 187: 207, 1956
7. Winer BJ: Statistical Principles in Experimen­
tal Design, New York, McGraw, 1971
8. Wolff. BM, Keltner RM, Willman VL:
Intestinal fistula output in regular, ele­
mental, and intravenous alimentation. Am 
J Surg 124: 803, 1972
9. Matthews DM, Adibi SA: Peptide absorp­
tion. Gastroenterology 71: 151, 1976
10. Harper AA: Control of pancreatic secretion.
Gut 13: 308, 1972
11. Wolfe BM, Keltner RM, Kaminski DL:
Effect of intraduodenal elemental diet on 
pancreatic secretion. Surg Gynecol Obstet 
140: 241, 1975
DYSPHAGIA LUSORIA: ANTERIOR APPROACH FOR DEFINITIVE
TREATMENT
GUY G. LEMIRE, MD, FRCSjC], FACS,* ANTOINE G. RABBAT, MD, FRCSfCl 
FACSf and JULES TRUDEL, MD, FRCSjC], FACSf
An aberrant right subclavian artery causing 
symptoms is rare in adults. Several surgical ap­
proaches have been advocated. On the basis of 
results obtained in two patients, the authors 
recommend an anterior approach, either a trans- 
ternal bilateral anterior thoracotomy or a me­
dian sternotomy, that affords excellent expos­
ure for flush ligation and division of the right 
subclavian artery at the aorta, and reconstruc­
tion on the ascending aorta.
Une anomalie de I’artere sous-claviere droite 
occasionnant des symptomes est rarement ren- 
contree chez I'adulte. Plusieurs voies d'abord 
ont ete proposees pour en faire la correction 
chirurgicale. A partir des resultats obtenus chez 
deux patients, les auteurs recommandent une 
voie d'abord anterieure, soit par thoracotomie 
anterieure bilaterale avec section transversale 
du sternum, soit par incision mediane du ster­
num; ceci offre une excellente mise a nu et 
permet la ligature lisse et la division de I’ar­
tere sous-claviere droite a I’aorte, et la recons­
truction a I'aorte ascendente.
The optimal management of the adult with 
dysphagia lusoria (dysphagia resulting 
from esophageal compression caused by an 
anomalous right subclavian artery) entails 
flush ligation or oversewing and division of 
the aberrant right subclavian artery at its 
origin on the aorta and reimplantation to
* Department of surgery, University Hospital, Uni­
versity of Saskatchewan, Saskatoon, Sask.
tDepartment of surgery, St. Luc Hospital, Univer­
sity of Montreal, Montreal, PQ.
Reprint requests to: Dr. Guy G. Lemire, Depart­
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hig. 1.—Sketch illustrating anterior approaches 
(1, 2) and trajectory of aberrant right subclavian 
artery.
prevent claudication,1 gangrene,- subclavian 
steal syndrome,:1 aneurysm formation4'11 or 
aortic dissection.7
On the basis of two case reports we pro­
pose that by an anterior approach (i.e., bi­
lateral thoracotomy through the fourth in­
terspace or median sternotomy) (Fig. I), 
both steps of the definitive procedure can 
be accomplished safely and easily.
Case Details and Operative
Technique
Two women (ages, 35 and 37 yr) were in­
vestigated for dysphagia to solids and retro­
sternal pain after swallowing solid foods. 
The symptoms became more severe over the 
6 months before admission, although both 
reported having had intermittent difficulty 
in swallowing over a period of years. Both 
had a recent weight loss of over 9 kg, at­
tributed to altered eating habits.
Esophagography showed an oblique and
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Fig. 2.—Aorta (oblique view) demonstrates frank 
posterior origin of aberrant right subclavian 
artery.
posterior compression typical of an aberrant 
right subclavian artery. Esophagoscopy de­
monstrated a posterior pulsatile extraluminal 
compression, and angiography confirmed 
the congenital anomaly (Fig. 2).
After consultation with the gastroentero­
logist, the symptoms were attributed to an 
aberrant right subclavian artery and correc­
tive surgery was recommended. The fact 
that both patients were right-handed and 
indulged in racquet sports constituted two 
additional indications for corrective surgery, 
since simple ligation advocated by some1 
could result in claudication of the right arm.
In the first patient, exposure to the retroe­
sophageal artery was obtained through a right 
thoracotomy in the fourth interspace. When 
it was obvious that ligation flush with the 
aorta and division of the aberrant artery was 
too blind to be safe, the sternum was tran­
sected and the left fourth interspace was en­
tered anteriorly. Based on the findings in 
this patient we believed that the retroeso­
phageal artery could be approached in the 
second patient through a median sternotomy 
also, with equal ease of exposure.
The proximal 2 cm of the right subclavian 
artery, before it crosses behind the esopha­
gus, is visualized by opening the pericardium 
vertically to its reflection on the great ves­
sels, by dividing the thymus and by retract­
ing the left main-stem bronchus and liga- 
mentum arteriosum medially with a narrow, 
malleable retractor. The main pulmonary
artery is retracted downwards with a dental 
pledget. The pulse in the aberrant artery is 
found by digital exploration and after proper 
retraction the artery can be encircled with 
an umbilical tape and pulled up into better 
view. At this point, the right subclavian 
artery crosses the operative field; it origin­
ates posteriorly on the aorta (not laterally 
as shown in most anatomical sketches) and 
approximately 1.5 cm distal to the left sub­
clavian artery. (In our two patients both 
pleura were opened, although theoretically, 
when the median sternotomy approach is 
used, the left pleura can remain intact.) Two 
secure vascular clamps, either coarctation 
clamps or clamps of the Leland-Jones va­
riety, are then applied. The artery is divided 
and the aortic end is either tied with a trans­
fixion suture or oversewn; we used the latter 
technique.
D isc u ssio n
Embryologically,8 the occurrence of an 
aberrant right subclavian artery has been ex­
plained by postulating the disappearance of 
the right fourth aortic arch, which normally 
forms the most proximal part of the right 
subclavian artery, and the persistence of 
the normally disappearing right dorsal aorta.
In infants, dysphagia lusoria is managed 
by simple ligation and division of the aberrant 
right subclavian artery through a left thora­
c o t o m y , 10 but in adults the problem is 
quite different since complications such as 
aortic dissection7 from the point of origin 
of the aberrant artery and aneurysm forma­
tion4- 3 have been reported. When dysphagia 
lusoria in adulthood has been corrected by 
simple division of the artery, either through 
a left or right thoracotomy, there have been 
reports of complications such as claudica­
tion1 and gangrene- of the right arm, and 
intermittent cerebral ischemia due to a sub­
clavian steal syndrome.3 Arterial reconstruc­
tion, therefore, is crucial in the adult with 
dysphagia lusoria.
A review of the literature reveals that the 
surgeon has several options for the defini­
tive treatment of this entity.11- 12 We believe, 
on the basis of our two cases, that the an­
terior approach, either a median sternotomy 
or a transternal bilateral anterior thoraco­
tomy, gives excellent exposure for ligation
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of the aberrant right subclavian artery flush 
with the descending aorta, which we believe 
is crucial, and affords excellent access to 
the ascending aorta for anastomosis of the 
extended right subclavian artery. The 
cosmetic advantages in women of the tran- 
sternal bilateral anterior thoracotomy must 
be balanced against the slightly higher fre­
quency of pulmonary complications and 
post-thoracotomy pain. These anterior ap­
proaches obviate the need for cross-clamp­
ing or shunting of the right common carotid 
artery, or both, when the cervical approach 
proposed by Siderys3 is used. Furthermore, 
such a cul-de-sac proximal to the carotid- 
subclavian anastomosis could become the 
nidus of thrombus formation that theoretical­
ly could extend to the anastomosis.
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DOES INTRA-ARTERIAL VASOPRESSIN CONTROL 
GASTROINTESTINAL BLEEDING IN CIRRHOTIC PATIENTS?*
ROBERT L. MACKENZIE, BSc, MD, FRCS[C], KATHERINE D. BURY, MD. FRCS[C], 
FACS, JOHN L. PROVAN, MB, BS, MS, FRCS, FRCS[C], FACS, EUGENE ST. LOUIS, 
MD, FRCP[C] and NORMAN MARCON, MD, FRCP[C]
Twenty-four patients with massive gastrointes­
tinal bleeding were treated by selective continu­
ous intra-arterial infusion of vasopressin (Pitres- 
sin). In all patients the bleeding was localized 
to esophageal varices or gastric erosions, or 
both. Seventeen (71%) patients initially re­
sponded to vasopressin. Five patients stopped 
bleeding; two of these survived and three died 
of liver failure. In 12 patients the bleeding 
stopped or partial control of bleeding was 
achieved, but 11 of them had further severe 
hemorrhage on one or more occasions; only 2 
of the 12 survived. Seven patients did not re­
spond to vasopressin: six of them died. The 
overall mortality was 79%.
The data suggest that the administration of 
intra-arterial vasopressin brings about temporary 
control of bleeding in some cirrhotic patients 
with gastrointestinal hemorrhage but that cur­
rent survival rates are poor.
Vingt-quatre patients souffrant d’hemorragie 
gastro-intestinale massive, ont ete traites se- 
lectivement par perfusion intra-arterielle conti­
nue de vasopressine (Pitressin). Chez tous ces 
patients, les saignements se situaient au niveau 
d’une varice oesophagienne ou d'une erosion 
gastrique, ou des deux. Au debut, 17 patients 
(71%) ont presente une reponse a la vasopres­
sine. L'hemorragie a cesse chez cinq patients; 
deux de ceux-ci ont survecu et trois sont morts 
d’insuffisance hepatique. Chez 12 patients, les 
saignements ont cesse ou un controle partiel 
de l'hemorragie a pu etre etabli; chez 11 d'entre 
eux toutefois, des recidives graves se sont pro­
duces en une ou plusieurs occasions. Seulement 
2 de ces 12 patients ont survecu. Sept patients 
n'ont pas repondu a la vasopressine; six sont de­
cides. Le taux de mortality global a ete de 79%. 
Ces donnees indiquent que I'administration de 
vasopressine par voie intra-arterielle peut procu­
rer un controle temporaire du saignement chez 
certains cirrhotiques souffrant d’hemorragie 
gastro-intestinale. Toutefois, le taux de survie 
demeure mauvais.
*From the Wellesley Hospital and the department 
of surgery, University of Toronto, Toronto, Ont.
Presented at the annual meeting of the Royal 
College of Physicians and Surgeons of Canada, 
Quebec City, PQ, Jan. 21, 1976.
Reprint requests to: Dr. R. L. Mackenzie, E. K. 
Jones Building, The Wellesley Hospital, 160 
Wellesley St. E, Toronto, Ont. M4Y 1J3
V asopressin  (Pitressin, Parke Davis) was 
used as an intravenous infusion in the man­
agement of bleeding from esophageal varices 
by Kehne, Hughes and Gompertz1 in 1956. 
This technique was relatively ineffective and 
the associated decrease in cardiac output 
and tachyphylaxis made the procedure 
dangerous. In 1967 Nusbaum and col­
leagues2 described a technique for the con­
tinuous infusion of vasopressin into the 
superior mesenteric artery. Subsequent clin­
ical studies by Conn, Ramsby and Storer3 
and Covey and Baue4 showed that this 
method was superior to the technique of 
intravenous infusion. Our experience with 
intra-arterial infusion of vasopressin was 
less satisfactory than that reported in the 
literature; in order to document this ex­
perience we assessed the control of bleeding 
and mortality rates of patients treated by 
intra-arterial infusion of vasopressin.
M aterial and  M ethods
We studied a group of 24 patients ad­
mitted, over a 2 Vi -year period to the sur­
gical or gastroenterologic services of the 
Wellesley Hospital, Toronto, with severe 
gastrointestinal hemorrhage. The criteria for 
inclusion in this study were as follows:
1. Severe hemorrhage requiring multiple 
transfusions.
2. Bleeding site localized to gastric ero­
sions or esophageal varices as demonstrated 
by early endoscopy.
3. Biochemical or clinical evidence of 
severe hepatic disease (Table I).
In each patient endoscopic examination 
was carried out during or soon after resus­
citation. Aortography and selective superior 
mesenteric arteriography were then per­
formed by the percutaneous femoral route, 
using the Seldinger technique. After success­
ful selection of the superior mesenteric 
artery the catheter was left in place for the 
infusion of vasopressin. Vasopressin (200 
pressor units [U]) was added to 1 l of either 
normal saline or 5 % dextrose in water 
and infused with a Holter pump at a rate
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sufficient to stop bleeding, or to a maximum 
of 60 ml/h or 0.2 U/ml *min. Each patient 
was monitored carefully in the intensive 
care unit. The catheter was withdrawn and 
the infusion discontinued when gastrointes­
tinal bleeding had not recurred for more 
than 24 hours, when local complications 
relating to the catheter developed requiring 
its removal, when bleeding was not con­
trolled, or when surgery was undertaken.
R esults
Of the 24 patients included in the study, 
6 had gastric erosions alone and 7 had eso­
phageal varices alone. The 11 remaining 
patients had both varices and erosions. Gas­
tric erosions were the source of bleeding in 
15 (63%) patients and esophageal varices 
in 8 (33%); in 1 (4%) patient bleeding 
arose from both sites.
Complete control of bleeding was defined 
as cessation of bleeding during the time of 
the infusion without further infusion of vaso­
pressin or further blood transfusion. This 
was achieved in five patients (21%); two 
survived and three died of liver failure.
Twelve patients initially responded to 
vasopressin infusion; in these patients there 
was a reduction in the rate of blood trans­
fusion or a clearing of blood in the naso­
gastric aspirate following gastric lavage with 
iced saline; in 11 of the 12 patients hemor­
rhage recurred at least once. Three of the
11 patients were operated on for persistent 
hemorrhage; of these, 1 survived following 
total gastrectomy. Of the entire group of
12 only 2 patients survived.
In 7 (29%) of the 24 patients no control 
of bleeding was achieved; 6 (86%) of them 
died during this admission. Four of the 
seven patients were operated on because 
medical management of their hemorrhage 
had failed; one, who underwent subtotal 
gastrectomy after an initial vagotomy and 
pyloroplasty survived, the others died. The 
remaining three were considered inoperable 
because of severe liver dysfunction and all 
three died.
Of the 24 patients in the study, 7 under­
went an operative procedure; only 2 patients 
survived, a mortality of 71% . All three 
patients who underwent vagotomy and pylo­
roplasty for control of hemorrhage from 
gastric erosions continued to bleed despite 
further infusion of vasopressin.
Complications
In five patients complications related to
TABLE I.—Clinical Data
Patient
no. Age, yr Sex
Serum
bilirubin
(mg/dl)
SGOT,
IU /l
Albumin,
g/dl
Prothrombin time 
(s, prolonged) Ascites
Hepatic
encephalopathy
i 50 M 2.2 16 2.8 4 Present Present
2 37 M 12.9 88 3.9 4 Present Absent
3 45 F 2.5 29 2.6 1 Present Present
4 52 F 9.9 9 3.1 2 Present Absent
5 80 M 19.8 43 2.4 Normal Present Absent
6 49 M 7.7 215 2.8 4 Present Present
7 58 F 4.7 21 2.5 2 Absent Present
8 69 M 3.0 28 2.6 2 Present Absent
9 61 M 2.9 14 2.8 4 Present Absent
10 57 F 10.2 144 — 4 Present Absent
11 46 M 1.6 9 2.1 2 Present Present
12 59 M 2.1 21 2.6 3 Present Present
13 61 M 19.8 36 2.4 3 Present Absent
14 55 M — 28 — 2 Absent Absent
15 53 M 12.9 206 2.0 2.5 Present Present
16 53 M 1.8 14 2.4 3 Present Absent
17 47 M 3.3 29 2.6 5 Absent Absent
*18 17 F 27.0 43 2.8 6 Present Present
19 48 M 9.5 40 3.0 2 Present Absent
20 55 F 13.2 22 2.4 8 Present Absent
21 58 M 20.6 21 3.1 3 Present Absent
22 45 M 3.8 26 2.9 2 Absent Absent
23 58 M 7.2 45 2.7 4 Present Present
24 60 M 3.1 14 3.0 1 Absent Absent
*Chronic active hepatitis (no cirrhosis).
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the presence of the catheter occurred from 1 
to 21 days after placement. Two complica­
tions were associated with impairment of 
blood flow to the limb in which the catheter 
was placed and two were due to bleeding 
at the site of insertion of the catheter. In 
this group of four patients, removal of the 
catheter led to immediate improvement in 
blood flow; local bleeding was successfully 
controlled with pressure. The fifth patient 
developed thrombophlebitis in the leg in 
which the catheter had been placed.
D is c u ssio n
Although several authors2"4 have reported 
an improvement of 50% in the general mor­
tality during the first hospital admission, 
our overall mortality of 79% is comparable 
to that of Murray-Lyon and associates5 and 
Marubbio, Lombardo and Holt.0 This high 
mortality cannot be explained by the pro­
portion of patients with variceal bleeding, 
as the source of bleeding did not appreciably 
alter the mortality; 82% of patients bleeding 
from varices died compared with 77% of 
those bleeding from gastric erosions. In sup­
port of these figures, a recent trial7 did not 
show any difference in the arrest of hemor­
rhage in those patients bleeding from varices 
or from other lesions when both were 
treated by intra-arterial infusion of vaso­
pressin.
The majority of our patients suffered 
from cirrhosis of the liver related to long­
standing alcoholism. While no patients were 
considered to have alcoholic hepatitis, all 
had a degree of hepatocellular failure such 
that primary surgical treatment was pre­
cluded. It is not customary at this centre 
to perform emergency portal decompression 
to control bleeding esophageal varices be­
cause of the associated high morbidity and 
mortality. It was hoped that the use of 
intra-arterial vasopressin would stop the 
bleeding and allow time for the liver func­
tion and general condition of these patients 
to improve sufficiently so that they could 
tolerate elective surgery; this did not occur. 
In all seven patients who underwent opera­
tion the procedure was performed as an 
emergency, and 71% of these patients died 
in the postoperative period.
The efficacy of intra-arterial vasopressin 
in the management of upper gastrointestinal 
hemorrhage must be judged both by its abil­
ity to stop bleeding and by improved survival 
rates. Of the 24 patients studied, 17 showed 
an initial response to vasopressin, but hem­
orrhage recurred in 70%; in only 5 (21%) 
were we able to achieve complete control. In 
terms of survival, only five patients in the 
entire group left hospital alive —  an over­
all mortality of 79% . Two of these were 
from the group that had complete control 
of bleeding, two were from the group that 
had initial temporary control and one was 
from those who showed no response to 
vasopressin. These figures show that vaso­
pressin neither improves survival nor brings 
about permanent control of hemorrhage. 
Conn and colleagues7 reported a prospective 
controlled study of intra-arterial vasopressin 
in patients with massive upper gastrointes­
tinal bleeding. Of those receiving “conven­
tional” treatment 44% survived without 
intra-arterial vasopressin and of those who 
had similar treatment but also received selec­
tive intra-arterial vasopressin 46% survived; 
clearly intra-arterial vasopressin had no ad­
vantage in terms of survival. While 50% 
of our patients responded initially to vaso­
pressin, ultimate failure of primary control 
appeared to be the rule and mortality re­
mained high.
The control of bleeding using intra­
arterial vasopressin might have been im­
proved if the left gastric artery had been 
cannulated rather than the superior mesen­
teric artery; unfortunately our expertise in 
left gastric artery cannulation was not well 
developed at the time that the study was 
carried out. There were several additional 
problems that arose in studying these pa­
tients. The procedures used could not be 
done on an elective basis; the cirrhosis and 
hepatic decompensation complicated man­
agement and predisposed them to gastro­
intestinal bleeding. All of these factors made 
the patients under study unsuitable can­
didates for surgical treatment. The initial 
control of bleeding with vasopressin might 
have provided time for stabilization but in 
practice did not improve the survival rate. 
Seventy-one percent of the patients died fol­
lowing surgery and, in the patients who had
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temporary initial control of hemorrhage, 
76% died.
Intravenous infusions of vasopressin were 
used because it was hoped that in the man­
agement of upper gastrointestinal hemor­
rhage this treatment would stop the bleeding 
by decreasing portal venous pressure. Intra­
arterial infusion of vasopressin was later 
advocated; the hypothesis presented was that 
the selective intra-arterial route with fewer 
side effects would produce a greater reduc­
tion in superior mesenteric blood flow and 
portal venous pressure. A number of favour­
able reports have supported this view.2'4 
Since then Barr, Lakin and Rosch8 and 
Millette and colleagues9 have noted that 
the systemic effects of vasopressin, as mani­
fested by an increase in blood pressure and 
decrease in cardiac output continued to oc­
cur when the selective intra-arterial route 
was used. With a low dose (2.75 U/kgrmin) 
venous infusion of vasopressin in dogs, Barr, 
Lakin and Rosch8 have shown that, with 
the same dose, similar decreases in portal 
venous pressure occur as with an intra­
arterial infusion. They suggested that if 
clinical studies verify these results, low-dose 
venous infusions would be preferable to 
selective intra-arterial infusion. While the 
current study has not attempted to document 
any of the side-effects of vasopressin, it has 
shown that control of bleeding is imperfect 
and that the mortality is high. Our findings 
also show that selective intra-arterial vaso­
pressin, although providing temporary con­
trol of bleeding, adds little in terms of 
survival to the management of gastrointes­
tinal hemorrhage.
As has been the experience of others,3’ 7 
complications related to catheter use were 
usually easily controlled.
An incidental finding in this study was 
that vagotomy and pyloroplasty did not ap­
pear to control hemorrhage in patients with 
gastric erosions. All three patients treated 
in this way continued to bleed and only one 
survived after a subsequent subtotal gastrec­
tomy. Esophagogastroscopy is important in
the diagnosis of the site of hemorrhage as 
has been noted previously;10 in 63% of 
patients in our series the hemorrhage origin­
ated from gastric erosions.
Finally, it is interesting that in none of 
the 24 cases of massive upper gastrointes­
tinal hemorrhage studied could the bleeding 
site be identified by angiography. Undoubt­
edly, despite the probability that the bleed­
ing was in excess of 0.5 ml/min the dilution 
of the dye in the venous blood of bleeding 
varices would make visualization unlikely. 
In the case of gastric erosions, the distribu­
tion of dye between multiple bleeding sites 
would have failed to localize a single one.
References
1. Kehne JH, H ughes FA, Gompertz JL: Use
of surgical pituitin in control of esophageal 
varix bleeding; experimental study and re­
port of two cases. Surgery 39: 917, 1956
2. Nusbaum M, Baum S, Sakiyai ak P, et al:
Pharmacologic control of portal hyperten­
sion. Surgery 62: 299, 1967
3. Conn HO, Ramsby GR, Storer EH: Selec­
tive intra-arterial vasopressin in treatment 
of upper gastrointestinal hemorrhage. Gas­
troenterology 63: 634, 1972
4. Covey TH, Baue AE: Selective arterial in­
fusion of vasopressin in treatment of acute 
gastrointestinal hemorrhage. Angiology 25: 
54, 1974
5. Murray-Lyon IM, Pugh RN, N unnerly HB,
et al: Treatment of bleeding oesophageal 
varices by infusion of vasopressin into 
superior mesenteric artery. Gut 14: 59, 
1973
6. Marubbio AT, Lombardo RP, H olt PR:
Control of variceal bleeding by superior 
mesenteric artery Pitressin infusions -—• 
complications and indications. Am 1 Dig 
Dis 18: 239, 1973
7. Conn HO, Ramsby GR, Storer EH, et al:
Intra-arterial vasopressin in treatment of 
upper gastrointestinal hemorrhage; prospec­
tive, controlled clinical trial. Gastroenter­
ology 68: 211, 1975
8. Barr JW, Lakin RC, Rosch J: Similarity of
arterial and intravenous vasopressin on 
portal and systemic hemodynamics. Gastro­
enterology 69: 13, 1975
9. Millette B, H uet BM, Lavoie P, et al:
Portal and systemic effects of selective 
infusion of vasopressin into superior mesen­
teric artery in cirrhotic patients. Ibid, p 6 
10. Waldram R, D avis M, Nunnerly HB, et al: 
Emergency endoscopy after gastrointestinal 
haemorrhage in 50 patients with portal 
hypertension. Br Med J 4: 94, 1974
360 THE CANADIAN JOURNAL OF SURGERY Vol. 20
WHEN YOU ORDER W ECK , YOU RECEIVE THE FINEST INSTRUMENTS 
BACKED BY THE FINEST SERVICE PROGRAM
/  FREE REPAIR AND SHARPENING PROGRAM
-  5 year Guarantee* on all forceps
— 3 year Guarantee* on all scissors & rongeurs
V  CATALOGUE NUMBER & DATE ON EACH INSTRUMENT
V  DEPARTMENT IDENTIFICATION IMPRINTED, if desired
/  PERIODIC INVENTORY CHECKS TO DETERMINE YOUR INSTRUMENT 
, NEED AND CONDITION
V  INSERVICE PROGRAMS (Films & Slides)
CAN YOU AFFORD TO BE WITHOUT OUR SERVICES?
*e x c e p t m icro 
in s tru m e n ts
( U
WECK
WECK Surgical Company
Division o l £ R Squibb 4 Sons Lid.
39 KLONDIKE DRIVE. WESTON. ONTARIO M9L 1S1
July 1977 THE CANADIAN JOURNAL OF SURGERY 361
GREY-SCALE ULTRASOUND IN THE DIAGNOSIS 
OF ABDOMINAL MASS LESIONS*
P. L. COOPERBERG, MD, FRCP[C] and M.
With the introduction of grey-scale imaging, the 
diagnostic capability of ultrasound has been 
greatly increased. Previously, ultrasound images 
were limited to a bistable presentation that did 
not distinguish between high- and low-level 
echoes. As a result the images could be inter­
preted by only a few experienced ultrasonogra- 
phers. Grey-scale imaging with the use of a 
television scan converter allows both the strong 
and the weaker echoes to be displayed, so that 
both the outline and the internal texture of nor­
mal abdominal organs and lesions can be visual­
ized on a single scan. Abnormalities are now 
more readily identified and their relation to 
normal organs is more easily appreciated so 
that the scans can be interpreted not only by 
the ultrasonographer but also by the clinician.
Several cases are presented in which grey­
scale ultrasound was used.
La capacite de diagnostic des ultrasons s’est 
amelioree considerablement avec I'arrivee du 
contraste d'image. Auparavant, les images obte- 
nues par ultrasons se limitaient a une presenta­
tion en deux tons qui ne pouvaient distinguer 
entre les echos de forte ou de faible intensity. 
Comme resultat seules quelques personnes ex- 
perimentees en ultrasonographie etaient capa- 
bles d'interpreter les images obtenues. Le con­
traste d'image et I'emploi d'un convertisseur 
pour ecran de television permettent de mettre 
en evidence les echos de forte et de faible in- 
tensites, de sorte que le contour et la texture 
interne des organes abdominaux normaux et des 
lesions peuvent etre representes sur un meme 
balayage cathodique. Les anomalies peuvent 
maintenant etre identifiees plus rapidement et 
leur relation avec les organes normaux est d e ­
preciation plus facile, de sorte que les images 
peuvent etre interpretees, non seulement par 
un expert de I'ultrasonographie, mais aussi par 
le clinicien.
On presente plusieurs cas oil I’ultrasonogra- 
phie a contraste d'image a ete utilisee.
*From the division of ultrasound, department of 
diagnostic radiology and the department of sur­
gery, University of British Columbia and the 
Vancouver General Hospital, Vancouver, BC.
Reprint requests to: Dr. P. L. Cooperberg, Direc­
tor, Division of ultrasound, University of British 
Columbia, 10th Ave. and Heather St., Vancouver, 
BC V5Z 1M9.
M. COHEN, MB, ChB, FRCS(Edin), FRCS[C]
Th e  recent technologic innovation of grey­
scale in diagnostic ultrasound has greatly 
extended and enhanced the capability of 
B-scan ultrasound in defining abdominal le­
sions. The advantage of the grey-scale B- 
scan is that weak as well as more intense 
echoes can be displayed at the same time on 
the television monitor. With the previous 
“bistable” technique only echoes above a 
certain threshold could be shown, and all 
echoes were displayed with equal intensity. 
This technique frequently led to images that 
were barely interpretable and required a se­
ries of images of the same section to de­
lineate a lesion and assess its texture. Al­
though several types of grey-scale technique 
are now used1"3 the most common type 
utilizes the television scan converter, which 
stores the B-scan information in a two-di­
mensional matrix of 1000X1000 cells.4 This 
information is then converted into eight 
shades or more of grey and is displayed on 
the television monitor.
With grey-scale the abdominal organs are 
not only outlined, but also have a diffuse 
echogenicity indicating the spectrum of small 
echoes that come from the parenchyma of 
the organ. The abdominal anatomy can be 
visualized by the location, outline and char­
acteristic echogenicity of these specific or­
gans. In a longitudinal (parasagittal) section, 
the liver can be identified by its relation to 
the right hemidiaphragm and right kidney, 
and its characteristic outline can be appre­
ciated. Furthermore the internal structure of 
the hepatic parenchyma with portal veins, 
hepatic veins and bile ducts can be identified.
As with bistable scans, cysts can be dif­
ferentiated from solid structures. Fluid-filled 
structures characteristically have a lack of 
echoes (white) and smooth deep borders, 
and enhance deeper echoes. The appearance 
of solid structures depends upon their homo­
geneity. The combination of findings asso­
ciated with solid lesions are echoes within 
the lesion, irregular outline and failure to 
enhance echoes deep to the lesion. With 
grey-scale the normal organs serve as land­
marks so that the origin or site of the lesion 
is more readily apparent.
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Fig. 2.—Case 1. Longitudinal section, 5 cm to 
right of midline through upper abdomen, shows 
echo-free space (A) within liver, with smooth 
borders and dark deep echoes indicating collec­
tion of fluid. (U =  umbilicus, arrows =  dia­
phragm, K =  right kidney).
Fig. 1.—(a) Longitudinal grey-scale B-scan, and 
(b) line drawing, 5 cm to right of midline, shows 
normal liver, right kidney and right hemidia- 
phragm.
Fig. 3.—Case 2. Longitudinal section, 8 cm to 
right of midline, shows intrahepatic area (M) of 
increased echoes with indistinct margins and at­
tenuation of echoes deep to lesion.
The cases reported below illustrate the 
value of grey-scale ultrasound in the diagno­
sis of abdominal mass lesions. Although B- 
scans are routinely done in both transverse 
and longitudinal sections, we have included 
only longitudinal illustrations; all are ori­
ented with the head of the patient to the 
left, the feet to the right and the anterior ab­
dominal wall at the top (Fig. 1).
Case R eports
Case. 1.— Fever, epigastric pain and tender­
ness developed in a 24-year-old man following 
a trip to Mexico. Results of liver function stu­
dies were abnormal. A grey-scale B-scan (Fig. 
2) disclosed an echo-free space within the liver, 
with smooth borders and dark deep echoes that 
indicated an accumulation of fluid. At opera­
tion a liver abscess was drained. The aspirate 
was sterile but there was a high titre of anti-
ameba antibody. Follow-up B-scans showed a 
gradual reduction in the size of the lesion.
Case 2 .— A 30-year-old man had hepato­
megaly, right upper quadrant pain and weight 
loss. The grey-scale B-scan showed a solid le­
sion in the right lobe of the liver, which, on 
biopsy, proved to be a metastatic adenocarci- 
.noma (Fig. 3).
Case 3 —A 53-year-old woman with a his­
tory of alcoholism and chronic pancreatitis had 
epigastric pain. A tender epigastric mass was 
palpated. An upper gastrointestinal series 
showed that the body of the stomach was dis­
placed anteriorly and inferiorly by a retrogas- 
tric mass. Grey-scale B-scan demonstrated a 
large cystic lesion (Fig. 4). A pancreatic pseu­
docyst within the lesser sac was drained by 
cystogastrostomy.
Case 4 .—A 68-year-old woman with weight 
loss, anemia and abdominal pain, had what
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Fig. 4. —Case 3. Longitudinal section, 2 cm to 
right of midline, shows large echo-free area with 
smooth borders and increased echoes deep to 
lesion indicating cystic structure (C). Inferior vena 
cava is compressed posteriorly (arrows).
Fig. 6.—Case 5. Longitudinal section in midline 
shows dilatation of distal abdominal aorta (Ao) 
with echogenic areas anteriorly and posteriorly, 
indicating thrombus circumferentially within di­
lated portion.
Fig. 5.—Case 4. Longitudinal section, 1 cm to 
right of midline, shows mass (M) between left 
lobe of liver and abdominal aorta (Ao) with 
echoes within lesion showing circular pattern, in­
dicating multinodular mass.
was thought to be a pulsating epigastric mass. 
To eliminate a possible abdominal aneurysm, 
grey-scale B-scanning was performed; a solid 
mass (diameter, 6 cm) between the aorta and 
the left lobe of the liver was visualized (Fig. 
5). The diagnosis was pancreatic carcinoma; 
this was proven at autopsy.
Case 5 .— A 67-year-old man had an asymp­
tomatic mid-abdominal pulsating mass. Grey­
scale B-scan confirmed the presence of a dis­
tal abdominal aortic aneurysm (diameter, 4.5 
cm) with circumferential thrombus in the di­
lated portion (Fig. 6).
Case 6 .—Excretory urography demon­
strated a mass lesion in the upper pole of the
Fig. 7.—Case 6. Longitudinal section, 7 cm to 
right of midline, shows echogenic mass (M) in 
upper pole of right kidney (K) posterior to right 
lobe of liver (L).
right kidney in a 63-year-old man who was 
asymptomatic. The grey-scale B-scan showed 
that the mass was solid (Fig. 7) and arterio­
graphy proved that it was a vascular lesion. 
Nephrectomy was performed; the mass was a 
hypernephroma.
Case 7.—Excretory urography disclosed a 
mass in the upper pole of the right kidney in 
an asymptomatic 53-year-old woman. The 
grey-scale B-scan demonstrated an echo-free 
lesion with smooth borders and dark echoes 
deep to it, indicating the presence of a cyst 
(Fig. 8). Under ultrasonic guidance through a 
posterior approach, the cyst was aspirated 
yielding a clear fluid with a yellowish tinge. 
Contrast medium was injected into the cyst and 
radiographs confirmed a smooth border. Cyto­
logic examination of the cyst aspirate indicated 
no abnormal cells.
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Fig. 8.—Case 7. Longitudinal section, 8 cm to 
right of midline, shows echo-free area (C) in 
upper pole of right kidney (K), posterior to right 
lobe of liver (L), that has smooth border and 
enhanced echoes deep to lesion.
Case 8.— A  38-year-old woman had a 
right-sided abdominal mass. The grey-scale 13- 
scan demonstrated a pear-shaped cystic struc­
ture projecting inferiorly from the right lobe 
of the liver (Fig. 9 ). Several echogenic struc­
tures in the most dependent portion caused an 
acoustic shadow deep to them. The diagnosis 
of hydrops of the gallbladder with gallstones 
was subsequently confirmed at operation.
Case 9 .— A 42-year-old man presented with 
hypertension. Urinary catecholamine and va- 
nillylmandelic acid values were elevated. No 
abdominal mass was palpable. The grey-scale 
B-scan showed a mass (diameter, 6 cm) in the 
region of the right adrenal gland compressing 
the inferior vena cava anteriorly (Fig. 10). A 
pheochromocytoma of the right sympathetic 
chain was removed at operation.
D iscussion
These case reports demonstrate the use­
fulness of grey-scale ultrasound in the diag­
nosis and evaluation of palpable or suspected 
abdominal mass lesions, particularly in con­
firming the presence of a mass lesion known 
to be present by palpation, radiographic or 
isotope studies and in determining whether 
the lesion is cystic or solid. Previous 
studies have demonstrated the high de­
gree of accuracy of ultrasonic diagnosis.5 8 
Its major limitation is the presence of gas or 
barium in the gastrointestinal tract, which 
prevents the passage of high-frequency sound 
so that the deeper structures cannot be eval­
uated. Thus, ultrasonic studies should be 
done before barium examination of the gas-
Fig. 9 .—Case 8. Longitudinal section, 8 cm to 
right of midline, shows elongated cystic structure 
(GB) inferior to right lobe of liver (L). Echo­
genic structures heaped up in dependent portion 
of gallbladder and causing acoustic shadow (S) 
posteriorly are gallstones.
Fig. 10.—Case 9. Longitudinal section, 4 cm to 
right of midline, shows inferior vena cava (C) 
bowed anteriorly by echogenic solid mass (M) 
(PV =  portal vein).
trointestinal tract or after a suitable delay. 
Many attempts have been made to alleviate 
the problem of gas in the bowel, but most 
have been unsuccessful. A large mass, intra- 
or retroperitoneal, tends to displace the 
bowel. Small- to moderate-sized masses, 
particularly in the pancreas, may be missed 
in the presence of bowel gas, especially if 
the bowel gas is due to an ileus. Examina­
tion of obese patients is difficult because 
large amounts of fat scatter the sound waves.
Grey-scale ultrasound has improved the 
diagnostic potential in obstetrical diagnosis 
and, in addition to mass lesions in the ab­
domen, has proved helpful in the diagnosis 
of thyroid, breast and pelvic masses. In the
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jaundiced patient ultrasound may help to 
differentiate obstructive from nonobstructive 
causes and may even delineate the exact type 
and nature of the obstruction. Gallstones can 
be detected and the size of abdominal organs 
can be assessed. Postoperative abdominal 
abscesses also can be evaluated.
Diagnostic B-scan ultrasound remains a 
safe, noninvasive, relatively easy and rela­
tively inexpensive technique. The addition 
of grey-scale has enhanced its diagnostic 
capabilities.
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COMPARISON OF EPICARDIAL AND ENDOCARDIAL PACEMAKER
INSERTION*
JEAN E. MORIN, MD, FRCS[C], FACS, ELIZABETH M. PAPPIUS, BA, 
and GORDON L. CRELINSTEN, MD, FRCP[C]
The authors compared the results of 100 pace­
maker insertion procedures: 50 endocardial and 
50 epicardial. The late pacing threshold and the 
postoperative pain and pulmonary complications 
were higher in the epicardial group. Although 
dislodgement occurred in 28% of cases of in­
sertion through the endocardial route, the 
authors concluded that this route was prefer­
able.
Nous avons compare 100 operations pour im­
plantation de cardio-stimulateur: 50 par voie 
endocardique et 50 par voie epicardique. Durant 
la phase postoperatoire, les complications pul- 
monaires et la douleur etaient plus frequentes 
chez le group epicardique. A long terme, le 
seuil de stimulation electrique des sondes epi- 
cardiques augmente de fa?on plus importante 
que pour les sondes endocardiques. L'incidence 
de deplacement des sondes endocardiques est 
de 28%. En conclusion, nous preferons la voie 
endocardique.
*From the cardio-vascular research unit, division 
of cardiovascular and thoracic surgery and car­
diology, Royal Victoria Hospital and McGill Uni­
versity, Montreal, PQ.
Presented at the annual meeting of the Canadian 
Cardiovascular Society, Edmonton, Alta., Oct. 
18-23, 1977.
Reprint requests to: Dr. Jean E. Morin, Depart­
ment of surgery, Room S8.30, Royal Victoria 
Hospital, 687 Pine Ave. W, Montreal, PQ 
H3A 1 Al.
In the 13 years from 1961 to 1973, 562 
surgical procedures for implantation or 
change of pacemakers were performed at 
the Royal Victoria Hospital, Montreal. In 
an attempt to determine which of the two 
routes of insertion (endocardial or epicar­
dial) is superior, we reviewed the case rec­
ords of 100 consecutive patients in whom 
a pacemaker was implanted between De­
cember 1970 and February 1973.
The decision to use a particular lead was 
not based on any rigid criteria or policy 
at the time of operation. It was left to the 
discretion of the surgeon. However, one or 
the other approach tended to predominate 
for extended periods as new leads became 
available for assessment.
M aterials and M ethods
Of the 100 patients, 50 had endocardial 
lead insertion (group 1) and 50 epicardial 
lead insertion (group 2). The mean age in 
group 1 was 71 years (range, 47 to 88 yr). In 
group 2 the mean age was 65 years (range, 
16 to 89 yr). A number of variables were 
compared in the two groups, including in­
dications for pacemaker insertion and other 
diagnoses, pacing threshold, anesthesia, anti­
biotics and analgesics used, postoperative
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TABLE I.—Indications for P acemaker 
Insertion
Diagnosis Endocardial Epicardial
3rd degree atrioven-
tricular block......... 22 18
Sick sinus syndrome . 11 13
Lesser degree atrio-
ventricular block . 17 15
O ther........................... 0 4
T otal................... 50 50
and late complications and length of hospital 
stay following surgery.
The epicardial lead was inserted through 
a left submammary incision; the costal car­
tilage of the fifth rib was excised at its 
junction with the sternum. An attempt 
was made to keep the pleura closed but 
this was not always possible. Forty-two of 
the 50 epicardial leads were of the Med­
tronic sutureless type (Medtronic Inc., 
Minneapolis, MN) implanted into either the 
left or right ventricle. For the insertion of 
an endocardial lead, a unipolar Cordis lead 
(Cordis Corp., Miami, FL) was inserted 
through the left cephalic vein and placed in 
the apex of the right ventricle under fluoro­
scopic control.
I n d ic a tio n  fo r  P a c e m a k e r  I n ser tio n
and  O t h e r  D iagnoses
The indications for permanent pacemaker 
transplantation were similar in the two 
groups (Table I); there was a similar dis­
tribution of third degree atrioventricular 
block and other conditions associated with 
a conduction disorder.
The general condition of the patient was 
evaluated by assessing the number of con­
comitant illnesses that may affect the cardio­
pulmonary system or the outcome of an 
operation. Coronary artery disease, conges­
tive heart failure, diabetes mellitus, hyper­
tension and renal failure were considered 
to be risk factors. In group 1, 28 patients 
(56%) had two or more associated illnesses. 
In group 2, only 14 (28%) had two or 
more associated illnesses (Table II). This 
difference is significant (P =  0.05).
R e s u l t s
Initial Pacing Threshold
The pacing threshold was determined at
TABLE II.—Associated Illnesses in Patients 
Requiring Pacemaker Insertion
No. of associated 
illnesses Group 1 Group 2
0 8 15
1 14 21
2 20 12
3 7 2
4 0 0
5 1 0
the time of lead insertion. In group 1, of 
48 patients in whom it was assessed, the 
threshold ranged from 0.1 to 5.0 mA (mean, 
1.04 mA). In group 2, of 44 patients as­
sessed, the threshold ranged from 0.5 to 1.7 
mA (mean, 1.03 mA).
Postoperative Morbidity
The pulmonary complications, which were 
defined as the presence of a pulmonary in­
filtrate, pleural effusion, pneumonia, atelec­
tasis, or pneumothorax, detected either clin­
ically or radiographically, were present in 
4 patients in group 1 and in 31 patients in 
group 2. The administration of opiates for 
pain was necessary in 24 patients in group 
1 and 36 in group 2. Fever, defined as an 
elevation of oral temperature over 37.7°C 
on 3 consecutive days, was not detected 
among group 1 patients, but was present in 
six group 2 patients. Other complications, 
including wound infection and septicemia, 
were present in eight patients from group 1 
and five from group 2 (Fig. 1).
Hospital Stay
The duration of postoperative hospitaliza­
tion varied considerably in both the endo­
cardial and the epicardial groups. The mean 
of 10 days in group 1 was less than the
opiates
Fig. 1.—Postoperative complications in 100 pa­
tients with pacemakers inserted.
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mean of 14 days in group 2; more impor­
tant, the median stay was 8 days in group 1, 
and 14 in group 2.
Late Pacing Threshold
In the follow-up period to October 1976, 
34 patients had a pulse-generator change 
either electively or for pulse-generator fail­
ure. At the time of battery change (a mean 
of 27 months following insertion of the 
endocardial lead) the mean threshold of 
the endocardial lead in 21 patients in group 
1 was 2.06 ±  0.62 mA. Eleven patients in 
group 2 had a battery change after a mean 
of 33 months following the initial insertion. 
At that time, the mean threshold of the epi- 
cardial leads was 3.12 ± 1.85 mA. While 
there was no difference in the initial thresh­
old in the two groups, the long-term thresh­
old was higher (P =  0.05) in group 2 (Table 
III), although it was measured an average 
of 6 months later.
TABLE I I I —Comparison of M ean Initial and 
Late Pacing T hresholds
Threshold, mA (and no. of patients)
Time Group 1 Group 2
Initial.......... 1.04 ±  0.69 1.03 ±  0.36
(48) (44)
L ate............  2.06 ±  0.62 3.12 ±  1-85
(21) (ID
Lead Assessment
The lead performance can be assessed 
independently of the pulse generator. Twen­
ty-one endocardial leads and 13 epicardial 
leads were still functioning well after the 
first battery change. Two endocardial and 
16 epicardial leads were still functioning 
well with their original pulse generator in 
place. Approximately equal numbers of pa­
tients in the two groups have died. Fourteen 
endocardial leads were unstable and had 
to be either repositioned or replaced, while 
only five epicardial leads failed to pace or 
sense normally; these were replaced before 
the pulse generator failed. One endocardial 
lead was totally removed and not replaced. 
Four patients with endocardial and five with 
epicardial leads were lost to follow-up (Fig. 
2).
D isc u ssio n
There has been much progress in the use 
of the artificial pacemaker since Callaghan 
and Bigelow1 initiated their work in 1951. 
In 1960, Chardack, Gage and Greatbatch2 
developed the first totally implantable pace­
maker. By 1976 Furman,8 reviewing the ex­
perience up to that time, called the pace­
maker the most successful electronic device 
implanted in the body; he estimated that 1 
of every 1500 persons in the United States 
needed a permanent pacemaker. Because 
pacemakers are so widely used, it is impor­
tant to seek the optimal route of insertion. 
The initial pacing thresholds for endocardial 
and epicardial leads were the same in this 
study. In the past, the endocardial lead had 
a higher threshold because the tip was larger 
and required more current, but with the 
introduction of new, small-tipped, endo- 
cavitary electrodes, this is no longer a prob­
lem.4
There has been great enthusiasm for the 
use of the epicardial sutureless lead.3 Our 
series shows that with time there is a meas­
urable increase in the pacing threshold and 
that it is much higher than for the endo­
cardial lead. Unfortunately, the instability 
of the endocardial lead is still a major prob­
lem. Displacement necessitating a second in­
tervention for repositioning or replacement 
occurred in 28% of our series. It is pos­
sible that this incidence could be decreased, 
for McLaughlin and colleagues6 reported 
an incidence of only 8% .
Much more important is the assessment 
of morbidity. Furman8 has documented that 
the average age of the patients who require 
a pacemaker is 72 years; our experience is 
similar. Mansour, Dorney and Tyras7 have
followed
Fig. 2.—Lead performance in 100 patients with 
pacemakers inserted.
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shown that the preferred route in the elderly 
is the endocardial. Our own study reveals 
that pulmonary complications were present 
in 62% of the patients receiving an epi- 
cardial lead compared with only 8% of the 
patients receiving an endocardial lead. Pain, 
necessitating the use of opiates, was en­
countered in 72% of the epicardial group 
(group 2) and in only 58% of the endo­
cardial group (group 1). These differences 
can be accounted for by the magnitude of 
the operation and the type of anesthesia 
used. Wynands8 has documented the phy­
siologic basis for the technique he advocates 
for administering anesthesia to patients re­
quiring pacemaker insertion. Finally, the 
hospital stay varied greatly between the two 
groups studied. This certainly has to be 
considered when health care is so expensive.
C o n c l u sio n
As pacemaker insertion is mainly directed 
towards an elderly, high-risk population, the 
best route of implantation is the one with 
the least morbidity. On the basis of pul­
monary complications, postoperative fever, 
pain and the duration of hospital stay, 
endocardial lead insertion through a trans­
venous approach is preferred.
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SPECIFIC ACTIVE IMMUNOCHEMOTHERAPY IN LUNG CANCER:
A SURVIVAL STUDY*
THOMAS H. M. STEWART, MB, ChB, FRCP[C], ARIEL C. HOLLINSHEAD, PhD,f 
JULES E. HARRIS, MD, FRCP[C], FACP, SANKARANARAYANAN RAMAN, PhD, 
RAYMOND BELANGER, MD, FRCS[C], ANDRE CREPEAU, MD, FRCS[C], 
ALFRED F. CROOK, MD, FRCS(Edin), FRCS[C], WOLFGANG E. HIRTE, MD, 
FRCP[C], FACP, DAVID HOOPER, MD, FRCS[C], DAVID J. KLAASSEN, MD, 
FRCP[C], EDNA F. RAPP, MD, FRCP[C] and HAROLD J. SACHS, MD, FRCS[C], FACS
A randomized clinical trial of chemotherapy, im­
munization and immunochemotherapy among 55 
patients with stages I and II carcinoma of the 
lung is reported. The survival rate in the im­
munized groups was significantly better (P =  
0.001) than that in the nonimmunized groups. The 
results are discussed in the light of the reac­
tivity of the patients to the specific cancer 
antigen.
On rapporte les resultats d'une etude, comparant 
la chimiotherapie, I'immunisation et I’immuno- 
chimiotherapie chez 55 patients souffrant d'un 
carcinome pulmonaire au stade I ou II. Le taux 
de survie au sein des groupes immunisee ont 
ete meilleurs de fagon significative (P =  0.001) 
que chez les non-immunises. Les resultats font 
I’objet d'une discussion a la lumiere de la reac- 
tivite des patients contre I'antigene tumoral 
specifique.
R e su lt s  of surgical treatment for resectable 
lung cancer have been disappointing. Recur­
rence of the disease and death within 3 years 
may be expected in half the patients with 
stage I or stage II (American Joint Commit­
tee for Cancer Staging and End Results Re­
porting) disease at the time of curative sur­
gery.1’ 2
A number of trials have been aimed at 
improving the prognosis following surgery 
by means of chemotherapy, either at the 
time of surgery3 or on a long-term basis 
postoperatively.4’ 5 Such chemotherapy has
* From the departments of medicine, surgery, epi­
demiology and community medicine, University 
of Ottawa, Ottawa, Ont.
Supported, in part, by the Ontario Cancer Treat­
ment and Research Foundation, grants 168 and 
292.
fDivision of hematology and oncology, Depart­
ment of medicine, George Washington University 
Medical Centre, Washington, DC.
Reprint requests to: Dr. T. H. M. Stewart, Depart­
ment of medicine, Ottawa General Hospital, 43 
Bruyere St., Ottawa, Ont. KIN 5C8.
resulted in unacceptable toxicity3’ 4 or in 
decreased survival.4’ 5 One study6 has 
shown a 35%, 5-year survival if stage I 
patients with node metastases had postoper­
ative irradiation. Clearly there is room for 
improvement in the management of such 
patients.
The importance of the patient’s capacity 
to exhibit a delayed hypersensitivity reac­
tion (DHR) on skin testing with purified 
protein derivative (PPD) has. been shown by 
Israel7 in patients with disseminated disease; 
in such patients the prognosis was better. 
Among patients who had had surgical re­
section of their tumour, those with a posi­
tive preoperative PPD fared significantly 
better than those in whom it was negative. 
Similarly, the capacity of a patient to re­
spond to 2-4 dinitrochlorobenzene (DNCB) 
correlated well with the presence or absence 
of recurrent disease at 12 months.8 Attempts 
have been made to increase the immune 
competence of the patient with lung cancer 
in order to improve the prognosis. The non­
specific effect of levamisole9 and the intra­
pleural injection of living bacille Calmette 
Guerin10 are promising, providing prolonga­
tion of the disease-free interval in stage I 
patients. A more specific approach has been 
that of Takita and colleagues11 who used 
autologous tumour cells homogenized with 
Freund’s complete adjuvant (FCA). Sur­
vival of stage III patients was improved to 
correspond to that of stage I patients.
To strengthen specific cellular defence 
mechanisms against residual cancer cells fol­
lowing surgery we chose to use separated 
soluble allogeneic lung cancer antigens, 
matched for histology and free of HLA an­
tigens, thoroughly homogenized with FCA 
(Difco Laboratories, Detroit, MI) as a speci­
fic vaccine, because it is known that specific 
organ damage can be induced in labora­
tory animals12 if the animal is inoculated
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with an homogenate of the target organ anti­
gen and FCA. Similarly derived soluble tu­
mour antigens have been shown effective in 
immunoprophylaxis of viral-13 and carcino­
gen-14 induced animal tumours. Further, 
we chose to combine the immunization with 
methotrexate (Lederle Laboratories, Mont­
real, PQ) (MTX), a drug that has been 
shown to act synergistically with the host 
cellular defence mechanisms in the effec­
tive treatment of malignant disease15’ 16 
and in advanced lung cancer.17 The sched­
ule of immunization following MTX was 
chosen so that advantage could be taken of 
the striking, rebound, overshoot phenome­
non that we and others have described18- 19 
in patients following chemotherapy. We 
chose high-dose MTX followed by citrovo- 
rum rescue because we hoped that long­
term immunosuppression would not be seen 
and because such a regimen has been shown 
effective in treating some cases of advanced 
lung cancer.20
The general parameters for phases I, II 
and III of specific active immunotherapy 
trials have been documented.21 In this pa­
per we report the preliminary findings 
(phase II) from a randomized clinical trial 
of immunotherapy and immunochemother- 
apy on patients with stages I and II lung 
cancer following surgical resection of the 
tumour. The design and rationale of this 
clinical trial have been reported in detail 
previously.22
M aterials and M ethod
Patients were drawn from those having 
surgical removal of their tumour at the 
Ottawa Civic Hospital, the National De­
fence Medical Centre, Ottawa, and the 
Ottawa General Hospital. Careful staging 
for tumour, node and metastasis1 was as­
sured by preoperative radiography, scan­
ning and mediastinoscopy, and postoperative 
consideration of the notes of the surgeon and 
pathologist. From August 1972 to May 
1976 we evaluated 55 patients with stages
1 and II disease. Of these, 16 patients, all 
classified as having stage I lesions, acted 
as a control group; they were operated upon 
by the same surgeons and would have been 
included in the treatment groups but for a 
delay of more than 30 days following sur­
gery when they were unavailable for im­
munization. The remaining 39 patients were 
randomized into one of three treatment 
groups. Group 1 consisted of 10 patients, 
8 with stage I and 2 with stage II disease, 
who received MTX once a month followed 
by citrovorum rescue for 3 months. Group
2 comprised 16 patients, 13 with stage 1 
lesions and 3 with stage II lesions, who re­
ceived soluble antigen homogenized with 
FCA once a month for 3 months. Group 3 
comprised 13 patients, 11 with stage I le­
sions and 2 with stage II, who were im­
munized 7 to 9 days after administration 
of MTX with citrovorum rescue, once a 
month for 3 months. Table I is a summary
TABLE I.—Data on Control and T reated Groups
Group
Control 1 2 3
Total no. of patients........................................ 16 10 16 13*
Sex: Male............................................................ 13 8 13 9
Female........................................................ 3 2 3 4
Age, yr: Median............................................... 58 53 58.4 56
Range................................................. 45-73 39-65 46-71 45-66
Physical status at surgery:
Asymptomatic and ambulant................. 2 1 5 3
Symptomatic and ambulant.................... 14 9 11 10
Stage: I ............................................................. 16 8 13 11
II............................................................. 0 2 3 2
Cell type: Epidermoid...................................... 7 4 11 7t
Adenocarcinoma............................. 6 5 3 4
Anaplastic (small cell)................... 1 — — i
(large cell).................... 2 i 2 1
Outcome: Died.................................................. 3 3 — 1
With metastases.............................. 1 1 1 —
With recurrence.............................. — — 3 —
‘Includes 1 patient from phase I trial immunized in 1969 who died after 6 yr. 
•(Includes 1 patient who also had adenocarcinoma.
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of the relevant characteristics of the pa­
tients.
The preparation of soluble allogeneic an­
tigens of lung cancers has already been 
described in detail-2’ 23 as has their charac­
terization with recognition of oncofetal 
antigens, tumour-associated antigens and a 
tumour-associated antigen of herpes sim­
plex virus.21 The mean total quantity of 
antigen given to patients in group 2 was 
1495 pg (range, 1125 to 2200 pg). The 
mean total quantity of antigen given patients 
in group 3 was 1610 pg (range, 900 to 
3000 pg). An average of 500 pg of antigen 
in 0.5 ml was homogenized with an equal 
volume of FCA, which contained 10 mg 
of killed Mycobacterium tuberculosis per 
10 ml, made up of 8.5 ml Bayol F (mineral 
oil; Difco Laboratories) and 1.5 ml Arlacel 
A (mannide monooleate; Difco Labora­
tories). The homogenate was given intra- 
dermally into the deltoid region of the arm, 
the thigh and again the arm, at monthly 
intervals. The details of the management of 
the ensuing ulcer have already been de­
scribed.22 The ulcer crater is the size of a 
quarter; it drains for an average of 2 months 
and heals within a further 10 months after 
the formation of a scab. During the period 
of draining, approximately half the ulcers 
become secondarily infected, but these re­
spond readily to oral antibiotics. We have 
found that patients usually suffer little dis­
comfort, unless, as with two of our patients, 
they do not receive attention for the infec­
tion. However, the Victorian Order of 
Nurses has helped us to follow such patients 
and ensure treatment. MTX was given by 
rapid intravenous infusion; 300 mg and 
then 700 mg were infused over 6 hours. A 
normal creatinine clearance is mandatory 
and the urine was made alkaline by giving 
sodium bicarbonate, 1.2 to 2.4 g q6h by 
mouth, starting 24 hours before the infu­
sion and continuing during the folinic acid 
rescue period of 60 hours. Urinary pH was 
monitored every 6 hours to ensure that the 
pH remained above 6. DHRs to allogeneic 
and occasionally autologous soluble cancer 
antigen have been tested on subsequent 
visits of the patients following the initial 3- 
month course of treatment: the skin test 
dose was 100 pg of antigen, unless dilution 
dose responses were measured.22 Indura­
tion at 48 hours, measured by the technique 
of Sokal,24 was recorded over the two great­
est diameters. Results were expressed as the 
surface area of an ellipse. Readings less 
than 5 mm in diameter were scored as 
negative. Biopsies of the test sites have been 
done to confirm a DHR.
R esults
Control Group
At the time of writing (Oct. 1, 1976) the 
16 control patients have been followed up 
for a mean of 23 months. Among these pa­
tients, three died and a fourth developed a 
cranial metastasis at 14 months.
Group 1
The 10 patients who received MTX have 
been followed for an average of 20 months; 
3 died and 1 had a metastasis at 14 
months in the opposite lung. This report 
excludes from analysis of the MTX-treated 
patients one who was included in error as 
stage I in our previous report and who died 
at 24 months.22
Group 2
The 16 patients have been followed for 
a mean of 18 months; all are alive. Two 
patients had stump recurrences and re­
ceived cobalt-60 irradiation; they remain 
well at 38 months. One patient had a local 
recurrence at 14 months; a complete pneu­
monectomy was followed by a stormy post­
operative course complicated by empyema. 
In one patient with stage II disease, meta- 
stases developed at 13 months; he is alive 
and is receiving chemotherapy.
Group 3
The 13 patients who received immuno- 
chemotherapy have been followed for a 
mean of 23 months. One patient died at 14 
months with a cerebral metastasis from a 
9-cm primary lesion, which on histologic 
examination was a poorly differentiated epi­
dermoid carcinoma. No recurrences or me- 
tastases were found in the remaining pa­
tients.
Survival
In Table II the life-table survival ex­
perience is summarized as calculated by the
/WJ^OSINS
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vitam in-deficient 
potiento doily  
theropeutic supply  
of vitam in G
' 2 7 boked  potatoes s^andaio, 
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TABLE II.—Life-Table Survival in T reated Groups (2 and 3) and Untreated Groups
(Control and Group 1)
Duration, 
mo
No. of patients 
alive,
treated (and 
untreated)
No. of patients 
dead or with 
metastases, treated 
(and
untreated)
No. of patients 
withdrawn in 
interval, treated 
(iand untreated)
Probability of 
surviving until 
termination of interval, 
treated {and 
untreated)
0 — 5 29 (26) — 4 (3) 1.0 (1.0 )
6 — 11 25 (23) - ( 3 ) 6 (1) 1.0 (0.8506)12 — 1/ 19 (19) 2 (3) 6 (2) 0.8674 (0.6894)
18 — 23 11 (14) - d ) —  (4) 0.8674 (0.6221)
24 — 29 11 ( 9) — 5 (2) 0.8674 (0.6221)
30 —• 35 6 ( 8) - U ) 3 (1) 0.8674 (0.517 )
36 — 41 3 (  5) —  (2) — (0.517 )42 —  47 - (  3) — —
method of Cutler and Ederer.20 The overall 
probability of no difference between the two 
groups is 0.0011. Figs. 1 and 2 show the 
survival curve for the nonimmunized (con­
trol and group 1) and the immunized groups 
(2 and 3). If one uses death only as an end 
point, the overall probability of no differ­
ence is 0.0025. However, we included meta- 
stases, believing that this gives a more real­
istic picture, although the survival probabil­
ity for the immunized group at 36 months 
is 87% , while with death alone as the end 
point it is predicted to be 93 %.
We included in the analysis of group 3 
one patient from our phase I trial for tox­
icity.21 He was the only patient immunized 
with a crude antigen and MTX in 1969;22 
he had a bronchial stump recurrence at 36 
months and died from metastases 6 years 
after operation.
Fig. 3 shows the results of late testing 
with soluble cancer antigen for DHR from 
4 to 42 months (mean, 18 mo) of 11 pa­
tients who were not immunized (5 control 
patients, 6 group 1 patients); almost half 
were anergic towards cancer antigen. All 
but one were ambulant and asymptomatic 
when tested. The 16 group 2 patients were 
tested at intervals ranging from 6 to 28 
months (mean, 18 mo); all showed a posi­
tive DHR to cancer antigen. The mean 
intensity of induration with one standard 
error is shown in the figure separately for 
the patient groups of nonimmunized (con­
trol and group 1), immunized (group 2) and 
immunochemotherapy (group 3). Clearly, 
immunization confers a positive reaction that 
is significantly greater than no immuniza­
tion, P <  0.05 for group 2 and P <  0.01 
for group 3. It was noted that patients in 
group 3 had a significantly stronger reaction
Fig. 1.—Survival probability curve (death) for 
immunized and nonimmunized groups.
Fig. 2.—Survival probability curve (death and 
metastases) for control, immunized and nonim­
munized groups.
NON IMMUNIZED IMMUNIZED IMMUNOCHEMOTHERAPY 
M T X  6 6 10
CONTROL 5
AUTOLOGOUS 1 2 3
Fig. 3.—Intensity of induration at 48 hours on 
late skin testing with soluble cancer antigen. Auto­
logous testing was done in some patients as 
indicated. Mean of greater diameter of induration 
was 4.8 mm, 11 mm and 33.4 mm, respectively.
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(P <  0.05) than the patients in group 2. 
Details of autologous testing have already 
been reported,-- but it should be empha­
sized that reactivity is retained with as little 
as 500 ng of autologous antigen. It is of 
interest that in one patient in group 3, who 
was tested at 10 months, the reaction was 
weaker than in most who received immuno- 
chemotherapy, the area of induration was 
11 mm, in-vitro blocking developed at 4 
months2- and the patient died at 14 months.
D iscussion
Immunization with allogeneic soluble 
lung-cancer antigen extends the disease-free 
interval significantly in stage I and possibly 
in stage II patients who have had surgical 
resection of tumour. Stage III lung cancer 
is less suitable for this approach, probably 
because the burden of residual tumour cells 
is too great for cellular defence mechanisms 
to become effective. Adjuvant MTX alone 
appears to have no beneficial effect, and 
conversion to give a positive DHR to cancer 
antigen was not seen. We have consistently 
observed conversion of immunized patients. 
The very strong DHR by those patients who 
had immunochemotherapy is gratifying, as 
it justifies immunization following MTX 
with folinic acid rescue. It is not an in­
variable phenomenon, however.22 We be­
lieve that the enhanced reactivity following 
immunization is desirable. The first skin 
tests in human cancer using autologous cell 
extracts by Hughes and Lytton20 were 
based on the observations by Brent, Brown 
and Medawar27 that guinea pigs actively 
rejecting foreign skin grafts showed a DHR 
to an acellular extract of the graft that 
correlated well with the presence or ab­
sence of a graft rejecting mechanism. In the 
induction of experimental allergic ence­
phalomyelitis in guinea pigs28 using a water- 
soluble basic protein derived from brain, a 
good correlation exists between the onset 
and severity of paralysis and the appearance 
and intensity of a DHR to the protein. 
Further examples of such a correlation in 
experimental induction of autoallergic dis­
ease in animals have been reviewed by 
Waksman.12 In man the induction of 
orchitis also correlates well with the presence 
of a DHR towards testicular antigen.20 
Thus we believe that the extension of the
disease-free interval in those patients who 
were immunized reflects a heightened cellu­
lar defence against microscopic foci of resi­
dual disease.
One may speculate on the conditions that 
exist during the 3 months of immunochemo­
therapy that are later reflected by the in­
tense skin reactions. A clear understanding 
of such conditions may allow one to en­
gineer a strong and long-lasting cellular host 
reaction directed towards cancer antigens. 
The essential ingredient of the Freund’s 
granuloma is dead tubercle bacilli. Such in­
flammatory granulomas have been charac­
terized as “high turnover”.30
It is recognized that rapidly dividing cells 
have a high requirement for folic acid. It 
has been shown that 25% of Canadians 
have very low folate values and that a 
further 35% have low values.31 Thus one 
may envisage that the folinic rescue given 
a total of 6 days in 3 months with high 
serum concentrations may encourage opti­
mal instructional function in the Freund’s 
granuloma. Bain32 has shown that optimal 
folate values for in-vitro mixed lymphocyte 
reactivity are 10 times the folic acid values 
considered normal in healthy man. Patients 
with very low folic acid values and anergy 
following treatment with folic acid have 
shown conversion to DNCB and rebound 
overshoot of their lymphocyte performance 
in vitro.33 The contribution of the folinic 
rescue to the function of the immune system 
in general and the instructional aspect of the 
Freund’s granuloma in particular may be 
important. The possibility exists that MTX 
given before immunization depletes a clone 
of suppressor cells, upsetting the balance 
in favour of effector cells in the immunizing 
schedule. Turk, Polak and Parker34 re­
viewed control mechanisms in DHRs and 
pointed out that depletion of suppressor 
cells accounts for strong DHRs in mice 
when cyclophosphamide has been given 3 
days before immunization with antigen with 
FCA. We planned the immunization to co­
incide with the period of rebound overshoot 
hoping to take advantage of the increased 
reactivity of the patients’ lymphocytes. Such 
rebound has been observed by Turk and 
Poulter3"' in mice following the administra­
tion of cyclophosphamide, which supports 
the rationale for our treatment schedule.
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The use of carefully characterized soluble 
allogeneic cancer antigens free of HLA has 
avoided the potential hazard of inducing 
autoallergic pneumonitis.
This small phase II study suggests further 
problems that have to be solved in future 
clinical trials. What is the optimal amount 
of soluble antigen that should be given and 
the frequency? How many cancer cells in 
man constitute the minimal residual tumour 
burden amenable to this approach? What 
are the optimal schedules that may make 
immunochemotherapy more effective? An­
swers to these crucial questions are impor­
tant if the general approach we outline is 
to be applied to other tumour systems in 
man.
We acknowledge the expert technical help of 
Peter Jones, Daphne Hyslop and Katherine 
Stilwell and the help of Mrs. T. Clayton in the 
follow-up of patients.
Addendum
Seven months have passed since the manu­
script was submitted for publication. The 
patients’ progress is now reported as of May 
1, 1977. New developments in this 7-month 
period are listed below.
Control Group (Stage I)
One patient had supraclavicular node meta- 
stases at 39 months (epidermoid carcinoma).
One patient had cerebral metastases at 27 
months (adenocarcinoma).
One patient with metastases at 14 months 
died at 22 months (large cell anaplastic car­
cinoma).
Group 1 (MTX)
One patient (stage I) had metastases at 18 
months (epidermoid carcinoma).
Group 2 (Immunotherapy)
One patient (stage I) died at 40 months 
(epidermoid carcinoma).
One patient (stage II) died at 17 months 
(epidermoid carcinoma).
One patient (stage II) died at 7 months 
(epidermoid carcinoma).
Group 3 (Immunochemotherapy)
No further recurrences, metastases or deaths.
If we now restrict the life-table analysis to 
stage I patients, we can compare two groups: 
those who may or may not have received 
MTX but all of whom were immunized and
TABLE I.—L ife-Table Analysis of Stage I 
P atients, M ay 1, 1977
Probability of survival
Non- Lower 95% 
Duration, Immunized immunized confidence 
mo (n  =  28) (n =  24) limit
0-5 1.0 1.0 1.0
6-11 1.0 0.91 1.0
12-17 0.95 0.81 1.0
18-23 0.95 0.59 0.98
24-29 0.95 0.59 0.90*
30-35 0.95 0.51 0.90*
36-41 0.81 0.42 —
‘Statistical significance of the 95% confidence limit 
is seen at 24 to 35 mo. The overall probability that 
the two groups are different is P < 0.0001.
those who may or may not have received 
MTX but who were not immunized (Table I).
From  May 1976 to September 1976 two 
patients were added to group 2 and two to 
group 3, all with stage I disease. The mean 
follow-up for the series is now: control, 29 
months; group 1, 26 months; group 2, 24 
months; group 3, 29 months.
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SPONTANEOUS SPINAL EXTRADURAL HEMATOMA
J. GEOFFREY HORNE, MB, ChB* and PAUL MULLER, MD, FRCS[C]f
Spontaneous spinal extradural hematoma is an 
uncommon but reversible cause of acute para­
plegia. Only 44 cases have been reported in the 
English literature. This paper adds two cases 
and analyzes the data in previous case reports 
to identify prognostic factors. Patients with a 
history of trauma or an incomplete myelographic 
block have a good prognosis. In most patients 
no cause of bleeding is found at operation.
L'hematome rachidien extra-dural spontane est 
une cause peu frequente mais reversible de 
paraplegie aigue. Seulement 44 cas apparais- 
sent dans la litterature de langue anglaise. 
Cette communication ajoute deux nouveaux cas 
et analyse les donnees tirees des cas prece­
dents dans le but d'identifier les facteurs de 
pronostic. Les patients ayant subit un trauma- 
tisme ou presentant un bloc myelographique in- 
complet ont un pronostic favorable. Chez la 
plupart des patients, aucune cause d’hemor- 
ragie n'est retrouvee a I'operation.
In 1869, Jackson1 reported the first case of 
spinal extradural hematoma in the English 
literature. In 1897, Bain- recorded the sec­
ond case and discussed the possible etiology 
of the condition. Since Bain’s publication, 
42 additional cases have been recorded in 
the English literature.3'25 The purpose of 
this paper is to report two more cases, and 
to review and analyze the English literature 
in the hope of discovering prognostic factors 
that might be of clinical importance.
C ase R eports
Case 1.—A 27-year-old woman was ad­
mitted with complaints of intermittent severe 
interscapular pain for 3 days and the sudden 
onset of weakness of the left leg that morning. 
No clear-cut history of trauma could be 
elicited and the past history was unremarkable. 
The interscapular pain began suddenly and 
lasted 3 hours before subsiding. On the morn­
ing of admission the patient awoke with severe 
pain accompanied by paresthesia in the left 
leg. She was able to get out of bed but soon 
was unable to move her left leg.
* Resident in neurosurgery, Toronto Western Hos­
pital, Toronto, Ont.
fDivision of neurosurgery, Toronto Western Hos­
pital.
Reprint requests to: Dr. J. G. Horne, 453 Soudan 
Ave., Toronto, Ont. M4S 1X1.
General physical examination was unre­
markable. There was tenderness on pressure 
over the spinous processes of the second and 
third thoracic vertebrae. Neurologic examina­
tion revealed a left Horner’s syndrome, but 
no other abnormalities in cranial nerve func­
tion were noted. Examination of the upper 
limbs was unremarkable. The left leg was 
flaccid, but the right had grade 5 (Medical 
Research Council grading system) power in 
all muscle groups except the hip flexors 
which were grade 4. There was a sensory 
level to pain and temperature on the right 
to T3, and a band of absent sensation from 
T2 to T4 on the left, below which pin­
prick sensation was decreased but not absent. 
There was no sacral sparing, but the anal 
sphincter was lax. The left knee jerk was 
absent, but the right knee and both ankle jerks 
were present. There was a left Babinski re­
sponse. She had urinary retention. Plain radio­
graphs of the cervical and thoracic spines 
were unremarkable, but emergency myelo­
graphy revealed a complete extradural block 
at T3 (Fig. 1). A laminectomy from T1 to 
T3 was performed approximately 16 hours
Fig. 1.—Anteroposterior myelogram showing 
complete block at T3.
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after the onset of symptoms. A large extra­
dural hematoma was found on the right post­
erolateral aspect of the cord extending from 
the inferior margin of C8 to the inferior 
margin of Tl. After removal of the clot, 
neither tumour nor arteriovenous malforma­
tion could be found. Within 12 hours of oper­
ation there was a dramatic improvement in 
function. The next morning there was move­
ment in the left leg in all muscle groups. Dur­
ing the remainder of the hospital stay, the 
patient continued to improve; when seen at 
follow-up 6 weeks after surgery, bowel and 
bladder function were normal and there was 
no objective weakness. (The patient com­
plained of weakness in the leg but tests showed 
grade 5 power in all muscles.) She had mild 
dysesthesia over the right leg but had returned 
to her former employment.
Case 2 .—A 78-year-old woman with hyper­
tension and diabetes mellitus was riding in a 
car when she felt a sudden snap in the lower 
thoracic spine. Within an hour she complained 
of weakness of both legs; 2 hours later she 
was paraplegic and incontinent of bladder but 
not bowel. On examination 18 hours after the 
onset of symptoms she had a flaccid paraplegia 
and a bilateral sensory level to pinprick at 
T12; the sensory level was slightly higher to 
light touch. There was perianal anesthesia
but normal sphincter tone. The lower limbs 
were areflexic. Results of neurologic examina­
tion of the upper limbs were entirely normal. 
Plain radiographs of the thoracic spine re­
vealed degenerative changes only. Emergency 
myelography was performed by cisternal punc­
ture and an almost complete block at the T10 
and T i l  levels was demonstrated. The ap­
pearance was consistent with an extradural 
lesion (Fig. 2). A wide laminectomy from T9 
to LI, performed within 24 hours after the 
onset of symptoms, disclosed a dorsal extra­
dural hematoma extending from T10 to T il  
with maximal thickness at T10. In this patient, 
as in case 1, we were unable to identify the 
source of the bleeding. Postoperatively there 
was some improvement of function with grade 
2 to 3 power in all muscle groups of the lower 
extremities; the patient retained her apprecia­
tion of pinprick, but had no other sensory 
modalities in the lower extremities. At follow­
up 1 year later there was no measurable im­
provement.
TABLE I.—R elation of T rauma to E xtradural 
H ematoma
Recovered
Not
recovered Total
History of 
trauma....... 9 5 14No history of 
trauma......... 12 20 32
D iscussion
Forty-six cases of spinal extradural hema­
toma have been recorded in the English 
literature. Twenty-eight of the patients were 
male and 18 female. The average age was 
37 years. In most patients, the recorded 
mode of onset was that of pain; 25 had 
either thoracic or lumbar back pain, 6 com­
plained of neck pain, 3 of chest pain, 1 of 
epigastric pain and 1 of pain in the limbs. 
Eight patients presented with motor abnor­
malities and two with sensory abnormalities. 
In 14 patients there was a history of either 
direct trauma to the spine or of a fall (Table 
I). In a number of patients the neurologic 
symptoms developed following urination or 
defecation, but these were not included as 
cases of trauma. In the majority the major 
neurologic deficit developed within 4 hours 
of the onset of symptoms (Table II). How­
ever, in 30 patients surgery was performed 
more than 12 hours after the onset of the 
major neurologic defect (Table III). Mye-
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lography was performed on 33 patients; in
4 the myelographic appearance was that of 
an intramedullary defect, while in 18 there 
was a complete block and in 8 an incom­
plete block. In three patients the findings 
were normal. The appearance of the myelo­
gram in the remaining patients was not re­
corded. Of the 18 patients with complete 
block, only 9 recovered completely, whereas 
of the 8 patients with an incomplete block
5 made a complete recovery. Thus it ap­
pears that an incomplete myelographic block 
is a favourable prognostic sign.
Of the 46 patients, 20 made a complete 
recovery, 11 died, 6 improved and in 9 
there was no change. The average age of 
the patients who made a complete recovery 
was similar to the age of those in whom 
there was no change.
Of the 20 patients in whom there was a 
complete recovery, 8 had complete neuro­
logic lesions preoperatively and 12 had in­
complete lesions. Of the nine patients in 
whom there was no change in the neurologic 
status postoperatively seven had complete 
neurologic lesions and two had incomplete 
lesions preoperatively. The time interval 
from the onset of symptoms to surgery was 
similar in the patients who had complete 
lesions and recovered completely and in 
those who had incomplete lesions with com­
plete recovery. Patients with complete neu­
rologic deficit in whom there was no change 
postoperatively were operated on slightly 
later than those who made a complete re-
TABLE II.—T ime Interval from Onset of 
Symptoms to M ajor Neurologic Deficit
Time interval, hr No. of patients
0-1 .................... 12
1_4 .................... 9
4_8 ...................... 4
>  12................................. 16
Unknown........................... 5
TABLE III .—T ime Interval from Onset of 
Neurologic Deficit to Operation
Time interval, hr No. of patients
0-4 ........................ 0
4_8 .................... 2
g_12 ...................... 4
12-24 ........................
tT 9A .................. 22................. in
covery. Also, there was no significant dif­
ference in the time between onset of the 
major neurologic deficit in patients who 
made a complete recovery compared with 
those in whom there was no change. This 
suggests that the rate of cord compression 
did not affect the ultimate outcome. Of the 
14 patients in whom there was a clear-cut 
history of trauma, 9 made a full recovery. 
However, only 12 patients with no history 
of trauma made a complete recovery. The 
patients with a clear-cut history of trauma 
were operated on slightly later than those 
with no clear-cut history of trauma, indicat­
ing that the prognosis is slightly better in 
patients with a history of trauma.
In 40 of the reported cases a hematoma 
was found either at surgery or autopsy. Only 
three patients had associated hemangiomas. 
The pathologic findings were not reported 
in three patients.
Co n c l u s io n s
Since the first case of spinal extradural 
hematoma was reported in 1869, there has 
been no critical analysis of the cases re­
ported, though several authors have at­
tempted to explain the etiology.5' 7' 12, 13, 21 
In this paper we have attempted to extract 
and analyze all the relevant data from the 
reported cases. We conclude that:
1. Patients with a history of trauma can 
be expected to do better than those in whom 
the onset is entirely spontaneous.
2. The speed of onset of the major neu­
rologic deficit does not alter the ultimate 
outcome.
3. An intramedullary myelographic block 
does not exclude the presence of an extra­
dural hematoma.
4. An incomplete myelographic block 
improves the chance of recovery.
5. In the majority of patients, as in our 
two patients, no cause of bleeding is found 
at operation.
We thank Drs. R. Fleming and R. G. Vander- 
linden for their encouragement in the preparation 
of this manuscript.
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CORRESPONDENCE
BASIC SURGERY EXAMINATION
To the editor: I have read with great interest 
the dialogue on the basic surgery examina­
tion of the Royal College of Physicians and 
Surgeons of Canada (Can J Surg 20: 9, 59, 
1977). The history of this examination is 
well outlined by Mueller (page 9) and in­
cludes the listing of general topics to be 
covered in this examination.
With this rather “bare bones” outline the 
department of surgery at the Montreal Gen­
eral Hospital has developed a teaching pro­
gram that involves weekly sessions with the 
residents for 1 academic year. These ses­
sions take the form of an initial didactic 
presentation by a local expert in the specific 
area being considered followed by a lively 
discussion period. The coordinators of this 
course then provide the residents with se­
lected multiple-choice questions taken from 
a variety of sources; the questions are in­
tended to illustrate the subject being dis­
cussed. The answers to the questions are 
then openly reviewed thus forming the basis 
for further debate.
The program has been in operation now 
for a full year and has been well received by 
the residents in attendance. We have limited 
the sessions to interns and residents in the 
first 2 years of their training and hope that 
the exposure they receive will allow them to 
approach the basic surgery examination with 
confidence.
I believe that Couture (page 59) has con­
fused somewhat the intent of the college 
when he refers to the examination as one in 
basic sciences. Indeed the basic sciences as 
applied to general surgical principles are 
discussed in our course; however, we have 
tried to emphasize clinical application in 
the course content and thus have required 
little input from the undergraduate medical- 
school faculty. I agree with Couture, that 
the outline of the program as supplied by 
the college lacks detail and thus leads to 
confusion. We are fortunate at McGill Uni­
versity to have a curriculum that includes 
a second exposure to the basic sciences in
Contributions to the Correspondence section are 
welcomed. They should be typewritten and double 
spaced.
the 4th year, aimed at the kind of deficiency 
in teaching that Couture outlines in his 
paper.
We hope that our approach to the teach­
ing of basic surgery will be an acceptable 
model for others who are faced with this 
problem in that it will lead to successful re­
sults in the basic surgery examination. The 
long-range goal of the college to have all 
surgical specialists trained in a 2-year core 
program will be furthered by urging all sub­
specialties to accept the principles of the 
basic surgery examination and to encourage 
their residents to take a full 2-year general 
surgical training before entering subspecial­
ty programs. In this way all surgical special­
ists could be exposed to the kind of teaching 
in basic surgical principles envisaged by the 
college.
J. K. M acF a r l a n e , m d , f r c s [c ]
Department of surgery,
Montreal General Hospital,
Montreal, PQ.
To the editor: I would like to thank Dr. 
MacFarlane for his comments. I hope the 
teaching program developed by the depart­
ment of surgery of the Montreal General 
Hospital fulfils the objectives of the basic 
surgical program of the Royal College of 
Physicians and Surgeons of Canada. While 
such an approach to the teaching of basic 
surgery should be encouraged, it is, I be­
lieve, only a partial answer to the problem. 
Such a program would be more valuable if 
specific objectives were defined in every 
surgical discipline; this could be achieved 
by a close cooperation between clinicians 
and basic scientists. However, before this 
is done, teaching programs in basic surgery 
as described by MacFarlane should be en­
couraged.
J. G. C o u t u r e , m d , f r c s [c ]
Chef du departement de chirurgie,
Hopital du Saint-Sacrement,
Quebec, PQ.
CANCER OF THE RECTUM: 
WHO DUNNIT — 0.014 OR 0.24?
To the editor: We appreciate the opportun­
ity of having a preview of Dr. R. G. C. Mac-
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Laren’s editorial in this issue of the Journal 
(page 307), which accompanies our paper 
on preoperative irradiation for operable rec­
tal cancer (page 335).We have re-evaluated our statistical meth­
ods critically, and also have tried to put our­
selves in the position of C. W. Dunnett. The 
only conclusion we can reach is that Dun- 
nett’s calculation (if indeed it was a calcula­
tion) was based on the small numbers at risk 
for 7 years, using a simple chi-square test 
without, even, a Yates correction for small 
numbers. Guessing numbers from a graph 
is to be condemned.
Our calculations were based on sophisti­
cated statistical methods, the details of which 
cannot be presented in graphic form. A Ka- 
plan-Meier1 actuarial curve was generated 
for each of the two groups of patients; these 
two survival curves were then compared by 
a generalized Wilcoxan test.2 This analysis 
gives a P value of 0.014, which, even for 
small numbers, is highly significant.
The statistical significance of the Toronto 
trial is far better than the US Veterans’ Ad­
ministration study.3 We believe, therefore, 
that the Toronto results are valid.
W. D. R id er , m b , f r c p [c ]
Department of radiology,The Princess Margaret Hospital,Toronto, Ont.
L . J. M ahon ey , m d , f r c s [c ]
Department of surgery,St. Michael’s Hospital,Toronto.
J. A. P a l m e r , m d , f r c s [c ]
Department of surgery,Toronto General Hospital.
C. T. R o b e r t so n , m d , f r c s [c ]
Department of surgery,Toronto East General and Orthopedic Hospital. 
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(Continued on page 392)
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CRITIQUE OF ITEM 253  (SESAP II)
Neutrophils are the most important cellular 
bulwark against bacterial infective disease. 
Their effectiveness is dependent on produc­
tion, release from the bone marrow, delivery 
to an inflammatory focus, and engulfment 
and killing of the infecting organisms. Inter­
ference at any one of these stages can 
markedly promote the development and 
spread of septic processes. While the vast 
majority of circulating neutrophils are ma­
ture, immature forms, before granules de­
velop, have a decreased efficiency for 
bacterial killing.
There are an estimated 20-30 billion cir­
culating neutrophils in a normal man, with 
an equal number marginated throughout the 
vascular system, and there is an estimated 
bone marrow reserve of 50-100 neutrophils 
for every one in circulation. Circulating 
neutrophils are short-lived, with a half-life 
of approximately 25 hours. The daily pro­
duction, which comes from a well-estab­
lished line of precursor cells, is quite large, 
and the body is estimated to eliminate 50- 
100 gm of expended neutrophils daily. Con­
ditions associated with neutropenia (eg, 
cyclic neutropenia, total-body irradiation, 
and drug-induced bone marrow suppression) 
are well known to be associated with clinical 
sepsis, but the spontaneous onset of sepsis 
is surprisingly infrequent unless the absolute 
neutrophil count falls below 1000/cu mm. 
Transfusions with neutrophils have been ad­
vocated as an adjunct to therapy in serious 
infections with neutropenia, but they have 
met with limited success because of the 
enormous number of cells required and the 
technical problems associated with their 
procurement. Leukophoresis of patients hav­
ing chronic myelogenous leukemia seems 
to be the most satisfactory source, although 
the necessary equipment and donors are not 
often available.
Until the discovery that chronic (fatal) 
granulomatous disease of childhood was 
associated with an abnormality of the intra­
cellular killing of bacteria by neutrophils, 
functional abnormalities of neutrophils were 
not recognized as contributing significantly 
to septic processes. There is now clear evi­
dence that populations of peripheral neutro­
phils may vary considerably in their ability 
to kill ingested bacteria, and that this varia­
tion occurs at periodic intervals which may 
vary from 10 to 40 days depending on the 
individual. This normal cycle may be ac­
centuated by treatment with steroids, or 
with stress such as may occur in severe bum 
injury. In addition, the overall neutrophilic 
antibacterial function is impaired in these 
states. Most important of all, the degree of 
neutrophilic abnormality directly reflects 
susceptibility of the individual for the de­
velopment of sepsis.
Despite the importance of the antibacterial 
function of neutrophils, the regulatory 
mechanisms responsible for this process are 
not known.
Monocytes may be especially important 
in many immune processes since they are 
thought to be capable of transferring anti­
genic information to immune-competent 
lymphocytes.
Fixed macrophages function to remove 
particulate matter, effete cells, and bacteria 
from the blood stream and tissues. The 
origin of these cells is disputed. Fixed ma­
crophages ingest bacteria in the same man­
ner as the neutrophil, although their chem­
ical mechanisms of intracellular killing 
probably differ.
Both eosinophils and basophils participate 
in inflammatory processes, but their im­
portance to antibacterial defense is probably 
not great.
It seems probable that many lymphocytes 
entering inflammatory foci interact with 
antigens to become activated immunocytes. 
The gut-dependent lymphocytes are essen­
tial for the synthesis and release of the 
immunoglobulins. Thymic-dependent lym­
phocytes participate primarily in the cell- 
mediated immunities including transplanta­
tion immunity and delayed hypersensitivity.
C
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B O O K  R E V I E W S
ADVANCES IN NEPHROLOGY FROM 
THE NECKER HOSPITAL. Vol. 6. Edited 
by Jean Hamburger, Jean Crosnier and 
Morton H. Maxwill. 474 pp. Illust. Year 
Book Medical Publishers, Inc., Chicago, 
1976. Price not stated. ISBN 0-8151-4115-7.
This is the sixth volume in a series published 
from the Necker Hospital in Paris, France. 
These books bring a written record of the 
annual symposia of the actualite nephrologique 
de l’Hopital Necker to the English-speaking 
world. Through recognized international au­
thorities we are given references to the French 
and European literature. Morton Maxwill has 
done an excellent job on the translation and 
editing. Chapter headings include such entities 
as systemic lupus erythematosus, glomerulo­
nephritis, blood pressure control, and new 
developments in dialysis and transplantation.
Although of greater importance to the 
nephrologist than the urologist, transplant sur­
geon, or general surgeon, this volume does 
contain information of value to those in the 
surgical specialties. The section on new devel­
opments in dialysis and transplantation in­
cludes a chapter on recipient presensitization; 
this is an excellent review of the source of 
presensitization prior to renal transplantation. 
Of special import is the section on latent and 
undetected presensitization and hyperacute 
graft rejection, which also contains an excel­
lent review and discussion of the phenomenon 
of allograft rejection and the methodology for 
antibody detection.
Other chapters of particular interest to the 
surgical specialties are those relating to nu­
tritional problems in patients with acute renal 
failure. The section on bacteriuria and kidney 
damage will be of special interest to the uro­
logist; it includes a discussion of the role of 
infection and obstruction in ureteral reflux. 
Urologists might note the authors report that 
persistent bacteriuria does not lead to pro­
gressive kidney damage, provided the condition 
is not associated with obstructive uropathy or 
hypertension. This will in some quarters at 
least be considered controversial.
Of interest to the general surgical readership 
is the section on progress in hemodialysis. In 
this section the authors summarize the recent 
advances in hemodialysis. They discuss the 
efficiency of the dialysis process and include 
reference to techniques of angioaccess. Uro­
logists working in hemodialysis centres will 
appreciate the discussion on recognition and
management of the common complications 
that follow the dialysis.
All the material has been prepared by ex­
perts; the exposition is clear and logical and 
the translations are good. The articles are 
readable, well indexed and extensively refer­
enced; the concepts presented, though com­
plex, are simply outlined and well summarized. 
They are therefore suitable for either careful 
or rapid perusal. This book is a portal of entry 
to the European literature; it is designed for 
nephrologists, but will be a useful reference 
text for urologists, transplant surgeons and 
general surgeons who do renal work.
N. M. Wolfish
Associate professor,
Department of pediatrics,
University of Ottawa, and 
Director,
Clinical investigation and dialysis unit,
Children’s Hospital of Eastern Ontario,
Ottawa, Ont.
BURN THERAPY AND RESEARCH. Wit­
old Rurowski, Wieslaw Nasilowski, Witold 
Zietkiewics and Konrad Zienkiewics. 332 pp. 
Illust. The Johns Hopkins University Press, 
Baltimore, 1976. Price not stated. ISBN 0- 
8018-1643-2.
This monograph co-authored by Nasilowski, 
Zietkiewics and Zienkiewics from the burn 
unit of the department of surgery, Institute of 
Hematology, Warsaw, Poland, is concerned 
primarily with the clinical problems of thermal 
injury and is written by clinicians. Treatment 
is presented in a scientific and critical manner 
with an excellent discussion of all the relevant 
pathophysiology, and a great many of the 
references are for the years 1970 to 1975.
The text does not cover any aspects of the 
late reconstructive surgery of burn deformities. 
Some aspects of bum patient rehabilitation are 
discussed throughout the text. There are spe­
cial sections on epidemiology of burn injuries 
as they relate to children, old people and 
pregnant women. The text ends by outlining 
further research needs in an extremely prac­
tical manner.
It is an excellent book for anyone interested 
in the current state of the art in the manage­
ment of the burn patient who, at the same time, 
is interested in the pathophysiology of the burn 
wound and wishes to become relatively up-to- 
date on the status of research into unsolved 
problems of the burn wound and burned pa­
tient.
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W. K. L indsay 
Chief,
Division of plastic surgery,
The Hospital for Sick Children,
Toronto, Onl.
CONTROVERSY IN SURGERY. Edited by 
L. Varco and John P. Delaney. 713 pp. 
Illust. W. B. Saunders Company, Philadel­
phia; W. B. Saunders Company Canada 
Limited, Toronto, 1976. $29.90.
“Remember that to change thy mind and to 
follow him that sets thee right, is to be none 
the less the free agent that thou wast before.” 
Henry Buchwald uses this quotation in his 
chapter, but it could be the theme of this entire 
volume.
The editors have put together a unique book 
with contributions by a number of authors 
with international reputations. There are 29 
chapters; each deals with a controversial issue 
in clinical surgery. Each topic is based on a 
clearly stated problem.
The first chapter on randomized clinical 
trials in surgery sets the stage for a critical 
evaluation of the data presented by the various 
contributors throughout the book. The editors 
provide a list of pertinent questions and the 
contributing authors take a position, discuss 
the issues and the evidence that supports their 
position. Each author provides key references 
particularly relevant to his point of view.
Topics of a controversial nature, such as the 
correct operation for the treatment of hyper­
parathyroidism and peripheral nerve injury: 
primary v. delayed repair, are handled like 
a legal court battle; two or more authors take 
alternative and sometimes diametrically op­
posite positions. This technique makes the 
book unusual and valuable, especially for the 
advanced surgical student.
M. O. IYPE
Department of surgery,
Dalhousie University,
Saint John General Hospital,
Saint John, NB.
MANAGEMENT OF THE PATIENT WITH 
CANCER. 2nd ed. Edited by Thomas F. 
Nealon, Jr., 1012 pp. Illust. W. B. Saunders 
Company, Philadelphia; W. B. Saunders 
Company Canada Limited, Toronto, 1976. 
$46.35.
This book is a well-written comprehensive re­
view of the modern management of cancer.
The first part on general considerations con­
tains concise chapters on radiotherapy, chemo­
therapy, immunotherapy, the treatment of 
bleeding and thrombosis in the cancer patient,
and rehabilitation. Each chapter clearly covers 
the basic principles involved.
The second and much longer part of the 
book deals with specific considerations. In­
dividual chapters on the various sites include 
a general discussion on each specific cancer 
and its management. While discussion of treat­
ment appears to be directed mainly to the sur­
gical reader, pertinent information concerning 
radiotherapy, chemotherapy and immuno­
therapy is also presented. Generally, the con­
temporary concept of combined modality treat­
ment is adhered to.
This book is easy to read and is well illus­
trated. The drawings showing surgical proce­
dures are particularly well done and supple­
ment the text adequately. This textbook will 
be a useful addition to the library of any 
physician or surgeon dealing with patients who 
have cancer. I highly recommend it.
E. F. R app
Ontario Cancer Treatment and 
Research Foundation,
Ottawa clinic,
Ottawa, Ont.
POSTGASTRECTOMY SYNDROMES. MA­
JOR PROBLEMS IN CLINICAL SUR­
GERY. Vol. XX. Edited by Frederic L. 
Bushkin and Edward R. Woodward. 167 pp. 
Illust. W. B. Saunders Company, Philadel­
phia; W. B. Saunders Company Canada Lim­
ited, Toronto, 1976. $12.10.
This monograph is dedicated to Lester R. 
Dragstedt, who is warmly remembered and 
respected by gastric surgeons and investigators 
everywhere. Dragstedt is remembered espe­
cially for his pioneering research and leader­
ship in this field and his concern for the pa­
tient with peptic problems.
Woodward and Bushkin and their associates 
from a number of departments at the Univer­
sity of Florida college of medicine have 
carefully reviewed current concepts in the phy­
siology and pathogenesis of the most trouble­
some sequelae of gastric surgery. The text is 
concise, useful and readable. The editors have 
appraised the adverse effects of these clinical 
syndromes in the light of their own experi­
ences and have provided an excellent biblio­
graphy at the end of each chapter. They have 
offered their own interpretations and have 
set down principles of therapy. They have 
suggested logical procedures and illustrated 
techniques that they have found useful. They 
appropriately remind us that the long-term 
results of some revisionary techniques are not 
yet known and later findings may require 
altered approaches.
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This book is recommended as required reading for all those embarking on a career in gastric surgery and gastroenterology. Cer­tainly, it would be most comforting to know, if one required such surgery, that the surgeon had read and understood the entire contents 
of this monograph.
J. A. Williams
Assistant professor,Division of surgery (urology),University of Calgary,Calgary, Alta.
PRINCIPLES OF ORTHOTIC TREAT­
MENT. Wilton H. Bunch and Robert D. 
Keagy. 144 pp. Illust. The C. V. Mosby 
Company, St. Louis, 1976. $18.40.
The authors’ intention is to provide a prac­tical book for the resident or student who is learning to prescribe an orthosis. In this regard they are successful. Orthoses are described and 
illustrated with line drawings and their spe­
cific indications are well outlined.The short chapter on wheelchairs is par­
ticularly useful for the resident, as is the 
chapter on cast bracing.One omission is the Boston orthosis for 
scoliosis, which is now used effectively in the 
treatment of this condition.This book can be recommended as an aid 
to orthopedic training programs.
G. W. D. Armstrong
Department of surgery,Ottawa Civic Hospital,Ottawa. Ont.
REVIEW OF ANATOMICAL NEURO­
LOGY. Walter Robinson Ingram. 428 pp. 
Illust. University Park Press, Baltimore, 
1976. $19.50. ISBN 0-8391-096 l-X.
The detailed structural anatomy of the central 
nervous system is probably one of the most difficult subjects in the medical curriculum to teach. The student must learn to construct a 
three dimensional image of the components of the system from two dimensional illustrations with varying planes of orientation and must then envision a large number of different af­ferent and efferent connections from each of these structures. Unless this complex recon­struction is based upon our rather primitive concepts of neurologic function, the student has great difficulty in imaging such a complex structure in his mind. Too often textbooks of neuroanatomy consist solely of a compilation of structures, their relations and connections.Dr. Ingram has endeavoured to avoid this problem by describing the functions of various structures wherever possible. Nevertheless I
found it difficult to construct a coherent whole from the numerous anatomical structures and their relations and connections described in the text. In part this may result from the fact that the author treats the nervous system on a regional basis working from the spinal nerves and cord upwards and only incidentally men­tions the major systems within the nervous sys­tem upon which function is presumably based. Perhaps for this reason I found the final chap­ters describing the thalamus, optic system, lim­bic system and the basal ganglia much easier to read since the author had less difficulty in 
these regions in relating structure to function.Despite this limitation, however, there are many attractive features about this book which can serve as a source of reference for readers seeking summarized, up-to-date information 
concerning specific components of the nervous system. Moreover, it should prove invaluable to residents in neurology preparing for their specialty examinations, as well as a novel re­fresher course in neuroanatomy for specialists 
in neurology and neurosurgery. The book is illustrated with many original and informative 
figures and diagrams.
D. N. White
Professor of medicine,Department of neurology,Queen’s University,Kingston, Ont.
VISIBLE AND PALPABLE LESIONS IN
CHILDREN. C. Everett Koop. 123 pp. Il­
lust. Grune & Stratton, Inc., New York;
Longman Canada Limited, Don Mills, 1976.
$15.75. ISBN 0-8089-0958-4.
This book was written for the pediatrician by a pediatric surgeon with many years of clinic­
al experience. Koop advises his readers to ex­plain to parents the nature of the child’s illness 
and the limitations of treatment; such an approach makes for better doctor-family un­derstanding and lowers the risk of litigation.
The book is divided on a regional anatomic basis; orthopedic and cardiovascular surgery 
are not included. Special chapters are provided on hemangiomas, lymphangiomas and screen­ing. There are some interesting illustrations of various neck swellings, including venous lakes, and excellent examples of cystic hygromas (lymphangiomas) arising from the anterior 
and posterior triangles.The value of the book is diminished by its technically poor quality. The illustrations and the text are frequently marred by smears, scratches and double images; these are an an­noyance and make the reading difficult. The presentation is superficial; there are no ref-
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THE YEAR BOOK OF UROLOGY 1976. 
Edited by John T. Grayhack. 385 pp. Illust. 
Year Book Medical Publishers, Inc., Chi­
cago, 1976. Price not stated. ISBN 0-8151- 
3910-1.
The editor has again provided a comprehen­
sive collection of abstracts from recent pub­
lications covering a large variety of topics in 
urology and the related clinical sciences. This 
makes for a convenient reference book. The 
abstracts are factual and presented in an in­
formative and readable style. Grayhack is to 
be congratulated for including matters of in­
terest to the urologist from the nonurological 
literature and this, coupled with the crisp, apt, 
editorial comments, gives the book considerable 
interest. The editor by intent has placed little 
emphasis on basic science publications; this is 
appropriate since the readership is composed 
primarily of clinicians interested in an over­
view of recent developments in urology and 
related fields.
A. M orales
Department of urology,
Etherington Hall,
Queen’s University,
Kingston, Ont.
(Continued from page 387)
Recent Advances in Urology. No. 2. Edited by 
W. F. Hendry. 353 pp. Illust. Churchill Living­
stone, Edinburgh; Longman Canada Limited, 
Toronto, 1976. $39.50.
Scientific Foundations of Urology. Vol. I. Renal 
Disorders, Infections and Calculi. Edited by 
David Innes Williams and Geoffrey D. Chis­
holm. 374 pp. Illust. William Heinemann Med­
ical Books Ltd., London; Year Book Medical 
Publishers Inc., Chicago, 1976. $27.25. ISBN 
0-8151-4821-6.
Scientific Foundations of Urology. Vol. II. Uro­
genital Tract, Oncology and the Urological 
Armamentarium. Edited by David Innes Wil­
liams and Geoffrey D. Chisholm. 474 pp. Il­
lust. William Heinemann Medical Books Ltd., 
London; Year Book Medical Publishers Inc., 
Chicago, 1976. $29.35. ISBN 0-8151-4822-4.
Traite de Technique Chirurgicale O.R.L. et Cer- 
vico-Faciale. Tome III. Pharynx et Larynx. Y. 
Guerrier. 502 pp. Illust. Masson, Paris, 1977. 
$121.00. ISBN 2-225-45420-5.
Vaginal Surgery. David H. Nichols and Clyde L. 
Randall. 246 pp. Illust. The Williams & Wilkins 
Company, Baltimore; Burns & MacEachern 
Limited, Don Mills, Ont., 1976. $27.50. ISBN 
0-683-06492-4.
